As filed with the Securities and Exchange Commission on June 29, 2022

    

Registration No. 333-259871

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

Form S-1/A

Amendment No. 3

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 GUIDED THERAPEUTICS, INC.

 (Exact name of Registrant as specified in its charter)

 

 Delaware

 

 3845 

 

 58-2029543

 (State or other jurisdiction of

incorporation or organization)

 

 (Primary Standard Industrial

Classification Code Number)

 

 (I.R.S. Employer

Identification No.)

 

5835 Peachtree Corners East, Suite B

Norcross, Georgia

(770) 242-8723

(Address, including zip code and telephone number, including area code, of registrant’s principal executive offices)

 

Mr. Gene S. Cartwright, Ph.D.

President and Chief Executive Officer

5835 Peachtree Corners East, Suite B

Norcross, Georgia

(770) 242-8723

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

 Copies to:

 

Robert F. Charron, Esq.

Sarah E. Williams, Esq.

Ellenoff Grossman & Schole LLP

1345 Avenue of the Americas

New York, New York 10105

Phone: (212) 370-1300

Fax: (212) 370-7889

 

M. Ali Panjwani, Esq.

Michael T. Campoli, Esq.

Pryor Cashman LLP

7 Times Square

New York, New York 10036

Phone: (212) 421-4100

 

Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement.

 

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, as amended, check the following box. ☒

 

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

 

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

 

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large Accelerated filer

Accelerated filer

Non-accelerated Filer

Smaller reporting company

 

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Commission acting pursuant to said Section 8(a), may determine.

 

 
2

Table of Contents

 

The information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting offers to buy these securities in any state or other jurisdiction where the offer or sale is not permitted.

 

SUBJECT TO COMPLETION, DATED June 29, 2022

 

PRELIMINARY PROSPECTUS

 

Up to 890,000 Shares of Common Stock

and

Up to 178,000 Pre-Funded Warrants to Purchase Shares of Common Stock

and

890,000 Warrants to Purchase Shares of Common Stock

 

gthp_s1aimg44.jpg

 

Guided Therapeutics, Inc.

 

We are offering 890,000 shares of common stock pursuant to this prospectus at a public offering price of $10.00 per share, together with warrants (“Public Warrants”) to purchase shares of common stock. Each Public Warrant is exercisable to purchase one share of common stock at an exercise price of $12.40, exercisable upon issuance and will expire five years from the date of issuance. The shares of common stock and Public Warrants will be separately issued, but the shares and warrants will be issued and sold to purchasers together. This prospectus also relates to the offering of the shares of common stock issuable upon exercise of Public Warrants.

  

We are also offering to certain purchasers whose purchase of common stock in this offering that would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of the outstanding shares of our common stock immediately following the consummation of this offering, the opportunity to purchase, if any such purchaser so chooses, up to 178,000 pre-funded warrants, in lieu of shares of common stock that would otherwise result in such purchaser’s beneficial ownership exceeding 4.99% (or, at the election of the purchaser, 9.99%) of the outstanding shares of our common stock. Each pre-funded warrant will be exercisable for one share of common stock. The purchase price of each pre-funded warrant and the accompanying Public Warrant will be equal to the price at which a share of common stock and accompanying Public Warrant are sold to the public in this offering, minus $0.001, and the exercise price of each pre-funded warrant will be $0.001 per share of common stock. The pre-funded warrants will be immediately exercisable and may be exercised at any time until all of the pre-funded warrants are exercised in full. This offering also relates to the shares of common stock issuable upon exercise of any pre-funded warrants sold in this offering. Each pre-funded warrant is being sold together with one Public Warrant. For each pre-funded warrant we sell, the number of shares of common stock we are offering will be decreased on a one-for-one basis. Because we will issue one Public Warrant for each share of common stock and for each pre-funded warrant to purchase one share of common stock sold in this offering, the number of Public Warrants sold in this offering will not change as a result of a change in the mix of the shares of common stock and pre-funded warrants sold. The shares of common stock and pre-funded warrants, and the accompanying Public Warrants, can only be purchased together in this offering but will be issued separately and will be immediately separable upon issuance.

 

Our common stock is currently quoted under the symbol “GTHP” on the OTC Markets. We have applied to list our common stock and the Public Warrants offered pursuant to this prospectus on the Nasdaq Capital Market (“Nasdaq”) under the symbols “GTHP” and “GTHPW”, respectively. The successful listing of our common stock and Public Warrants on Nasdaq is a condition of this offering. No assurance can be given that our application will be approved. We do not intend to apply for listing of the pre-funded warrants on any national securities exchange or trading system.

      

Investing in our common stock involves a high degree of risk. Please read “Risk Factors” beginning on page 11 of this prospectus.

 

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

 

 

 

Per Common Share and related Public Warrant

 

 

Per Pre-Funded Warrant and related Public

Warrant

 

 

Total

 

Public offering price

 

$ 10.00

 

 

$ 10.00

 

 

$ 8,900,000

 

Underwriting discount(1)(2)

 

$ .70

 

 

$ .70

 

 

$ 541,000

 

Proceeds, before expenses, to us

 

$ 9.30

 

 

$ 9.30

 

 

$ 8,359,000

 

     

(1)

Does not include our obligation to reimburse the underwriters for their expenses in an amount not to exceed $100,000. We refer you to “Underwriting” beginning on page 94 of this prospectus for information regarding expenses reimbursable by us to the underwriter.

 

 

(2)

The public offering price and underwriting discount corresponds to (x)(i) a public offering price per share of common stock of $9.99 and (ii) a public offering price per Public Warrant of $0.01, and (y)(i) a public offering price per pre-funded warrant of $9.989 and (ii) a public offering price per Public Warrant of $0.01.

 

 

(3)

The underwriters may also exercise their option to purchase up to an additional shares of common stock and/or Public Warrants to purchase up to an aggregate of shares of common stock from us, in any combination thereof, at the public offering price, less the underwriting discounts and commissions, for 45 days after the date of this prospectus.

 

 
3

Table of Contents

 

Roth Capital Partners

 

Prospectus dated    , 2022.

 

 
4

Table of Contents

 

TABLE OF CONTENTS

 

ABOUT THIS PROSPECTUS

 

6

 

PROSPECTUS SUMMARY

 

7

 

RISK FACTORS

 

16

 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

31

 

USE OF PROCEEDS

 

33

 

DIVIDEND POLICY

 

34

 

CAPITALIZATION

 

36

 

DILUTION

 

39

 

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

40

 

BUSINESS

 

48

 

REGULATORY OVERVIEW

 

56

 

MANAGEMENT

 

58

 

EXECUTIVE COMPENSATION

 

60

 

CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS

 

63

 

PRINCIPAL STOCKHOLDERS

 

64

 

DESCRIPTION OF SECURITIES

 

66

 

MATERIAL UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS

 

76

 

UNDERWRITING

 

87

 

LEGAL MATTERS

 

90

 

EXPERTS

 

90

 

ADDITIONAL INFORMATION

 

90

 

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

 

F-1

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

F-2

 

PART II INFORMATION NOT REQUIRED IN PROSPECTUS

 

II-1

 

 

 
5

Table of Contents

  

ABOUT THIS PROSPECTUS

 

Neither we nor the underwriters have authorized anyone to provide you with information different from, or in addition to, that contained in this prospectus or any free writing prospectus prepared by or on behalf of us or to which we may have referred you in connection with this offering. We take no responsibility for and can provide no assurance as to the reliability of, any other information that others may give you. Neither we nor the underwriters are making an offer to sell or seeking offers to buy these securities in any jurisdiction where, or to any person to whom, the offer or sale is not permitted. The information in this prospectus is accurate only as of the date on the front cover of this prospectus, regardless of the time of delivery of this prospectus or of any sale of our securities and the information in any free writing prospectus that we may provide you in connection with this offering is accurate only as of the date of that free writing prospectus. Our business, financial condition, results of operations and future growth prospects may have changed since those dates.

 

We obtained the industry, market and competitive position data in this prospectus from our own internal estimates and research as well as from industry and general publications and research surveys and studies conducted by third parties. This information involves many assumptions and limitations, and you are cautioned not to give undue weight to these estimates. We have not independently verified the accuracy or completeness of the data contained in these industry publications and reports. The industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of factors, including those described in “Risk Factors,” that could cause results to differ materially from those expressed in these.

 

This prospectus contains references to our trademark and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus, including logos, artwork and other visual displays, may appear without the ® or ™ symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other companies’ trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

 

Unless otherwise indicated, references in this prospectus to “$”, “dollars”, “USD” or “United States dollars” are to United States dollars.

 

 
6

Table of Contents

  

PROSPECTUS SUMMARY

 

This summary highlights information contained in other parts of this prospectus. Because it is only a summary, it does not contain all of the information that you should consider before investing in our securities and it is qualified in its entirety by, and should be read in conjunction with, the more detailed information appearing elsewhere in this prospectus. Investing in our securities involves a high degree of risk. You should carefully consider the risks and uncertainties described below, together with all of the other information in this prospectus, including our financial statements and related notes, before investing in our securities. If any of the following risks materialize, our business, financial condition, operating results and prospects could be materially and adversely affected. In that event, the price of our securities could decline, and you could lose part or all of your investment.

 

Unless the context indicates otherwise, as used in this prospectus, the terms “Guided,” “Guided Therapeutics,” “we,” “us,” “our,” “our company” and “our business” refer to Guided Therapeutics, Inc.

 

On December 30, 2021 our Board approved a 1-for-20 reverse stock split of all outstanding shares of our common stock, and the Company filed a Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company with the Secretary of State of the State of Delaware (the “Certificate of Amendment”) to effect the Reverse Stock Split. An Issuer Company Related Action Notification regarding a reverse stock split (the “Reverse Stock Split”) was submitted to Financial Industry Regulatory Authority (“FINRA”) on November 18, 2021, which was approved on May 9, 2022 and will be effective on the approximate date of the Nasdaq uplisting and financing, expected to be on or near June 30, 2022. Throughout this prospectus, references to a number of our issued and outstanding shares of common gives effect to the Reverse Stock Split, unless otherwise indicated.

 

Our Company

 

Overview

 

We are a medical technology company focused on developing innovative medical devices that have the potential to improve healthcare. Our primary focus is the sales and marketing of our LuViva® Advanced Cervical Scan non-invasive cervical cancer detection device. The underlying technology of LuViva primarily relates to the use of biophotonics for the non-invasive detection of cancers. LuViva is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point of care by scanning the cervix with light, then analyzing the reflected and fluorescent light.

 

LuViva is designed to provide a less invasive and painless alternative to conventional tests for cervical cancer screening and detection. Additionally, LuViva is designed to improve patient well-being not only because it eliminates pain, but also because it is convenient to use and provides rapid results at the point of care. We focus on two primary applications for LuViva: first, as a cancer screening tool in the developing world, where infrastructure to support traditional cancer-screening methods is limited or non-existent, and second, as a triage following traditional screening in the developed world, where a high number of false positive results cause a high rate of unnecessary and ultimately costly follow-up tests.

 

Screening for cervical cancer represents one of the most significant demands on the practice of diagnostic medicine. As cervical cancer is linked to a sexually transmitted disease -the human papillomavirus (HPV)-every woman essentially becomes “at risk” for cervical cancer simply after becoming sexually active. In the developing world, there are approximately 2.0 billion women aged 15 and older who are potentially eligible for screening with LuViva. Guidelines for screening intervals vary across the world, but U.S. guidelines call for screening every three years. Traditionally, the Pap smear screening test, or Pap test, is the primary cervical cancer screening methodology in the developed world. However, in developing countries, cancer screening using Pap tests is expensive and requires infrastructure and skill not currently existing, and not likely to be developed in the near future, in these countries.

 

We believe LuViva is the answer to the developing world’s cervical cancer screening needs. Screening for cervical cancer in the developing world often requires working directly with foreign governments or non-governmental agencies (NGOs). By partnering with governments or NGOs, we can provide immediate access to cervical cancer detection to large segments of a nation’s population as part of national or regional governmental healthcare programs, eliminating the need to develop expensive and resource-intensive infrastructures.

 

In the developed world, we believe LuViva offers a more accurate and ultimately cost-effective triage medical device, to be used once a traditional Pap test or HPV test indicates the possibility of cervical cancer. Due to the high number of false positive results from Pap tests, traditional follow-on tests entail increased medical treatment costs. We believe these costs can be minimized by utilizing LuViva as a triage to determine whether and to what degree follow-on tests are warranted.

 

 
7

Table of Contents

  

We believe our non-invasive cervical cancer detection technology can be applied to the early detection of other cancers as well. For example, we have developed prototypes and conducted limited clinical studies using our biophotonic technology for the detection of esophageal cancer. We believe that skin cancer detection is also a promising target for our biophotonic technology, but currently we are focused primarily on the large-scale commercialization of LuViva.

 

Our Potential Market

 

The Developing World

 

According to the most recent data published by the World Health Organization (WHO), cervical cancer is the fourth most frequent cancer in women worldwide, with an estimated 570,000 new cases in 2018, an increase of 40,000 cases from 2012. For women living in less developed regions, however, cervical cancer is the second most common cancer, and 9 out of 10 women who die from cervical cancer reside in low- and middle-income countries. In 2018, GLOBOCAN, the international cancer tracking agency, estimated that approximately 311,000 women died from cervical cancer, with 85% of these deaths occurring in low- and middle-income countries.

 

As noted by the WHO, in developed countries, programs are in place that enable women to get screened, making most pre-cancerous lesions identifiable at stages when they can easily be treated. Early treatment prevents up to 80% of cervical cancers in these countries. In developing countries, however, limited access to effective screening means that the disease is often not identified until it is further advanced and symptoms develop. In addition, prospects for treatment of such late-stage disease may be poor, resulting in a higher rate of death from cervical cancer in these countries.

 

We have executed formal distribution agreement covering 40 countries, some of which have since expired. Presently, we still have active contracts in place for 24 countries that cover roughly half of the world’s population, including China and certain countries in Southeast Asia (including Indonesia), and certain countries in Eastern Europe and Russia.

 

We believe that the greatest need and market opportunity for LuViva lies in screening for cervical cancer in developing countries where the infrastructure for traditional screening may be limited or non-existent.

 

In addition to private care markets, we are actively working with distributors in the following countries to implement government-sponsored screening programs: Turkey, Indonesia and several countries in Eastern Europe. The number of screening candidates in those countries is approximately 155 million.

 

The Developed World

 

The Pap test, which involves a sample of cervical tissue being placed on a slide and observed in a laboratory, is currently the most common form of cervical cancer screening. Since the introduction of screening and diagnostic methods, the number of cervical cancer deaths in the developed world has declined dramatically, due mainly to the increased use of the Pap test. However, the Pap test has a wide variation in sensitivity, which is the ability to detect the disease, and specificity, which is the ability to exclude false positives. A study by Duke University for the U.S. Agency for Health Care Policy and Research published in 1999 showed Pap test performance ranging from a 22%-95% sensitivity and 78%-90% specificity, although new technologies improving the sensitivity and specificity of the Pap test have recently been introduced and are finding acceptance in the marketplace. Currently, about 50 million Pap tests are given annually in the United States, and combined with a pelvic exam as the standard of care, has an average price of approximately $380 per exam.

 

After a Pap test returns a positive result for cervical cancer, accepted protocol calls for a visual examination of the cervix using a colposcope, usually followed by a biopsy, or tissue sampling, at one or more locations on the cervix. This method looks for visual changes attributable to cancer. There are about two million colposcope examinations annually in the United States and Europe. According to industry reports by MD Save and Costhelper Health, leading online medical service providers, the average cost of a colposcopy examination with biopsy in the United States is currently $943.

 

 
8

Table of Contents

  

Given this landscape, we believe that there is a material need and market opportunity for LuViva as a triage device in the developed world where LuViva represents a more cost- effective method of verifying a positive Pap test than the alternatives.

 

The LuViva Advanced Cervical Scan

 

LuViva is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point of care by scanning the cervix with light, then analyzing the light reflected from the cervix. The information presented by the light would be used to indicate the likelihood of cervical cancer or precancers. Our product, in addition to detecting the structural changes attributed to cervical cancer, is also designed to detect the biochemical changes that precede the development of visual lesions. In this way, cervical cancer may be detected earlier in its development, which should increase the chances of effective treatment. In addition to the device itself, operation of LuViva requires employment of our single-use, disposable calibration and alignment cervical guide.

 

To date, thousands of women in multiple international clinical settings have been tested with LuViva. As a result, more than 25 papers and presentations have been published regarding LuViva in a clinical setting, including at the International Federation of Gynecology and Obstetrics Congress in London in 2015 and at the Indonesian National Obstetrics and Gynecology (POGI) Meeting in Solo in 2016.

 

Internationally, we contract with country-specific or regional distributors. We believe that the international market will be significantly larger than the U.S. market due to the international demand for cervical cancer screening. We have executed formal distribution agreements covering over 40 countries, some of which have expired. We still have active contracts in place for countries including China and Southeast Asia (including Indonesia), Eastern Europe and Russia. In 2022, we intend to focus on other large markets such as those in the European Union, India and certain Latin American countries, such as Mexico. The ongoing conflict in Ukraine may delay filing and approval to market in Russia.

 

We currently have regulatory approval to sell LuViva in 44 countries, including the 33 countries in Europe under our Edition 3 CE Mark. In addition, we have approval to sell LuViva in 11 additional countries under country specific approvals including India, Indonesia, Singapore and Kenya. Finally, several non-EU countries such as Saudi Arabia, Egypt and South Africa rely on the CE Mark for medical devices. LuViva has also previously obtained marketing approval from Health Canada and COFEPRIS in Mexico but these have expired. In addition, in 2018, we were approved for sales and marketing in India. We currently are seeking regulatory approval to market LuViva in the United States but have not yet received approval from the U.S. Food and Drug Administration (“FDA”). As of March 31, 2022, we have sold 144 LuViva devices and approximately 76,980 single-use disposable cervical guides to international distributors.

      

We believe our non-invasive cervical cancer detection technology can be applied to the early detection of other cancers as well. As we develop LuViva as a commercial product, we continue to seek new collaborative partners focused on marketing and sales of our biophotonic technology.

 

 
9

Table of Contents

  

Manufacturing, Sales, Marketing and Distribution

 

We manufacture LuViva at our Norcross, Georgia facility. Most of the components of LuViva are custom made for us by third-party manufacturers. We adhere to ISO 13485:2003 quality standards in our manufacturing processes. Our single-use cervical guides are manufactured by a vendor that specializes in injection molding of plastic medical products. On January 22, 2017, we entered into a license agreement with Shandong Yaohua Medical Instrument Corporation (“SMI”), as amended on March 28, 2017, pursuant to which we granted SMI an exclusive global license to manufacture the LuViva device and related disposables (subject to a carve-out for manufacture in Turkey). On December 18, 2018, we entered into a co-development agreement with Newmars Technologies, Inc. (“NTI”), whereby NTI will perform final assembly of the LuViva device for its contracted distribution countries in Eastern Europe and Russia at its ISO 13485 facility in Hungary. This additional carve out has been agreed to by SMI. On August 12, 2021 the Company entered into a second amendment with SMI pursuant to which the Company has continued to grant SMI exclusive distribution, sales and manufacturing rights of the LuViva for China, Taiwan, Hong Kong and Macau.

 

We rely on distributors to sell our products. Distributors can be country exclusive or cover multiple countries in a region. We manage these distributors, provide them marketing materials and train them to demonstrate and operate LuViva. We seek distributors that have experience in gynecology and in introducing new technology into their assigned territories. Currently, we rely on SMI in distributing our products in the People's Republic of China, Macau, Hong Kong and Taiwan; we rely on NTI in distributing our products in Eastern Europe and Russia.

 

We have only limited experience in the production planning, quality system management, facility development, and production scaling that will be needed to bring production to increased sustained commercial levels. We will likely need to develop additional expertise in order to successfully manufacture, market, and distribute any future products.

 

Our Team

 

Our management team is comprised of highly experienced pharmaceutical and biotechnology executives with successful track records in researching, developing, gaining approval for and commercializing novel medicines to treat serious diseases. Each member of our management team has over 20 to 30 years of industry experience, including our CEO and COO. These individuals have held leadership positions with industry leaders such as Abbott Laboratories, and GE Health among others, and also with early stage biotechnology and emerging technology companies such as Biofield Corp and SpectRx, Inc. Additionally, the team has significant experience in company formation, capital raises, mergers/acquisitions, business development, and sales and marketing in the pharmaceutical industry. Our board of directors (the “Board”) is constituted by individuals with significant experience in the pharmaceutical and biotechnology industries.

 

Our Strengths

 

Currently, we are the only commercial stage company with a biophotonic technology that potentially addresses a large primary screening market and a potential R&D pipeline that could improve the early detection of numerous cancers that afflict men and women. Key strengths include:

     

 

·

The engineering and production risks have been largely addressed as we have sold over 100 working systems worldwide.

 

 

 

 

·

Regulatory approvals have been granted covering over 40 countries.

 

 

 

 

·

We have legitimate pathways for securing marketing approvals in the two largest medical markets - the US and China, within a 2-3 year period.

 

 

 

 

·

The clinical results of our technology have been published in leading peer-reviewed journals by world-famous, thought-leading physicians.

   

Our Business Strategy

 

Our near term goals are to accomplish the following over the next two years by pursuing the following strategies:

 

 

·

Seek US FDA approval by completing a clinical trial.

 

 

 

 

·

Contingent upon FDA approval, discuss opportunities to partner with a larger U.S. based company for distribution in the U.S. At the same time, we intend to build a small dedicated sales force based near major metropolitan centers and focused on generating sales at large centralized Ob-Gyn practices.

 

 

 

 

·

Seek Chinese FDA approval working with our existing partner in China, Shandong Medical Instrumentation Co. Ltd.

 

 

 

 

·

Pursue regulatory approval in Russia and work with our partner in Eastern Europe, Newmars Technology, Inc. to generate sales in Europe.

 

 

 

 

·

Continue to selectively support sales through our distributors in large countries such as Indonesia.

 

While we plan to pursue regulatory approval in Russia, the ongoing conflict in Ukraine may delay filing and approval to market.

 

 
10

Table of Contents

  

Risk Factor Summary

 

Our ability to implement our business strategy is subject to numerous risks that you should be aware of before making an investment decision. These risks are described more fully in the section entitled “Risk Factors” in this prospectus. These risks include, among others:

 

 

·

Although we will be required to raise additional funds in 2022, there is no assurance that such funds can be raised on terms that we would find acceptable, on a timely basis, or at all.

 

 

 

 

·

If we cannot obtain additional funds when needed, we will not be able to implement our business plan.

 

 

 

 

·

We have a history of losses, and we expect losses to continue.

 

 

 

 

·

Our ability to sell our products is controlled by government regulations, and we may not be able to obtain any necessary clearances or approvals.

 

 

 

 

·

In foreign countries, including European countries, we are subject to government regulation, which could delay or prevent our ability to sell our products in those jurisdictions.

 

 

 

 

·

In the United States, where we are subject to regulation by the U.S. FDA, our product has not yet been approved which could prevent us from selling our products domestically.

 

 

 

 

·

Even if we obtain clearance or approval to sell our products, we are subject to ongoing requirements and inspections that could lead to the restriction, suspension or revocation of our clearance.

 

 

 

 

·

We are currently delinquent on our federal payroll and unemployment taxes.

 

Listing on the Nasdaq Capital Market

 

Our common stock is currently quoted on the OTC Markets under the symbol “GTHP”. In connection with this offering, we have applied to list our common stock and Public Warrants offered in the offering on the Nasdaq under the symbols “GTHP” and “GTHPW”, respectively. If our listing application is approved, we expect to list our common stock and the Public Warrants offered in the offering on Nasdaq upon consummation of the offering, at which point our common stock will cease to be traded on the OTC Markets. No assurance can be given that our listing application will be approved. Nasdaq listing requirements include, among other things, a stock price threshold. As a result, in order to meet such requirement, on December 20, 2021 we approved a 1-for-20 reverse stock split of our common stock. There can be no assurance that our common stock and Public Warrants will be listed on the Nasdaq. However, we will not complete this offering if we are not so listed. We do not intend to apply for listing of the pre-funded warrants on any national securities exchange or trading system.

 

Corporate Information

 

We were incorporated in the state of Delaware in 1992, under the Delaware General Corporation Law, or “DGCL”, under the name “SpectRx, Inc.” and subsequently changed our name to Guided Therapeutics, Inc. on February 22, 2008. At the same time, we renamed our wholly owned subsidiary, InterScan, Inc. which originally had been incorporated as “Guided Therapeutics, Inc.” Our telephone number is (770) 242-8723. Our website address is https://www.guidedinc.com/. The information contained in or accessible from our website is not incorporated into this prospectus, and you should not consider it part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference.

 

 
11

Table of Contents

  

The Offering

 

Common stock offered by us 

 

890,000 shares, based on a public offering price of $10.00 per share of common stock and related Public Warrant.

 

 

 

Pre-funded warrants offered by us

 

We are also offering to certain purchasers whose purchase of common stock in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of the outstanding shares of our common stock immediately following the consummation of this offering, the opportunity to purchase, if such purchasers so choose, up to 178,000 pre-funded warrants, in lieu of shares of common stock that would otherwise result in any such purchaser’s beneficial ownership exceeding 4.99% (or, at the election of the purchaser, 9.99%) of the outstanding shares of our common stock. Each pre-funded warrant will be exercisable for one share of common stock. The purchase price of each pre-funded warrant and the accompanying Public Warrant will equal the price at which the shares of common stock and the accompanying Public Warrant are being sold to the public in this offering, and the exercise price of each pre-funded warrant will be $0.001 per share. The pre-funded warrants will be exercisable immediately and may be exercised at any time until all of the pre-funded warrants are exercised in full. This offering also relates to the shares of common stock issuable upon exercise of any pre-funded warrants sold in this offering. For each pre-funded warrant we sell, the number of shares of common stock we are offering will be decreased on a one-for-one basis. Because we will issue one Public Warrant for each share of common stock and for each pre-funded warrant to purchase one share of common stock sold in this offering, the number of Public Warrants sold in this offering will not change as a result of a change in the mix of the shares of common stock and pre- funded warrants sold. For additional information, see “Description of Securities—Pre-Funded Warrants to be Issued as Part of this Offering” on page 73 of this prospectus.

 

 

 

Description of Public Warrants

 

We are offering Public Warrants to purchase an aggregate of 890,000 shares of common stock. Each share of common stock and each pre-funded warrant to purchase one share of common stock is being sold together with one Public Warrant to purchase one share of common stock. Each Public Warrant will have an exercise price of $12.40 per share, will be upon issuance exercisable and will expire on the fifth anniversary of the original issuance date. The shares of common stock and pre-funded warrants, and the accompanying Public Warrants, as the case may be, can only be purchased together in this offering but will be issued separately and will be immediately separable upon issuance. This prospectus also relates to the offering of the shares of common stock issuable upon exercise of the Public Warrants. For additional information, see “Description of Securities—Public Warrants to be Issued as Part of this Offering” on page 70 of this prospectus.

 

 

 

Shares of common stock to be outstanding after this offering

 

2,269,174 shares (or 2,402,674 shares if the underwriters exercise their option to purchase additional shares in full).

 

 

 

Underwriters’ option to purchase additional securities

 

We have granted the underwriters a 45-day option to purchase up to 133,500 additional shares of common stock and/or Public Warrants at the public offering price, less underwriting discounts and commissions on the same terms as set forth in this prospectus.

 

 
12

Table of Contents

 

Use of proceeds 

 

We estimate that the proceeds to us from the sale of shares of our common stock in this offering will be approximately $8,900,000, or $10,235,000 if the underwriters exercise their option to purchase additional shares in full, assuming an initial public offering price of $10 per share and related Public Warrants as set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. We intend to use the net proceeds of this offering to fund completion of the US FDA clinical trial and application for FDA approval for LuViva, sales and marketing, debt repayment, and general corporate purposes. See “Use of Proceeds.”

 

 

 

Proposed Nasdaq Capital Market symbols

 

We have applied to list our common stock and Public Warrants offered pursuant to this prospectus on the Nasdaq under the symbols “GTHP” and “GTHPW”, respectively. The successful listing of our common stock and Public Warrants on Nasdaq is a condition of this offering. However, there can be no assurance that Nasdaq will approve our listing application.

 

 

 

No Listing of Pre-funded Warrants

 

We do not intend to apply for listing of the pre-funded warrants on any national securities exchange or trading system. Without an active trading market, the liquidity of the pre-funded warrants will be limited.

 

 

 

Risk Factors

 

Investment in our securities involves substantial risks. You should read this prospectus carefully, including the section entitled “Risk Factors” and the financial statements and the related notes to those statements included in this prospectus, before investing in our common stock.

    

The number of shares of common stock to be outstanding after this offering is based on an aggregate of 1,379,174 shares outstanding as of June 5, 2022. The disclosure above does not include:

   

 

·

75,000 shares of common stock issuable upon exercise of outstanding options as of March 31, 2022, at a weighted average exercise price of $9.80 per share, of which 52,261 shares were vested as of such date;

 

 

 

 

·

250,470 shares of common stock reserved for future issuance under our stock option plan as of March 31, 2022, plus any future increases in the number of shares of common stock reserved for issuance under our stock option plan pursuant to evergreen provisions;

 

 

 

 

·

shares of common stock that may be issued upon the exercise of pre-funded warrants and Public Warrants issued in this offering; and

 

 

 

 

·

1,552,227 shares of common stock underlying warrants and convertible debt at a weighted average exercise price of $6.24 per share.

 

Except as otherwise indicated herein, all information in this prospectus, including the number of shares that will be outstanding after this offering, assumes no exercise by the underwriters of their option to purchase additional securities.

 

 
13

Table of Contents

 

GUIDED THERAPEUTICS, INC. AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited, in thousands)

 

 

 

Three Months Ended

 

 

 

March 31,

 

 

 

2022

 

 

2021

 

 

 

 

 

 

 

 

Sales - devices and disposables

 

$ 5

 

 

$ -

 

Cost of goods sold

 

 

1

 

 

 

-

 

Gross profit

 

 

4

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

Research and development

 

 

21

 

 

 

16

 

Sales and marketing

 

 

40

 

 

 

36

 

General and administrative

 

 

386

 

 

 

771

 

Total operating expenses

 

 

447

 

 

 

823

 

 

 

 

 

 

 

 

 

 

Loss from operations

 

 

(443 )

 

 

(823 )

 

 

 

 

 

 

 

 

 

Other income (expenses):

 

 

 

 

 

 

 

 

Interest expense

 

 

(101 )

 

 

(141 )

Change in fair value of derivative liability

 

 

(6 )

 

 

(88 )

Gain from extinguishment of debt

 

 

41

 

 

 

87

 

Change in fair value of warrants

 

 

-

 

 

 

448

 

Other expenses

 

 

2

 

 

 

-

 

Total other income (expense)

 

 

(64 )

 

 

306

 

 

 

 

 

 

 

 

 

 

Loss before income taxes

 

 

(507 )

 

 

(517 )

Provision for income taxes

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

(507 )

 

 

(517 )

Preferred stock dividends

 

 

(548 )

 

 

(55 )

 

 

 

 

 

 

 

 

 

NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS

 

$ (1,055 )

 

$ (572 )

  

 
14

Table of Contents

 

SUMMARY FINANCIAL DATA 

GUIDED THERAPEUTICS, INC. AND SUBSIDIARY 

CONSOLIDATED STATEMENTS OF OPERATIONS  

(in thousands) 

 

 

 

Years Ended

 

 

 

December 31,

 

 

 

2021

 

 

2020

 

 

 

 

 

 

 

 

Sales - devices and disposables

 

$ 81

 

 

$ 102

 

Cost of goods sold (recovered)

 

 

61

 

 

 

(41 )

Gross profit

 

 

20

 

 

 

143

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

Research and development

 

 

69

 

 

 

143

 

Sales and marketing

 

 

141

 

 

 

139

 

General and administrative

 

 

2,172

 

 

 

913

 

Total operating expenses

 

 

2,382

 

 

 

1,195

 

 

 

 

 

 

 

 

 

 

Loss from operations

 

 

(2,362 )

 

 

(1,052 )

 

 

 

 

 

 

 

 

 

Other income (expenses):

 

 

 

 

 

 

 

 

Interest expense

 

 

(1,150 )

 

 

(1,056 )

Change in fair value of derivative liability

 

 

(91 )

 

 

(25 )

Gain (loss) from extinguishment of debt

 

 

578

 

 

 

(296 )

Change in fair value of warrants

 

 

448

 

 

 

1,879

 

Other income

 

 

507

 

 

 

271

 

Total other income

 

 

292

 

 

 

773

 

 

 

 

 

 

 

 

 

 

Loss before income taxes

 

 

(2,070 )

 

 

(279 )
Provision for income taxes

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

(2,070 )

 

 

(279 )
Preferred stock dividends

 

 

(361 )

 

 

(122 )

 

 

 

 

 

 

 

 

 

NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS

 

$ (2,431 )

 

$ (401 )

 

 

 

 

Year ended December 31,

 

 

 

2021

 

 

2020

 

Balance Sheet Data:

 

 

 

 

 

 

Total current assets

 

$ 1,637

 

 

$ 896

 

Total noncurrent assets

 

 

403

 

 

 

454

 

Working capital

 

 

(4,057 )

 

 

(8,066 )
Total assets

 

 

2,040

 

 

 

1,350

 

Current liabilities

 

 

5,694

 

 

 

8,962

 

Non current liabilities

 

 

1,791

 

 

 

3,243

 

Total liabilities

 

 

7,485

 

 

 

12,205

 

Accumulated deficit

 

 

(142,387 )

 

 

(139,956 )
Total stockholders deficit

 

$ (5,445 )

 

$ (10,855 )

 

 
15

Table of Contents

 

RISK FACTORS

 

Investing in our common stock involves a high degree of risk. You should carefully consider each of the following risks, together with all other information set forth in this prospectus, including the consolidated financial statements and the related notes, before making a decision to buy our securities. If any of the following risks actually occurs, our business could be harmed. In that case, the trading price of our common stock could decline, and you may lose all or part of your investment.

 

Risks Related to Our Business and Industry

 

Although we may be required to raise additional funds in 2022, if the proceeds of this offering is not sufficient to carry out our business, there is no assurance that such funds can be raised on terms that we would find acceptable, on a timely basis, or at all.

 

Additional debt or equity financing may be required for us to continue as a going concern. We may seek to obtain additional funds for the financing of our cervical cancer detection business through additional debt or equity financings and/or new collaborative arrangements. Management believes that additional financing, if obtainable, will be sufficient to support planned operations only for a limited period. Management has implemented operating actions to reduce cash requirements. Any required additional funding may not be available on terms attractive to us, on a timely basis, or at all. If we cannot obtain additional funds or achieve profitability, we may not be able to continue as a going concern.

 

Because we must obtain additional funds through financing transactions or through new collaborative arrangements in order to grow the revenues of our cervical cancer detection product line, there exists substantial doubt about our ability to continue as a going concern. Therefore, it will be necessary to raise additional funds.  There can be no assurance that we will be able to raise these additional funds. If we do not secure additional funding when needed, we will be unable to conduct all of our product development efforts as planned, which may cause us to alter our business plan in relation to the development of our products. Even if we obtain additional funding, we will need to achieve profitability thereafter.

 

Our independent registered public accountants’ report on our consolidated financial statements as of and for the year ended December 31, 2021, indicated that there was substantial doubt about our ability to continue as a going concern because we had suffered recurring losses from operations and had an accumulated deficit of $142.4 million at December 31, 2021. The accumulated deficit from December 31, 2018 through March 31, 2022 is summarized as follows:

 

Accumulated deficit, from inception to 12/31/2018

$

137.7 million

 

Net loss for fiscal year 2019, ended 12/31/2019

$

1.9 million

 

Accumulated deficit, from inception to 12/31/2019

$

139.6 million

 

Preferred dividends for fiscal year 2020

$

0.1 million

 

Net loss for the year ended 12/31/2020

$

0.3 million

 

Accumulated deficit, from inception to 12/31/2020

$

140.0 million

 

Preferred dividends for fiscal year 2021

$

0.4million

 

Net loss for the year ended 12/31/2021

$

2.0 million

 

Accumulated deficit, from inception to 12/31/2021

$

142.4 million

 

Preferred dividends for the quarter ended 3/31/2022

$

0.5 million

 

Net loss for the quarter ended 3/31/2022

$

0.5 million

 

Accumulated deficit, from inception to 3/31/2022

$

143.4 million

 

 

Our management has implemented reductions in operating expenditures and reductions in some development activities. We have determined to make cervical cancer detection the focus of our business. We are managing the development of our other programs only when funds are made available to us via grants or contracts with government entities or strategic partners. However, there can be no assurance that we will be able to successfully implement or continue these plans.

 

 
16

Table of Contents

  

If we cannot obtain additional funds when needed, we will not be able to implement our business plan.

 

We require substantial additional capital to develop our products, including completing product testing and clinical trials, obtaining all required regulatory approvals and clearances, beginning and scaling up manufacturing, and marketing our products. We have historically financed our operations though the public and private sale of debt and equity, funding from collaborative arrangements, and grants. Any failure to achieve adequate funding in a timely fashion would delay our development programs and could lead to abandonment of our business plan. To the extent we cannot obtain additional funding, our ability to continue to manufacture and sell our current products, or develop and introduce new products to market, will be limited. Further, financing our operations through the public or private sale of debt or equity may involve restrictive covenants or other provisions that could limit how we conduct our business or finance our operations. Financing our operations through collaborative arrangements generally means that the obligations of the collaborative partner to fund our expenditures are largely discretionary and depend on a number of factors, including our ability to meet specified milestones in the development and testing of the relevant product. We may not be able to obtain an acceptable collaboration partner, and even if we do, we may not be able to meet these milestones, or the collaborative partner may not continue to fund our expenditures.

 

We have a history of losses, and we expect losses to continue.

 

We have never been profitable and we have had operating losses since our inception. We expect our operating losses to continue as we continue to expend substantial resources to complete commercialization of our products, obtain regulatory clearances or approvals; build our marketing, sales, manufacturing and finance capabilities, and conduct further research and development. The further development and commercialization of our products will require substantial development, regulatory, sales and marketing, manufacturing and other expenditures. We have only generated limited revenues from product sales. As of March 31, 2022 and December 31, 2021, our accumulated deficit was approximately $143.4 million and $142.4 million, respectively.

 

We are currently delinquent with our federal and state payroll and unemployment taxes.

 

Although we have been experiencing recurring losses, we are obligated to file tax returns for compliance with IRS regulations and that of applicable state jurisdictions. We have established payment plans for the outstanding federal and state payroll and unemployment taxes with IRS, the Department of Revenue for the State of Georgia and Department of Labor for the State of Georgia. As of the date of this prospectus, we are delinquent on federal payroll taxes for first quarter of 2017, and federal unemployment taxes for the year 2016. Per the terms of our payment plan we are required to make monthly payments in the amount of $1,009 until the balances are paid in full. We are delinquent on state payroll taxes for first quarter of 2017 and fourth quarter of 2016. Per the terms of our payment plan we are required to make monthly payments in the amount of $210 until the balances are paid in full. We are delinquent on our state unemployment taxes and per the terms of our payment plan we are required to make a minimum monthly payment in the amount of $2,629 until the balance is paid in full.

 

Our ability to sell our products is controlled by government regulations, and we may not be able to obtain any necessary clearances or approvals.

 

The design, manufacturing, labeling, distribution and marketing of medical device products are subject to extensive and rigorous government regulation in most of the markets in which we sell, or plan to sell, our products, which can be expensive and uncertain and can cause lengthy delays before we can begin selling our products in those markets.

 

In foreign countries, including European countries, we are subject to government regulation, which could delay or prevent our ability to sell our products in those jurisdictions.

 

In order for us to market our products in Europe and some other international jurisdictions, we and our distributors and agents must obtain required regulatory registrations or approvals. We must also comply with extensive regulations regarding safety, efficacy and quality in those jurisdictions. We may not be able to obtain the required regulatory registrations or approvals, or we may be required to incur significant costs in obtaining or maintaining any regulatory registrations or approvals we receive. Delays in obtaining any registrations or approvals required for marketing our products, failure to receive these registrations or approvals, or future loss of previously obtained registrations or approvals would limit our ability to sell our products internationally. For example, international regulatory bodies have adopted various regulations governing product standards, packaging requirements, labeling requirements, import restrictions, tariff regulations, duties and tax requirements. These regulations vary from country to country. In order to sell our products in Europe, in 2018 we had to undergo an inspection and re-file for ISO 13485:2016 and the CE Mark, which is an international symbol of quality and compliance with applicable European medical device directives. Failure to maintain ISO 13485:2016 certification or CE mark certification or other international regulatory approvals would prevent us from selling in some countries in the European Union.

 

 
17

Table of Contents

  

As of March 31, 2022, our products have achieved and maintained both ISO 13485:2016 certification and the CE Mark through our contract manufacturer, Newmars Technologies.

 

For our products to be marketed and sold in the People’s Republic of China, they must gain approval from the Chinese National Medical Products Administration (NMPA), formerly known as the Chinese Food and Drug Administration (Chinese FDA). We are working with our Chinese partner, Shandong Yaohua Medical Instrument Corporation, to achieve NMPA approval and as of December 31, 2021 had passed compliance testing for device safety and has enrolled approximately 150 people in their clinical trial, which is expected to be completed in 2022, although there can be no assurances that this schedule will be met.

    

Our business is subject to the risks of international operations.

 

Our business and financial results could be adversely affected due to a variety of factors, including:

 

 

·

changes in a specific country or region’s political and cultural climate or economic condition, including change in governmental regime;

 

·

unexpected or unfavorable changes in foreign laws, regulatory requirements and related interpretations;

 

·

difficulty of effective enforcement of contractual provisions in local jurisdictions;

 

·

inadequate intellectual property protection in foreign countries;

 

·

trade protection measures, import or export licensing requirements such as Export Administration Regulations promulgated by the U.S. Department of Commerce and fines, penalties or suspension or revocation of export privileges;

 

·

trade sanctions imposed by the United States or other governments with jurisdictional authority over our business operations;

 

·

the effects of applicable and potentially adverse foreign tax law changes;

 

·

significant adverse changes in foreign currency exchange rates;

 

·

longer accounts receivable cycles;

 

·

managing a geographically dispersed workforce; and

 

·

compliance with the U.S. Foreign Corrupt Practices Act, or FCPA, and the Office of Foreign Assets Control regulations, particularly in emerging markets.

 

In foreign countries, particularly in those with developing economies, certain business practices may exist that are prohibited by laws and regulations applicable to us, such as the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act and other anti-corruption laws. Although our policies and procedures require compliance with these laws and are designed to facilitate compliance with these laws, our employees, contractors and agents may take actions in violation of applicable laws or our policies. Any such violation, even if prohibited by our policies, could have a material adverse effect on our business and reputation.

 

Our international businesses must comply with applicable laws such as the U.S. Foreign Corrupt Practices Act. Failure to maintain compliance with or adapt to changes in any of the aforementioned requirements could result in fines, penalties or regulatory actions that could have an adverse impact on our business, results of operations and financial condition.

 

While we plan to pursue regulatory approval in Russia, the ongoing conflict in Ukraine may delay filing and approval to market in Russia.  It is unclear how long any delays may last due to the uncertainty of the situation both in Ukraine and Russia..

 

The conflict in Ukraine, which has already had an impact on financial markets, could result in additional repercussions in our operating business, including delays in obtaining regulatory approval to market our products in Russia. The future impact of the conflict is highly uncertain and cannot be predicted, and we cannot provide any assurance that the conflict will not have a material adverse impact on our operations or future results or filings with regulatory health authorities.

 

Russia’s invasion of Ukraine, and sanctions brought by the United States and other countries against Russia, have caused disruptions in many business sectors outside of the medical sector and have resulted in significant market disruptions and increased volatility in the price of certain commodities, including oil and natural gas.

 

On February 24, 2022, Russia launched a large-scale invasion of Ukraine. The extent and duration of the military action, resulting sanctions and future market disruptions in the region are impossible to predict, but could be significant and may have a severe adverse effect on the region. Among other things, the conflict has resulted in increased volatility in the markets for certain securities and commodities, including oil and natural gas, and other sectors.

 

The United States and other countries and certain international organizations have imposed broad-ranging economic sanctions on Russia and certain Russian individuals, banking entities and corporations as a response to Russia’s invasion of Ukraine.  On March 8, 2022, the United States announced that it would ban imports of oil, natural gas and coal from Russia. The impact of this announcement on commodities and futures prices is difficult to predict and depends on a number of factors, including whether other countries act in the same manner, but such impact could be significant.

 

Actual and threatened responses to Russia’s invasion, as well as a rapid peaceful resolution to the conflict, may also impact the markets for certain commodities, such as oil and natural gas, and may have collateral impacts, including increased volatility, and cause disruptions to availability of certain commodities, commodity and futures prices and the supply chain globally. At this time, the situation is rapidly evolving and may evolve in a way that could have a negative impact on the fund in the future.

 

In the United States, our products would be subject to regulation by the U.S. FDA, which could prevent us from selling our products domestically.

 

In order for us to market our products in the United States, we must obtain clearance or approval from the U.S. Food and Drug Administration, or U.S. FDA. We cannot be sure that:

 

 

·

we, or any collaborative partner, will make timely filings with the U.S. FDA;

 

·

the U.S. FDA will act favorably or quickly on these submissions;

 

·

we will not be required to submit additional information or perform additional clinical studies; or

 

·

we will not face other significant difficulties and costs necessary to obtain U.S. FDA clearance or approval.

 

 
18

Table of Contents

  

It can take several years from initial filing of a PMA application and require the submission of extensive supporting data and clinical information. The U.S. FDA may impose strict labeling or other requirements as a condition of its clearance or approval, any of which could limit our ability to market our products domestically. Further, if we wish to modify a product after U.S. FDA approval of a PMA application, including changes in indications or other modifications that could affect safety and efficacy, additional clearances or approvals will be required from the U.S. FDA. Any request by the U.S. FDA for additional data, or any requirement by the U.S. FDA that we conduct additional clinical studies, could result in a significant delay in bringing our products to market domestically and require substantial additional research and other expenditures. Similarly, any labeling or other conditions or restrictions imposed by the U.S. FDA could hinder our ability to effectively market our products domestically. Further, there may be new U.S. FDA policies or changes in U.S. FDA policies that could be adverse to us.

 

Currently, we have not obtained clearance or approval from the U.S. FDA, however we have agreed with the U.S. FDA on the clinical trial protocol and are preparing to start the study of approximately 400 women in the third quarter of 2022 at up to three clinical sites where the protocol is now under review for approval to allow the start of the study.

 

Even if we obtain clearance or approval to sell our products, we are subject to ongoing requirements and inspections that could lead to the restriction, suspension or revocation of our clearance.

 

We, as well as any potential collaborative partners, will be required to adhere to applicable regulations in the markets in which we operate and sell our products, regarding good manufacturing practice, which include testing, control, and documentation requirements. Ongoing compliance with good manufacturing practice and other applicable regulatory requirements will be strictly enforced applicable regulatory agencies. Failure to comply with these regulatory requirements could result in, among other things, warning letters, fines, injunctions, civil penalties, recall or seizure of products, total or partial suspension of production, failure to obtain premarket clearance or premarket approval for devices, withdrawal of approvals previously obtained, and criminal prosecution. The restriction, suspension or revocation of regulatory approvals or any other failure to comply with regulatory requirements would limit our ability to operate and could increase our costs.

 

We depend on a limited number of distributors and any reduction, delay or cancellation of an order from these distributors or the loss of any of these distributors could cause our revenue to decline.

 

Each year we have had one or a few distributors that have accounted for substantially all of our limited revenues. As a result, the termination of a purchase order with any one of these distributors may result in the loss of substantially all of our revenues. We are constantly working to develop new relationships with existing or new distributors, but despite these efforts we may not be successful at generating new orders to maintain similar revenues as current purchase orders are filled. In addition, since a significant portion of our revenues is derived from a relatively few distributors, any financial difficulties experienced by any one of these distributors, or any delay in receiving payments from any one of these distributors, could have a material adverse effect on our business, results of operations, financial condition and cash flows.

 

To successfully market and sell our products internationally, we must address many issues with which we have limited experience.

 

All of our sales of LuViva to date have been to distributors outside of the United States. We expect that substantially all of our business will continue to come from sales in foreign markets, through increased penetration in countries where we currently sell LuViva, combined with expansion into new international markets. However, international sales are subject to a number of risks, including:

 

 

·

difficulties in staffing and managing international operations;

 

·

difficulties in penetrating markets in which our competitors’ products may be more established;

 

·

reduced or no protection for intellectual property rights in some countries;

 

·

export restrictions, trade regulations and foreign tax laws;

 

·

fluctuating foreign currency exchange rates;

 

·

foreign certification and regulatory clearance or approval requirements;

 

·

difficulties in developing effective marketing campaigns for unfamiliar, foreign countries;

 

 
19

Table of Contents

 

 

·

customs clearance and shipping delays;

 

·

political and economic instability; and

 

·

preference for locally produced products.

 

If one or more of these risks were realized, it could require us to dedicate significant resources to remedy the situation, and even if we are able to find a solution, our revenues may still decline.

 

To market and sell LuViva internationally, we depend on distributors and they may not be successful.

 

We currently depend almost exclusively on third-party distributors to sell and service LuViva internationally and to train our international distributors, and if these distributors terminate their relationships with us or under-perform, we may be unable to maintain or increase our level of international revenue. We will also need to engage additional international distributors to grow our business and expand the territories in which we sell LuViva. Distributors may not commit the necessary resources to market, sell and service LuViva to the level of our expectations. If current or future distributors do not perform adequately, or if we are unable to engage distributors in particular geographic areas, our revenue from international operations will be adversely affected.

 

Our success largely depends on our ability to maintain and protect the proprietary information on which we base our products.

 

Our success depends in large part upon our ability to maintain and protect the proprietary nature of our technology through the patent process, as well as our ability to license from others patents and patent applications necessary to develop our products. If any of our patents are successfully challenged, invalidated or circumvented, or our right or ability to manufacture our products was to be limited, our ability to continue to manufacture and market our products could be adversely affected. In addition to patents, we rely on trade secrets and proprietary know-how, which we seek to protect, in part, through confidentiality and proprietary information agreements. The other parties to these agreements may breach these provisions, and we may not have adequate remedies for any breach. Additionally, our trade secrets could otherwise become known to or be independently developed by competitors.

 

As of March 31, 2022, we have been issued, or have rights to, 27 U.S. patents (including those under license). In addition, we have filed for, or have rights to, one U.S. patents (including those under license) that is still pending. There are additional international patents and pending applications. One or more of the patents we hold directly or license from third parties, including those for our cervical cancer detection products, may be successfully challenged, invalidated or circumvented, or we may otherwise be unable to rely on these patents. These risks are also present for the process we use or will use for manufacturing our products. In addition, our competitors, many of whom have substantial resources and have made substantial investments in competing technologies, may apply for and obtain patents that prevent, limit or interfere with our ability to make, use and sell our products, either in the United States or in international markets.

  

The medical device industry has been characterized by extensive litigation regarding patents and other intellectual property rights. In addition, the U.S. Patent and Trademark Office, or USPTO, may institute interference proceedings. The defense and prosecution of intellectual property suits, USPTO proceedings and related legal and administrative proceedings are both costly and time consuming. Moreover, we may need to litigate to enforce our patents, to protect our trade secrets or know-how, or to determine the enforceability, scope and validity of the proprietary rights of others. Any litigation or interference proceedings involving us may require us to incur substantial legal and other fees and expenses and may require some of our employees to devote all or a substantial portion of their time to the proceedings. An adverse determination in the proceedings could subject us to significant liabilities to third parties, require us to seek licenses from third parties or prevent us from selling our products in some or all markets. We may not be able to reach a satisfactory settlement of any dispute by licensing necessary patents or other intellectual property. Even if we reached a settlement, the settlement process may be expensive and time consuming, and the terms of the settlement may require us to pay substantial royalties. An adverse determination in a judicial or administrative proceeding or the failure to obtain a necessary license could prevent us from manufacturing and selling our products.

 

 
20

Table of Contents

 

We may not be able to generate sufficient sales revenues to sustain our growth and strategy plans.

 

Our cervical cancer diagnostic activities have been financed to date through a combination of government grants, strategic partners and direct investment. Growing revenues for this product is the main focus of our business. In order to effectively market the cervical cancer detection product, additional capital will be needed.

 

Additional product lines involve the modification of the cervical cancer detection technology for use in other cancers. These product lines are only in the earliest stages of research and development and are currently not projected to reach market for several years. Our goal is to receive enough funding from government grants and contracts, as well as payments from strategic partners, to fund development of these product lines without diverting funds or other necessary resources from the cervical cancer program.

 

Because our products, which use different technology or apply technology in different ways than other medical devices, are or will be new to the market, we may not be successful in launching our products and our operations and growth would be adversely affected.

 

Our products are based on new methods of cancer detection. If our products do not achieve significant market acceptance, our sales will be limited and our financial condition may suffer. Physicians and individuals may not recommend or use our products unless they determine that these products are an attractive alternative to current tests that have a long history of safe and effective use. To date, our products have been used by only a limited number of people, and few independent studies regarding our products have been published. The lack of independent studies limits the ability of doctors or consumers to compare our products to conventional products.

 

If we are unable to compete effectively in the highly competitive medical device industry, our future growth and operating results will suffer.

 

The medical device industry in general and the markets in which we expect to offer products in particular, are intensely competitive. Many of our competitors have substantially greater financial, research, technical, manufacturing, marketing and distribution resources than we do and have greater name recognition and lengthier operating histories in the health care industry. We may not be able to effectively compete against these and other competitors. A number of competitors are currently marketing traditional laboratory-based tests for cervical cancer screening and diagnosis. These tests are widely accepted in the health care industry and have a long history of accurate and effective use. Further, if our products are not available at competitive prices, health care administrators who are subject to increasing pressures to reduce costs may not elect to purchase them. Also, a number of companies have announced that they are developing, or have introduced, products that permit non-invasive and less invasive cancer detection. Accordingly, competition in this area is expected to increase.

 

Furthermore, our competitors may succeed in developing, either before or after the development and commercialization of our products, devices and technologies that permit more efficient, less expensive non-invasive and less invasive cancer detection. It is also possible that one or more pharmaceutical or other health care companies will develop therapeutic drugs, treatments or other products that will substantially reduce the prevalence of cancers or otherwise render our products obsolete.

 

We have limited manufacturing experience, which could limit our growth.

 

We do not have manufacturing experience that would enable us to make products in the volumes that would be necessary for us to achieve significant commercial sales, and we rely upon our suppliers. In addition, we may not be able to establish and maintain reliable, efficient, full-scale manufacturing at commercially reasonable costs in a timely fashion. Difficulties we encounter in manufacturing scale-up, or our failure to implement and maintain our manufacturing facilities in accordance with good manufacturing practice regulations, international quality standards or other regulatory requirements, could result in a delay or termination of production. In the past, we have had substantial difficulties in establishing and maintaining manufacturing for our products and those difficulties impacted our ability to increase sales. Companies often encounter difficulties in scaling up production, including problems involving production yield, quality control and assurance, and shortages of qualified personnel.

 

 
21

Table of Contents

 

Since we rely on sole source suppliers for several of the components used in our products, any failure of those suppliers to perform would hurt our operations.

 

Several of the components used in our products or planned products, are available from only one supplier, and substitutes for these components could not be obtained easily or would require substantial modifications to our products. Any significant problem experienced by one of our sole source suppliers may result in a delay or interruption in the supply of components to us until that supplier cures the problem or an alternative source of the component is located and qualified. Any delay or interruption would likely lead to a delay or interruption in our manufacturing operations. For our products that require premarket approval, the inclusion of substitute components could require us to qualify the new supplier with the appropriate government regulatory authorities. Alternatively, for our products that qualify for premarket notification, the substitute components must meet our product specifications.

 

Because we operate in an industry with significant product liability risk, and we have not specifically insured against this risk, we may be subject to substantial claims against our products.

 

The development, manufacture and sale of medical products entail significant risks of product liability claims. We currently have no product liability insurance coverage beyond that provided by our general liability insurance. Accordingly, we may not be adequately protected from any liabilities, including any adverse judgments or settlements, we might incur in connection with the development, clinical testing, manufacture and sale of our products. A successful product liability claim or series of claims brought against us that result in an adverse judgment against or settlement by us in excess of any insurance coverage could seriously harm our financial condition or reputation. In addition, product liability insurance is expensive and may not be available to us on acceptable terms, if at all.

 

The availability of third party reimbursement for our products is uncertain, which may limit consumer use and the market for our products.

 

In the United States and elsewhere, sales of medical products are dependent, in part, on the ability of consumers of these products to obtain reimbursement for all or a portion of their cost from third-party payors, such as government and private insurance plans. Any inability of patients, hospitals, physicians and other users of our products to obtain sufficient reimbursement from third-party payors for our products, or adverse changes in relevant governmental policies or the policies of private third-party payors regarding reimbursement for these products, could limit our ability to sell our products on a competitive basis. We are unable to predict what changes will be made in the reimbursement methods used by third-party health care payors. Moreover, third-party payors are increasingly challenging the prices charged for medical products and services, and some health care providers are gradually adopting a managed care system in which the providers contract to provide comprehensive health care services for a fixed cost per person. Patients, hospitals and physicians may not be able to justify the use of our products by the attendant cost savings and clinical benefits that we believe will be derived from the use of our products, and therefore may not be able to obtain third-party reimbursement.

 

Reimbursement and health care payment systems in international markets vary significantly by country and include both government-sponsored health care and private insurance. We may not be able to obtain approvals for reimbursement from these international third-party payors in a timely manner, if at all. Any failure to receive international reimbursement approvals could have an adverse effect on market acceptance of our products in the international markets in which approvals are sought.

 

We have a substantial amount of indebtedness, which may adversely affect our cash flow and our ability to operate our business.

 

Our outstanding indebtedness, which includes all of the liabilities, was $7.2 million at March 31, 2022.      

 

The terms of our indebtedness could have negative consequences to us, such as:

 

 

·

we may be unable to obtain additional financing to fund working capital, operating losses, capital expenditures or acquisitions on terms acceptable to us, or at all;

 

 

 

 

·

the amount of our interest expense may increase if we are unable to make payments when due;

 

 

 

 

·

our assets might be subject to foreclosure if we default on our secured debt;

 

 

 

 

·

our vendors or employees may, and some have, instituted proceedings to collect on amounts owed them;

 

 

 

 

·

we have to use a substantial portion of our cash flows from operations to repay our indebtedness, including ordinary course accounts payable and accrued payroll liabilities, which reduces the amount of money we have for future operations, working capital, inventory, expansion, or general corporate or other business activities; and

 

 

 

 

·

we may be unable to refinance our indebtedness on terms acceptable to us, or at all.

 

 
22

Table of Contents

 

Our ability to meet our expenses and debt obligations will depend on our future performance, which will be affected by financial, business, economic, regulatory and other factors. We will be unable to control many of these factors, such as economic conditions. We cannot be certain that our earnings will be sufficient to allow us to pay the principal and interest on our debt and meet any other obligations. If we do not have enough money to service our debt, we may be required, but unable, to refinance all or part of our existing debt, sell assets, borrow money or raise equity on terms acceptable to us, if at all.

 

Our success depends on our ability to attract and retain scientific, technical, managerial and finance personnel.

 

Our ability to operate successfully and manage our future growth depends in significant part upon the continued service of key scientific, technical, managerial and finance personnel, as well as our ability to attract and retain additional highly qualified personnel in these fields. We may not be able to attract and retain key employees when necessary, which would limit our operations and growth. In addition, if we are able to successfully develop and commercialize our products, we will need to hire additional scientific, technical, marketing, managerial and finance personnel. We face intense competition for qualified personnel in these areas, many of whom are often subject to competing employment offers.

 

Certain provisions of our certificate of incorporation that authorize the issuance of additional shares of preferred stock may make it more difficult for a third party to effect a change in control.

 

Our certificate of incorporation authorizes our board of directors to issue up to 5.0 million shares of preferred stock of which 10,977 were outstanding as of March 31, 2022. Our undesignated shares of preferred stock may be issued in one or more series, the terms of which may be determined by the board without further stockholder action. These terms may include, among other terms, voting rights, including the right to vote as a series on particular matters, preferences as to liquidation and dividends, repurchase rights, conversion rights, redemption rights and sinking fund provisions. The issuance of any preferred stock could diminish the rights of holders of our common stock, and therefore could reduce the value of our common stock. In addition, specific rights granted to future holders of preferred stock could be used to restrict our ability to merge with or sell assets to a third party. The ability of our board to issue preferred stock could make it more difficult, delay, discourage, prevent or make it more costly to acquire or effect a change in control, which in turn could prevent our stockholders from recognizing a gain in the event that a favorable offer is extended and could materially and negatively affect the market price of our common stock.

  

Risks Related to Our Securities

  

The market prices for our common stock are volatile and will fluctuate.

 

The market price for our common stock may be volatile and subject to wide fluctuations in response to numerous factors, many of which are beyond our control, including the following: (i) actual or anticipated fluctuations in our quarterly financial results; (ii) recommendations by securities research analysts; (iii) changes in the economic performance or market valuations of other issuers that investors deem comparable to ours; (iv) addition or departure of our executive officers or members of our Board and other key personnel; (v) release or expiration of lock-up or other transfer restrictions on outstanding common stock; (vi) sales or perceived sales of additional common stock; (vii) liquidity of the common stock; (viii) significant acquisitions or business combinations, strategic partnerships, joint ventures or capital commitments by or involving us or our competitors; and (ix) news reports relating to trends, concerns, technological or competitive developments, regulatory changes and other related issues in our industry or target markets. Financial markets often experience significant price and volume fluctuations that affect the market prices of equity securities of public entities and that are, in many cases, unrelated to the operating performance, underlying asset values or prospects of such entities. Accordingly, the market price of our common stock may decline even if our operating results, underlying asset values or prospects have not changed. Additionally, these factors, as well as other related factors, may cause decreases in asset values that are deemed to be other than temporary, which may result in impairment losses. As well, certain institutional investors may base their investment decisions on consideration of our environmental, governance and social practices and performance against such institutions’ respective investment guidelines and criteria, and failure to meet such criteria may result in limited or no investment in our common stock by those institutions, which could materially adversely affect the trading price of our common stock. There can be no assurance that continuing fluctuations in price and volume will not occur. If such increased levels of volatility and market turmoil continue for a protracted period of time, our operations could be materially adversely impacted and the trading price of our common stock may be materially adversely affected.

 

 
23

Table of Contents

 

There is a limited market for our securities.

 

Our common stock is listed on the OTC Markets. We have applied to list our common stock on Nasdaq. The successful listing of our common stock on the Nasdaq is a condition of this offering. However, there can be no assurance that Nasdaq will approve our listing application, or that an active and liquid market for the common stock will develop or be maintained on the applicable stock exchanges, and an investor may find it difficult to resell any of our securities.

 

Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies.

 

We may seek additional capital through a combination of private and public equity offerings, debt financings, strategic partnerships and alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, existing ownership interests will be diluted and the terms of such financings may include liquidation or other preferences that adversely affect the rights of existing stockholders. Debt financings may be coupled with an equity component, such as warrants to purchase shares, which could also result in dilution of our existing stockholders’ ownership. The incurrence of indebtedness would result in increased fixed payment obligations and could also result in certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business and may result in liens being placed on our assets and intellectual property. If we were to default on such indebtedness, we could lose such assets and intellectual property. If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or grant licenses on terms that are not favorable to us.

 

Future offerings of debt or equity securities may rank senior to common stock.

 

If we decide to issue debt or equity securities in the future ranking senior to our common stock or otherwise incur additional indebtedness, it is possible that these securities or indebtedness will be governed by an indenture or other instrument containing covenants restricting our operating flexibility and limiting our ability to pay dividends to stockholders. Additionally, any convertible or exchangeable securities that we issue in the future may have rights, preferences and privileges, including with respect to dividends, more favorable than those of common stock and may result in dilution to stockholders. Because our decision to issue debt or equity securities in any future offering or otherwise incur indebtedness will depend on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing or nature of our future offerings or financings, any of which could reduce the market price of our common stock and dilute their value.

 

Common stockholders are subordinated to our lenders.

 

In the event of bankruptcy, liquidation or reorganization, any holders of our debt and our trade creditors will generally be entitled to payment of their claims from our assets before any assets are made available for distribution to us or our stockholders. The common stock is effectively subordinated to our debt and other obligations. As of March 31, 2022, we have $7.2 million in total liabilities and out of it $514,415 is related to deferred revenue.

 

 
24

Table of Contents

 

Future sales of common stock by officers and directors may negatively impact the market price for our common stock.

 

Subject to compliance with applicable securities laws, our directors and officers and their affiliates may sell some or all of their common stock in the future. No prediction can be made as to the effect, if any, such future sales of common stock may have on the market price of the common stock prevailing from time to time. However, the future sale of a substantial number of common stock by our directors and officers and their affiliates, or the perception that such sales could occur, could adversely affect prevailing market prices for our common stock.

 

We do not currently pay dividends on our common stock and have no intention to pay dividends on our common stock for the foreseeable future.

 

No dividends on our common stock have been paid by us to date. We do not intend to declare or pay any cash dividends in the foreseeable future. Payment of any future dividends will be at the discretion of our Board, after taking into account a multitude of factors appropriate in the circumstances, including our operating results, financial condition and current and anticipated cash needs. In addition, the terms of any future debt or credit facility may preclude us from paying any dividends unless certain consents are obtained and certain conditions are met.

 

We may not be able to maintain the listing of our common stock on Nasdaq.

 

We must meet certain financial and liquidity criteria to maintain the listing of our common stock on Nasdaq. If we fail to meet any of Nasdaq’s continued listing standards, our common stock may be delisted. These continued listing standards include specifically enumerated criteria, such as:

 

 

·

a $1.00 minimum closing bid price;

 

 

 

 

·

stockholders’ equity of $2.5 million;

 

 

 

 

·

500,000 shares of publicly-held common stock with a market value of at least $1 million;

 

 

 

 

·

300 round-lot stockholders; and

 

 

 

 

·

Compliance with Nasdaq’s corporate governance requirements, as well as additional or more stringent criteria that may be applied in the exercise of Nasdaq’s discretionary authority.

 

There can be no assurance that we will be able to maintain compliance and remain in compliance in the future. In particular, our share price may continue to decline for a number of reasons, including many that are beyond our control.

 

In addition, our board may determine that the cost of maintaining our listing on a national securities exchange outweighs the benefits of such listing. A delisting of our common stock from Nasdaq would materially impair our stockholders’ ability to buy and sell our common stock and could have an adverse effect on the market price of, and the efficiency of the trading market for, our common stock. A delisting of our common stock would also significantly impair our ability to raise capital.

 

 
25

Table of Contents

 

We have broad discretion in the use of our cash and cash equivalents, including the net proceeds we receive in this offering, and may not use them effectively.

 

Our management has broad discretion to use our cash and cash equivalents, including the net proceeds we receive in this offering, to fund our operations and could spend these funds in ways that do not improve our results of operations or enhance the value of our common stock, and you will not have the opportunity as part of your investment decision to assess whether the net proceeds are being used appropriately. The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse effect on our business, cause the price of our common stock to decline. Pending their use to fund our operations, we may invest our cash and cash equivalents, including the net proceeds from this offering, in a manner that does not produce income or that loses value.

 

Holders of the warrants offered hereby will have no rights as common stockholders with respect to the shares our common stock underlying the warrants until such holders exercise their warrants and acquire our common stock, except as otherwise provided in the warrants.

 

Until holders of the Public Warrants and the pre-funded warrants acquire shares of our common stock upon exercise thereof, such holders will have no rights with respect to the shares of our common stock underlying such warrants, except to the extent that holders of such warrants will have certain rights to participate in distributions or dividends paid on our common stock as set forth in the warrants. Upon exercise of the Public Warrants and the pre-funded warrants, the holders will be entitled to exercise the rights of a common stockholder only as to matters for which the record date occurs after the exercise date.

 

If our shares of common stock become subject to the penny stock rules, it would become more difficult to trade our shares.

 

The SEC has adopted rules that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks are generally equity securities with a price of less than $5.00, other than securities registered on certain national securities exchanges or authorized for quotation on certain automated quotation systems, provided that current price and volume information with respect to transactions in such securities is provided by the exchange or system. If we are unable to maintain the listing of our common stock on Nasdaq or another national securities exchange and if the price of our common stock is less than $5.00, our common stock will be deemed a penny stock. The penny stock rules require a broker- dealer, before a transaction in a penny stock not otherwise exempt from those rules, to deliver a standardized risk disclosure document containing specified information. In addition, the penny stock rules require that before effecting any transaction in a penny stock not otherwise exempt from those rules, a broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive (i) the purchaser’s written acknowledgment of the receipt of a risk disclosure statement; (ii) a written agreement to transactions involving penny stocks; and (iii) a signed and dated copy of a written suitability statement. These disclosure requirements may have the effect of reducing the trading activity in the secondary market for our common stock, and therefore stockholders may have difficulty selling their shares.

 

 
26

Table of Contents

 

In connection with the audit of our financial statements as of and for the year ended December 31, 2021, material weaknesses in our internal control over financial reporting was identified and we may identify additional material weaknesses in the future.

 

In connection with the preparation and audits of our financial statements as of and for the years ended December 31, 2021 and 2020, material weaknesses (as defined under the Exchange Act and by the auditing standards of the U.S. Public Company Accounting Oversight Board, or “PCAOB”), were identified in our internal control over financial reporting. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual financial statements will not be prevented or detected on a timely basis. The material weaknesses identified arose from a lack of recourses to properly research and account for complex transactions and lack of oversight and approval by the Board of Directors and Audit Committee, including formally documented approval of significant transactions, including related party transactions.

 

In light of the identified material weaknesses, it is possible that, had we performed a formal assessment of our internal control over financial reporting or had our independent registered public accounting firm performed an audit of our internal control over financial reporting in accordance with PCAOB standards, additional control deficiencies may have been identified.

 

We have begun taking measures, and plan to continue to take measures, to remediate these material weaknesses. However, the implementation of these measures may not fully address these material weaknesses in our internal control over financial reporting, and, if so, we would not be able to conclude that they have been fully remedied. Our failure to correct these material weaknesses or our failure to discover and address any other control deficiencies could result in inaccuracies in our financial statements and could also impair our ability to comply with applicable financial reporting requirements and make related regulatory filings on a timely basis. As a result, our business, financial condition, results of operations and prospects, as well as the trading price of our common stock, may be materially and adversely affected.

 

We have incurred, and will continue to incur, increased costs as a result of operating as a public company, and our management has been required, and will continue to be required, to devote substantial time to new compliance initiatives.

 

As a public company, we have incurred and are continuing to incur significant legal, accounting and other expenses. We are subject to the reporting requirements of the Exchange Act and the rules adopted, and to be adopted, by the SEC. Our management and other personnel devote a substantial amount of time to these compliance initiatives.

 

Moreover, these rules and regulations have substantially increased our legal and financial compliance costs and made some activities more time-consuming and costly. The increased costs have increased our net loss. These rules and regulations may make it more difficult and more expensive for us to maintain sufficient director’s and officer’s liability insurance coverage. We cannot predict or estimate the amount or timing of additional costs we may continue to incur to respond to these requirements. The ongoing impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our Board, our Board committees or as executive officers.

 

Anti-takeover provisions in our Amended and Restated Certificate of Incorporation and By-laws may reduce the likelihood of a potential change of control, or make it more difficult for our stockholders to replace management.

 

Certain provisions of our Amended and Restated Certificate of Incorporation and By-laws could have the effect of making it more difficult for our stockholders to replace management at a time when a substantial number of stockholders might favor a change in management. These provisions include authorizing the board of directors to fill vacant directorships or increase the size of its board of directors.

 

Furthermore, our board of directors has the authority to issue up to 5.0 million shares of preferred stock in one or more series and to determine the rights and preferences of the shares of any such series without stockholder approval. Any series of preferred stock is likely to be senior to the common stock with respect to dividends, liquidation rights and, possibly, voting rights. The board’s ability to issue preferred stock may have the effect of discouraging unsolicited acquisition proposals, thus adversely affecting the market price of our common stock.

 

 
27

Table of Contents

 

If securities or industry analysts publish inaccurate or unfavorable research about our business, our share price and trading volume may decline.

 

The trading market for our common stock depends in part on the research and reports that securities or industry analysts publish about us or our business. If one or more of the analysts who cover us downgrade our shares or publish inaccurate or unfavorable research about our business, our shares price may decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, demand for our shares may decrease, which may cause our shares price and trading volume to decline.

 

Our Board approved a reverse stock split at a ratio of 1-for-20 on December 30, 2021 and there are risks associated with effectuating the reverse stock split.

 

In order to qualify for an uplisting to Nasdaq, we plan to effect a reverse stock split at a ratio of up to 1-for-20. All fractional shares created by the reverse stock split were rounded up to the nearest whole share. There are certain risks associated with the reverse stock split, including the following:

 

 

·

We will have additional authorized shares of common stock that the board could issue in future without stockholder approval, and such additional shares could be issued, among other purposes, in financing transactions or to resist or frustrate a third-party transaction that is favored by a majority of the independent directors. This could have an anti-takeover effect, in that additional shares could be issued, within the limits imposed by applicable law, in one or more transactions that could make a change in control or takeover of us more difficult.

 

 

 

 

·

There can be no assurance that our stockholders will approve the reverse stock split or the reverse stock split will achieve the benefits that we hope it will achieve. The total market capitalization of our common stock after the reverse stock split may be lower than the total market capitalization before the reverse stock split.

 

The reverse stock split may decrease the liquidity of the shares of our common stock.

 

The liquidity of our common stock may be affected adversely by the reverse stock split given the reduced number of shares that were outstanding immediately following the reverse stock split, especially if the market price of our common stock does not increase as a result of the reverse stock split. In addition, the reverse stock split may have increased the number of stockholders who own odd lots of our common stock, creating the potential for such stockholders to experience an increase in the cost of selling their shares and greater difficulty effecting such sales.

 

Following the reverse stock split, the resulting market price of our common stock may not attract new investors, including institutional investors, and may not satisfy the investing requirements of those investors. Consequently, the trading liquidity of our common stock may not improve.

 

Although we believe that a higher market price of our common stock may help generate greater or broader investor interest, there can be no assurance that the reverse stock split will result in a share price that will attract new investors, including institutional investors. In addition, there can be no assurance that the market price of our common stock will satisfy the investing requirements of those investors. As a result, the trading liquidity of our common stock may not necessarily improve.

 

The number of shares of our common stock issuable upon the conversion of our outstanding convertible debt and preferred stock or exercise of outstanding warrants and options is substantial.

 

As of March 31, 2022, our outstanding convertible debt was convertible into an aggregate of 311,659 shares of our common stock, and the outstanding shares of our Series C, Series C1, Series C2, Series D, Series E, Series F, Series F-2 preferred stock were convertible into an aggregate of 1,697,400 shares of common stock. Also, as of that date we had warrants outstanding that were exercisable for an aggregate of 1,269,266 shares, and outstanding options to purchase 75,000 shares. The shares of common stock issuable upon conversion or exercise of these securities would have constituted approximately 75.0% of the total number of shares of common stock then issued and outstanding.

 

 
28

Table of Contents

 

Further, under the terms of our convertible debt and preferred stock, as well as certain of our outstanding warrants, the conversion price or exercise price, as the case may be, could be adjusted downward, causing substantial dilution. See “-Adjustments to the conversion price for our convertible debt and preferred stock, and the exercise price for certain of our warrants, will dilute the ownership interests of our existing stockholders.”

 

Adjustments to the conversion price of some of our convertible debt and preferred stock, and the exercise price for certain of our warrants, will dilute the ownership interests of our existing stockholders.

 

Under the terms of a portion of our convertible debt, the conversion price fluctuates with the market price of our common stock. Additionally, under the terms of our Series C preferred stock, any dividends we choose to pay in shares of our common stock will be calculated based on the then-current market price of our common stock. Accordingly, if the market price of our common stock decreases, the number of shares of our common stock issuable upon conversion of the convertible debt or upon payment of dividends on our outstanding Series C preferred stock will increase, and may result in the issuance of a significant number of additional shares of our common stock.

 

Under the terms of some of our preferred stock and certain of our convertible notes and outstanding warrants, the conversion price or exercise price will be lowered if we issue common stock at a per share price below the then-conversion price or then-exercise price for those securities. Reductions in the conversion price or exercise price would result in the issuance of a significant number of additional shares of our common stock upon conversion or exercise, which would result in dilution in the value of the shares of our outstanding common stock and the voting power represented thereby.

 

Our need to raise additional capital in the near future or to use our equity securities for payments could have a dilutive effect on your investment.

 

In order to continue operations, we will need to raise additional capital. We may attempt to raise capital through the public or private sale of our common stock or securities convertible into or exercisable for our common stock. In addition, from time to time we have issued our common stock or warrants in lieu of cash payments. If we sell additional shares of our common stock or other equity securities, or issue such securities in respect of other claims or indebtedness, such sales or issuances will further dilute the percentage of our equity that you own. Depending upon the price per share of securities that we sell or issue in the future, if any, your interest in us could be further diluted by any adjustments to the number of shares and the applicable exercise price required pursuant to the terms of the agreements under which we previously issued convertible securities.

 

The perceived risk of dilution may cause our stockholders to sell their shares, which may cause a decline in the price of our common stock. Moreover, the perceived risk of dilution and the resulting downward pressure on our stock price could encourage investors to engage in short sales of our common stock. By increasing the number of shares offered for sale, material amounts of short selling could further contribute to progressive price declines in our common stock.

 

Risks Related to this Offering

  

Management will have broad discretion as to the use of the net proceeds from this offering, and we may not use these proceeds effectively.

 

We intend to use the net proceeds from this offering for working capital and general corporate purposes. Our management will have broad discretion in the application of the net proceeds from this offering and could spend the proceeds in ways that do not improve our results of operations or enhance the value of our common stock. Accordingly, you will be relying on the judgment of our management with regard to the use of these net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. Our failure to apply these funds effectively could have a material adverse effect on our business, delay the development of our product candidates and cause the price of our common stock to decline.

 

 
29

Table of Contents

 

You will experience immediate and substantial dilution in the net tangible book value per share of the common stock you purchase.

 

Because the price per share of our common stock being offered is substantially higher than the net tangible book value per share of our common stock, you will suffer substantial dilution in the net tangible book value of the common stock you purchase in this offering. Based on a public offering price of $10.00 per share, if you purchase shares of common stock in this offering, you will suffer immediate and substantial dilution of approximately $7.44 per share in the net tangible book value of the common stock. See the section entitled “Dilution” in this prospectus for a more detailed discussion of the dilution you will incur if you purchase common stock in this offering.

  

In addition, we have a significant number of stock options, warrants and convertible preferred stock outstanding. To the extent that outstanding stock options, warrants have been or may be exercised or other shares issued, you may experience further dilution.

 

There is no public market for the pre-funded warrants being offered by us in this offering.

 

There is no established public trading market for the pre-funded warrants, and we do not expect a market to develop. In addition, we do not intend to apply to list the pre-funded warrants on any national securities exchange or other nationally recognized trading system. Without an active market, the liquidity of the pre-funded warrants will be limited.

 

Future sales of substantial amounts of our common stock could adversely affect the market price of our common stock.

 

We may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. If additional capital is raised through the sale of equity or convertible debt securities, or perceptions that those sales could occur, the issuance of these securities could result in further dilution to investors purchasing our common stock in this offering or result in downward pressure on the price of our common stock, and our ability to raise capital in the future.

 

A large number of shares issued in this offering may be sold in the market following this offering, which may depress the market price of our common stock.

 

A large number of shares issued in this offering may be sold in the market following this offering, which may depress the market price of our common stock. Sales of a substantial number of shares of our common stock in the public market following this offering could cause the market price of our common stock to decline. If there are more shares of our common stock offered for sale than buyers are willing to purchase, then the market price of our common stock may decline to a market price at which buyers are willing to purchase the offered shares of our common stock and sellers remain willing to sell the shares. All of the securities issued in the offering will be freely tradable without restriction or further registration under the Securities Act.

 

For all of the aforesaid reasons and others set forth in this registration statement, an investment in our common stock, warrants and any other securities that we may offer from time to time involves a certain degree of risk. Any person considering an investment in our common stock , warrants or any other of our securities should be aware of these and other factors set forth in this registration statement and should consult with his or her legal, tax and financial advisors prior to making an investment in our common stock, warrants or any other of our securities that may be offered from time to time. Our common stock, warrants and any other securities that we may offer from time to time should only be purchased by persons who can afford to lose all of their investment.

 

 
30

Table of Contents

 

FORWARD-LOOKING STATEMENTS

 

This prospectus contains a number of “forward-looking statements”. Specifically, all statements other than statements of historical facts included in this prospectus regarding our financial position, business strategy and plans and objectives of management for future operations are forward-looking statements. These forward-looking statements are based on the beliefs of management at the time these statements were made, as well as assumptions made by and information currently available to management. When used in this prospectus and the documents incorporated by reference herein, the words “anticipate,” “believe,” “estimate,” “expect,” “may,” “will,” “continue” and “intend,” and words or phrases of similar import, as they relate to our financial position, business strategy and plans, or objectives of management, are intended to identify forward-looking statements. These statements reflect our current view with respect to future events and are subject to risks, uncertainties and assumptions related to various factors.

 

A variety of factors, some of which are outside our control, may cause our operating results to fluctuate significantly. They include:

 

 

·

access to sufficient debt or equity capital to meet our operating and financial needs;

 

 

 

 

·

the extent of dilution of the holdings of our existing stockholders upon the issuance, conversion or exercise of securities issued as part of our capital raising efforts;

 

 

 

 

·

the extent to which certain debt holders may call the notes to be paid;

 

 

 

 

·

the effectiveness and ultimate market acceptance of our products and our ability to generate sufficient sales revenues to sustain our growth and strategy plans;

 

 

 

 

·

whether our products in development will prove safe, feasible and effective;

 

 

 

 

·

whether and when we or any potential strategic partners will obtain required regulatory approvals in the markets in which we plan to operate;

 

 

 

 

·

our need to achieve manufacturing scale-up in a timely manner, and our need to provide for the efficient manufacturing of sufficient quantities of our products;

 

 

 

 

·

the lack of immediate alternate sources of supply for some critical components of our products;

 

 

 

 

·

our ability to establish and protect the proprietary information on which we base our products, including our patent and intellectual property position;

 

 

 

 

·

the current outbreak of the Coronavirus SARS-CoV-2, the pathogen responsible for COVID-19, which has already had an impact on financial markets, could result in additional repercussions in our operating business, including but not limited to, the sourcing of materials for product candidates, manufacture of supplies for preclinical and/or clinical studies, delays in clinical operations, which may include the availability or the continued availability of patients for trials due to such things as quarantines, conduct of patient monitoring and clinical trial data retrieval at investigational study sites;

 

 

 

 

·

the future impact of the outbreak is highly uncertain and cannot be predicted, and we cannot provide any assurance that the outbreak will not have a material adverse impact on our operations or future results or filings with regulatory health authorities. The extent of the impact, if any, we will depend on future developments, including actions taken to contain the coronavirus;

 

 

 

 

·

the impact of the conflict between Russia and Ukraine on economic conditions in general and on our business and operations;

 

 
31

Table of Contents

 

 

·

the need to fully develop the marketing, distribution, customer service and technical support and other functions critical to the success of our product lines;

 

 

 

 

·

the dependence on potential strategic partners or outside investors for funding, development assistance, clinical trials, distribution and marketing of some of our products; and

 

 

 

 

·

other risks and uncertainties described from time to time in our reports filed with the SEC.

 

These forward-looking statements reflect our management’s beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this prospectus and are subject to risks and uncertainties. We discuss many of these risks in greater detail under “Risk Factors.” Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Given these uncertainties, you should not place undue reliance on these forward-looking statements.

 

You should read this prospectus and the documents that we reference in this prospectus and have filed as exhibits to the registration statement, of which this prospectus is a part, completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in this prospectus by these cautionary statements. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

 

 
32

Table of Contents

 

USE OF PROCEEDS

 

We estimate that we will receive proceeds of approximately $8.9 million (or approximately $10.8 million if the underwriters’ option to purchase additional shares and/or warrants is exercised in full) from the sale of the securities offered by us in this offering, based on an initial offering price of $10.00 per share of common stock (or pre-funded warrant) and related Public Warrants and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.

  

The principal purposes of this offering are to obtain additional capital to support our operations. We intend to use the net proceeds from this offering for the following purposes:

 

 

·

Fund completion of the US FDA clinical trial and application for FDA approval for LuViva.

 

 

 

 

·

Support international sales and marketing partners for distribution of our products, especially LuViva.

 

 

 

 

·

Build and train a U.S. sales force once U.S. FDA approval for LuViva is achieved.

 

 

 

 

·

Pay off remaining debt, of approximately $887,000, as needed to complete current agreements for debt reduction, including forgiveness from consultants and legal firms.

 

 

 

 

·

Order parts for manufacturing LuViva and it disposable accessories.

 

 

 

 

·

Other expenses as deemed necessary by the Company’s Board.

 

 
33

Table of Contents

 

DIVIDEND POLICY

 

We do not anticipate declaring or paying, in the foreseeable future, any cash dividends on our common stock. We currently intend to retain all available funds and any future earnings to support our operations and finance the growth and development of our business. Any future determination related to our dividend policy will be made at the discretion of our Board and will depend upon, among other factors, our results of operations, financial condition, capital requirements, contractual restrictions, business prospects and other factors our Board may deem relevant.

 

The Company pays dividends on its preferred stock.

 

Holders of the Series C preferred stock are entitled to quarterly cumulative dividends at an annual rate of 12.0% until 42 months after the original issuance date (the “Dividend End Date”), payable in cash or, subject to certain conditions, the Company’s common stock. In addition, upon conversion of the Series C preferred stock prior to the Dividend End Date, the Company will also pay to the converting holder a “make-whole payment” equal to the number of unpaid dividends through the Dividend End Date on the converted shares. At December 31, 2021 and 2020, the “make-whole payment” for a converted share of Series C preferred stock would convert to 10 shares of the Company’s common stock. The Series C preferred stock generally has no voting rights except as required by Delaware law. Upon the Company’s liquidation or sale to or merger with another corporation, each share will be entitled to a liquidation preference of $1,000, plus any accrued but unpaid dividends. In addition, the purchasers of the Series C preferred stock received, on a pro rata basis, warrants exercisable to purchase an aggregate of approximately 1 share of Company’s common stock. The warrants contained anti-dilution adjustments in the event that the Company issues shares of common stock, or securities exercisable or convertible into shares of common stock, at prices below the exercise price of such warrants. As a result of the anti-dilution protection, the Company was required to account for the warrants as a liability recorded at fair value each reporting period. The warrants expired at the end of 2020.

 

Series C1 and Series C2 preferred stock do not pay dividends (unless and to the extent declared on the common stock) or at-the-market “make-whole payments” and, while it has the same anti-dilution protections afforded the Series C preferred stock, it does not automatically reset in connection with a reverse stock split or conversion of our outstanding convertible debt.

 

The Series D Preferred Stock has cumulative dividends at the rate per of 10% per annum, calculated on the basis of a 360-day year, consisting of twelve 30 calendar day periods, payable quarterly on January 15, April 15, July 15 and October 15, beginning on the first such date after the original issue date and on each optional redemption date in cash, or, following the approval of Canadian Trading Market and at the Company’s option, in duly authorized, validly issued, fully paid and non-assessable shares of common stock, or a combination based on the dividend conversion rate which is equal to the average of the 20 volume weighted average prices of the Common Stock on the principal Trading Market immediately prior to the dividend payment date.

 

As of March 31, 2022, the Company issued an aggregate of 14,040 common stock shares for the payment of Series D Preferred Stock dividends accrued. As of March 31, 2022, the Company had accrued Series D dividends of $14,306.

  

The Series E Preferred Stock has cumulative dividends at the rate per share of 8% per annum, calculated on the basis of a 360-day year, consisting of twelve 30 calendar day periods, payable annually, beginning on the first such date after the original issue date and on each optional redemption date. in cash, or, following the approval of Canadian Trading Market and at the Company’s option, in duly authorized, validly issued, fully paid and non-assessable shares of common stock, or a combination based on the dividend conversion rate which is equal to the average of the 20 volume weighted average prices of the Common Stock on the principal Trading Market immediately prior to the dividend payment date. As of March 31, 2022, the Company issued an aggregate of 15,018 common stock shares for the payment of Series E Preferred Stock dividends accrued. As of March 31, 2022, the  Company had accrued Series E dividends of $71,099.

 

 
34

Table of Contents

 

The Series F Preferred Stock has cumulative dividends at the rate per share of 6% per annum, calculated on the basis of a 360-day year, consisting of twelve 30 calendar day periods, payable annually, beginning on the first such date after the original issue date and on each optional redemption date. in cash, or, following the approval of Canadian Trading Market and at the Company’s option, in duly authorized, validly issued, fully paid and non-assessable shares of common stock, or a combination based on the dividend conversion rate which is equal to the average of the 20 volume weighted average prices of the Common Stock on the principal Trading Market immediately prior to the dividend payment date. In addition to the 6% annual dividend, the Company was also required to pay a one-time, non-recurring, dividend equal to 15% of the aggregate stated value of preferred stock then held by the holder, in cash or common stock, as the corporation was unable to successfully uplist to the NASDAQ Stock Exchange by December 31, 2021; and was unable to file its clinical data intended for FDA approval of its primary product, LuViva, by December 31, 2021.

 

During the three months ended March 31, 2022, the Company issued 7,933 common stock shares for the payment of annual Series F Preferred Stock dividends. Additionally, During the three months ended March 31, 2022, the Company issued 12,770 common stock shares for the payment of the one-time, non-recurring 15% dividend to the Series F Preferred shareholders. As of March 31, 2022, the Company had accrued Series F dividends of $1,998.

 

The Series F-2 Preferred Stock has cumulative dividends at the rate per share of 6% per annum, calculated on the basis of a 360-day year, consisting of twelve 30 calendar day periods, payable annually, beginning on the first such date after the original issue date and on each optional redemption date. in cash, or, following the approval of Canadian Trading Market and at the Company’s option, in duly authorized, validly issued, fully paid and non-assessable shares of common stock, or a combination based on the dividend conversion rate which is equal to the average of the 20 volume weighted average prices of the Common Stock on the principal Trading Market immediately prior to the dividend payment date. In addition to the 6% annual dividend, the Company was also required to pay a one-time, non-recurring, dividend equal to 15% of the aggregate stated value of preferred stock then held by the holder, in cash or common stock, as the corporation was unable to successfully uplist to the NASDAQ Stock Exchange by December 31, 2021; and was unable to file its clinical data intended for FDA approval of its primary product, LuViva, by December 31, 2021.

 

During the three months ended March 31, 2022, the Company issued 4,777 common stock shares for the payment of annual Series F-2 Preferred Stock dividends. Additionally, during the three months ended March 31, 2022, the Company issued 18,425 common stock shares for the payment of the one-time, non-recurring 15% dividend to the Series F-2 Preferred shareholders. As of March 31, 2022, the Company had accrued Series F-2 dividends of $91,592.

 

The Series G Preferred Stock preferred stock carries 8% annual dividend, cumulative and payable solely upon redemption, liquidation or conversion. Upon the occurrence of an Event of Default (, the Dividend Rate shall automatically increase to twenty two percent (22%).

 

On June 4, 2021, the Company paid $2,952 and $4,992 for the Series G Preferred Stock dividends accrued, respectively. As of March 31, 2022, the Series G Preferred Stock was fully redeemed, leaving a null balance.

  

 
35

Table of Contents

 

CAPITALIZATION

 

The following table sets forth our cash and cash equivalents as well as capitalization as of March 31, 2022:

 

 

·

on an actual basis; and

 

 

 

 

·

on an as adjusted basis to give effect to the sale of 890,000 securities offered hereby at the combined offering price of $10 per share, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. The offering price may not be the final price of the Offering and will be adjusted based on the actual initial public offering price and other terms of our initial public offering determined at pricing.

 

You should read this table together with “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included elsewhere in this prospectus, and our financial statements and related notes thereto.

 

 
36

Table of Contents

    

 

 

 

 

 

 

 

 

Pro forma

 

 

 

 

 

 

 

 

 

as adjusted

 

 

 

March 31, 2022

 

 

Adjustments

 

 

March 31, 2022

 

CURRENT ASSETS:

 

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$ 725 (a)

 

 

7,150

 

 

 

7,875

 

Accounts receivable, net of allowance for doubtful accounts of $126 at March 31, 2022

 

 

39

 

 

 

-

 

 

 

39

 

Inventory, net of reserves of $785 at December 31, 2021

 

 

570

 

 

 

-

 

 

 

570

 

Other current assets

 

 

453 (b)

 

 

(339 )

 

 

114

 

Total current assets

 

 

1,787

 

 

 

6,811

 

 

 

8,598

 

NONCURRENT ASSETS:

 

 

 

 

 

 

 

 

 

 

 

 

Property and equipment, net

 

 

28

 

 

 

-

 

 

 

28

 

Operating lease asset-right, net of amortization

 

 

355

 

 

 

-

 

 

 

355

 

Other assets

 

 

17

 

 

 

-

 

 

 

17

 

Total noncurrent assets

 

 

400

 

 

 

-

 

 

 

400

 

TOTAL ASSETS

 

 

2,187

 

 

 

6,811

 

 

 

8,998

 

 

 

 

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ DEFICIT

 

 

 

CURRENT LIABILITIES:

 

 

 

 

 

 

 

 

 

 

 

 

Accounts payable

 

$ 2,476 (c)

 

 

(2,072 )

 

 

404

 

Accounts payable, related parties

 

 

80 (q)

 

 

(30 )

 

 

50

 

Accrued liabilities

 

 

1,228 (d)

 

 

(655 )

 

 

573

 

Deferred revenue

 

 

514

 

 

 

-

 

 

 

514

 

Current portion of lease liability

 

 

70

 

 

 

-

 

 

 

70

 

Current portion of long-term debt

 

 

67 (e)

 

 

(62 )

 

 

5

 

Current portion of long-term debt, related parties

 

 

27

 

 

 

-

 

 

 

27

 

Short-term notes payable

 

 

12

 

 

 

-

 

 

 

12

 

Short-term notes payable, related parties

 

 

31 (q)

 

 

(31 )

 

 

-

 

Convertible notes payable in default

 

 

161 (f)

 

 

(161 )

 

 

-

 

Short-term convertible notes payable

 

 

745 (f)

 

 

(745 )

 

 

-

 

Derivative liability

 

 

38 (g)

 

 

(38 )

 

 

-

 

Total current liabilities

 

 

5,449

 

 

 

(3,794 )

 

 

1,655

 

LONG-TERM LIABILITIES:

 

 

 

 

 

 

 

 

 

 

 

 

Long-term lease liabilities

 

 

307

 

 

 

-

 

 

 

307

 

Long-term debt

 

-

(h)

 

 

1,127

 

 

 

1,127

 

Long-term convertible debt

 

 

852 (i)

 

 

(852 )

 

 

-

 

Long-term debt-related parties

 

 

568 (j)

 

 

(147 )

 

 

421

 

Total long-term liabilities

 

 

1,727

 

 

 

128

 

 

 

1,855

 

TOTAL LIABILITIES

 

 

7,176

 

 

 

(3,666 )

 

 

3,510

 

 

 

 

 

 

 

 

 

 

 

 

 

 

COMMITMENTS & CONTINGENCIES (Note 7)

 

 

 

 

 

 

 

 

 

 

 

 

STOCKHOLDERS’ DEFICIT:

 

 

 

 

 

 

 

 

 

 

 

 

Series C convertible preferred stock, $.001 par value; 9.0 shares authorized, 0.3 shares issued and outstanding as of March 31, 2022. Liquidation preference of $286 at March 31, 2022.

 

 

105

 

 

 

-

 

 

 

105

 

Series C1 convertible preferred stock, $.001 par value; 20.3 shares authorized, 1.0 shares issued and outstanding as of March 31, 2022. Liquidation preference of $1,049 at March 31, 2022.

 

 

170

 

 

 

-

 

 

 

170

 

Series C2 convertible preferred stock, $.001 par value; 5,000 shares authorized, 3.3 shares issued and outstanding as of March 31, 2022. Liquidation preference of $3,263 at March 31, 2022.

 

 

531

 

 

 

-

 

 

 

531

 

Series D convertible preferred stock, $.001 par value; 6.0 shares authorized, 0.8 shares issued and outstanding as of March 31, 2022. Liquidation preference of $763 at March 31, 2022.

 

 

276

 

 

 

-

 

 

 

276

 

Series E convertible preferred stock, $.001 par value; 5.0 shares authorized, 1.0 shares issued and outstanding as of March 31, 2022. Liquidation preference of $968 at March 31, 2022.

 

 

914 (k)

 

 

(914 )

 

 

-

 

Series F convertible preferred stock, $.001 par value; 1.5 shares authorized, 1.4 shares issued and outstanding as of March 31, 2022. Liquidation preference of $1,411 at March 31, 2022.

 

 

1,174 (l)

 

 

(1,174 )

 

 

-

 

Series F-2 convertible preferred stock, $.001 par value; 5.0 shares authorized, 3.2 shares issued and outstanding as of March 31, 2022. Liquidation preference of $3,237 at March 31, 2022.

 

 

2,963 (m)

 

 

(2,963 )

 

 

-

 

Series G convertible preferred stock, $.001 par value; 1,000 shares authorized, nil shares issued and outstanding as of March 31, 2022. Liquidation preference of nil at March 31, 2022.

 

 

-

 

 

 

-

 

 

 

-

 

Common stock, $.001 par value; 500,000 shares authorized, 1,116 shares issued and outstanding as of March 31, 2022.

 

 

3,410 (n)

 

 

2

 

 

 

3,412

 

Additional paid-in capital

 

 

129,042 (o)

 

 

14,510

 

 

 

143,552

 

Treasury stock, at cost

 

 

(132 )

 

 

-

 

 

 

(132 )

Accumulated deficit

 

 

(143,442 )(p)

 

 

1,016

 

 

 

(142,426 )

TOTAL STOCKHOLDERS’ DEFICIT

 

 

(4,989 )

 

 

10,477

 

 

 

5,488

 

TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT

 

 

2,187

 

 

 

6,811

 

 

 

8,998

 

     

 
37

Table of Contents

  

Pro-forma as adjusted does not give effect to the impact of Public or Pre-Funded Warrants.    

   

(a)

Assumes $8,900,000 in new cash from the NASDAQ uplist, less legal expenses and commissions related to closing of approximately $200,000 and $541,400, respectively, additional accounting costs of $100,000 and consulting fees of $21,897 to Donohoe Advisory Associates (b) for net funding of $8,036,703. The Company will use the proceeds to make payments of approximately $887,299 on its contractual obligations with various vendors and debt holders, including $325,000 to Jones Day (c), $65,299 per the July 8, 2020 exchange agreement (c), $147,000 to a former executive (g), and $350,000 to GPB Holdings, LLC in connection with the December 21, 2021 warrant exchange agreement. The warrants exchanged per the December 21, 2021 exchange agreement were not considered in the proforma adjustments above.

 

 

(b)

Reflects recognition of $285,261 of deferred legal fees (after forgiveness of $104,879) and $54,174 of offering-related costs related to the uplist.

 

 

(c)

Per exchange agreement dated January 6, 2020, we assume a reduction of Accounts Payable balance with a $325,000 payment to Jones Day and issuance of a long term note payable in the amount of $444,768 followed by a forgiveness of approximately $975,000 (p). Additionally, we assume a reduction of $304,924 of outstanding legal fees and payment of $21,897 to Donohoe Advisory Associates.

 

 

(d)

Per exchange agreement dated July 9, 2020, $62,052 of accrued executive compensation and $3,247 of accrued interest will be forgiven upon our payment of $62,052 on an unsecured note payable owed to a former employee. Furthermore; per exchange agreement with one of the former executives, dated March 22, 2021, the Company will make a payment of $146,775, including accrued interest of $375, on amounts owed to a former executive and will record debt forgiveness of $253,429 for amounts owed to former executive, included in the aforementioned exchange agreement; per the exchange agreement dated June 22, 2022, $29,776 of related-party payables, $31,285 of short-term related-party debt (q) and $8,939 of accrued expenses owed to executives will be converted into 7,000 shares of common stock. Additionally, we will issue common stock in lieu of Series D preferred stock dividends and will exchange the Series E, Series F and Series F-2 preferred stock dividends into common stock as part of the new financing. Total accrued dividends converted or settled with common stock will result in the decrease of approximately $178,995 in accrued liabilities. We also assume a decrease of $28,250 related to accrued interest on 10% Senior Unsecured Convertible Debenture. In accordance with the February 1, 2022 Auctus Fund, LLC exchange agreement, interest of $120,877 will be exchanged for a combination of shares of common stock, warrants and prefunded warrants, as amended.

 

 

(e)

Per exchange agreement dated July 9, 2020, we will make a payment of $62,052 on an unsecured note payable owed to a former employee.

 

 

(f)

Assumes conversion of $350,000 of prepayment penalty payable to Auctus Fund, LLC, per exchange agreement dated June 2, 2021 and subsequently amended on February 2, 2022 and June 1, 2022, into 35,000 shares of common stock. Assumes exchange of $161,184 note financed on April, 2, 2020 and $400,000 note dated May 28, 2020, less expensing of unamortized debt issuances costs of $5,211 into a $682,061 long-term note payable due thirteen (13) months after the close of the offering (h).

 

 

(g)

Reflects removal of a derivative liability valued at $39,129, related to conversion option associated with a $400,000 note that will be exchanged for a long-term note (h).

 

 

(h)

Per the exchange agreement dated January 6, 2020, we will issue a long-term note payable to Jones Day in the amount $444,768. Assumes exchange of $161,184 note financed on April, 2, 2020 and $400,000 note dated May 28, 2020, less expensing of unamortized debt issuances costs of $5,211 into a $682,061 long-term note payable due thirteen (13) months after the close of the offering.

 

 

(i)

Assumes conversion of $1,130,000 less the expensing of the debt issuance costs of $61,920 and reversal of $215,854 of unamortized debt discount associated with warrants related to 10% Senior Unsecured Convertible Debenture into 115,173 shares of common       stock. The purchasers are contractually obligated to participate in the NASDAQ uplist and convert the outstanding balance into shares of common stock.

 

 

(j)

Per exchange agreement with one of the former executives, dated March 22, 2021, the Company will make a payment of $146,775 on long term note payable.

 

 

(k)

Conversion of 968 Series E Preferred Shares, stated value $1,000 into 193,600 common shares, par value $0.001. The transaction will decrease Series E Preferred Stock balance and increase additional paid in capital by $913,806.

 

 

(l)

Conversion of 1,411 Series F Preferred Shares, stated value $1,000 into 282,200 common shares, par value $0.001. The transaction will decrease Series F Preferred Stock balance and increase additional paid in capital by $1,173,718.

 

 

(m)

Conversion of 3,237 Series F-2 Preferred Shares, stated value $1,000 into 647,400 common shares, par value $0.001. The transaction will decrease Series F-2 Preferred Stock balance and increase additional paid in capital by $2,961,353.

 

 

(n)

Assumes an issuance of 890,000 new common shares at $10.00 per share, par value $0.001 from the NASDAQ uplist investment of $8,900,000. Additional increases from conversions related to the following: payables and accrued expenses owed to executives (q), 10% Senior Unsecured Convertible Debenture (i), Series E Preferred Stock (k), Series F Preferred Stock (l), and Series F-2 Preferred Stock (m), and the settlement of accrued preferred stock dividends (d).

 

 

(o)

Assumes an issuance of 890,000 new common shares at $10.00 per share, par value $0.001, from the NASDAQ uplist investment of $8,900,000; issuances of an aggregate of 13,811 of common shares for the settlement of dividends payable on preferred stock totaling $178,995; issuance of an aggregate of 1,123,200 common shares for the conversion of Series E, Series F and Series F-2 preferred shares totaling $5.62 million; conversion of $1,130,000, plus accrued interest of $28,250, less unamortized debt discount related to warrants of $215,853, on 10% Senior Unsecured Convertible Debenture into 115,175 common shares (i), and issuance of 7,000 common shares for the conversion of $29,776 of related-party payables, $31,285 of short-term related-party debt and $8,939 of accrued expenses owed to executives (q). The warrants exchanged per the February 1, 2022 and June 1, 2022 Auctus Fund, LLC exchange agreements were not considered in the proforma adjustments above. 

 

 

(p)

The decrease in the Company's accumulated deficit will be a result of income statement transactions related to the debt forgiveness from Jones Day of $975,000 (b), $62,052 from the July 9, 2020 exchange agreement (c), $253,429 from March 22, 2021 exchange agreement, and $104,879 of accounts payable forgiven based on an agreement signed with a vendor on June 6, 2022, and reversal of a $38,129 derivative liability associated with Auctus Fund, LLC debt.  This will be offset by the $350,000 payment made in accordance with the December 21, 2021 warrant exchange agreement with GPB Holdings, LLC (a), debt issuance costs of $5,211 on Auctus Fund, LLC debt (d) and debt issuance costs of $61,920 on 10% Senior Unsecured Convertible Debenture (f).

 

 

(q)

Per the exchange agreement dated June 22, 2022, $29,776 of related-party payables, $31,285 of short-term related-party debt and $8,939 of accrued expenses owed to executives will be converted into 7,000 shares of common stock.

 

 
38

Table of Contents

       

DILUTION

 

Investors purchasing shares of common stock in this offering will experience immediate and substantial dilution in the as adjusted net tangible book value of their shares of common stock. Dilution in as adjusted net tangible book value represents the difference between the public offering price per share and the as adjusted net tangible book value per share of Common Stock immediately after the offering.

 

The historical net tangible book value of our common stock as of March 31, 2022 was $(5,344,000) or $(4.79) per share post-split. Historical net tangible book value per share of common stock represents our total tangible assets (total assets less intangible assets) less total liabilities divided by the number of shares of common stock outstanding as of that date.

 

After giving effect to the sale of 890,000 shares of common stock and related Public Warrants in this offering at the offering price of $10 per share and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, our net tangible book value as of March 31, 2022 would have been $5,133,000, or $2.56 per share. The offering price may not be the final price of the Offering and will be adjusted based on the actual initial public offering price and other terms of our initial public offering determined at pricing. This amount represents an immediate increase in net tangible book value of $7.35 per share to our existing stockholders and an immediate dilution in net tangible book value of approximately $7.44 per share to new investors purchasing our common stock in this offering. We determine dilution by subtracting the net tangible book value per share after the offering from the amount of cash that a new investor paid for a share of common stock.

 

The following table illustrates this dilution on a per share basis:

 

Offering price per share of common stock and associated Public Warrant(1)

 

$ 10.00

 

Historical net tangible book value per share as of March 31, 2022

 

$ (4.79 )

Increase in net tangible book value per share attributable to Investors

 

$ 7.35

 

Net tangible book value per share after the offering

 

$ 2.56

 

Dilution per share to new investors

 

$ 7.44

 

 

 

(1)

The offering price may not be the final price of the Offering and will be adjusted based on the actual initial public offering price and other terms of our initial public offering determined at pricing.

 

Each $1.00 increase or decrease in the combined public offering price of $10 per share and related Public Warrant would increase or decrease our net tangible book value after this offering by approximately $0.40 or ($0.43) per share, and increase or decrease the dilution per share to new investors by approximately $0.60 or ($0.57) per share, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number of shares we are offering. An increase or decrease of 100,000 securities in the number of securities offered by us would increase or decrease our net tangible book value after this offering by approximately $0.31 or ($0.37) per share, and increase or decrease the dilution per share to new investors by approximately ($0.31) or $0.37 per share, assuming that the public offering price remains the same, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. The information discussed above is illustrative only and will be adjusted based on the actual public offering price and other terms of this offering determined at pricing.

 

If the underwriters exercise their option to purchase additional shares in full, the net tangible book value per share after giving effect to the offering would be $2.97 per share. This represents an immediate increase in pro forma net tangible book value of $0.41 per share to existing stockholders and an immediate dilution in net tangible book value of $(0.41) per share to new investors purchasing our common stock in this offering.

 

 
39

Table of Contents

 

Management’s Discussion and Analysis of financial condition and results of operations presented below does not give effect to the Reverse Stock Split.

 

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion should be read in conjunction with the “Selected Financial Data” and our financial statements and related notes thereto included elsewhere in this prospectus. In addition to historical information, this discussion contains forward-looking statements that involve risks, uncertainties and assumptions that could cause actual results to differ materially from management’s expectations. Factors that could cause such differences are discussed in the sections entitled “Forward-Looking Statements” and “Risk Factors.” We are not undertaking any obligation to update any forward-looking statements or other statements we may make in the following discussion or elsewhere in this document even though these statements may be affected by events or circumstances occurring after the forward-looking statements or other statements were made. Therefore, no reader of this document should rely on these statements being current as of any time other than the time at which this document is declared effective by the SEC.

 

Overview

 

We are a medical technology company focused on developing innovative medical devices that have the potential to improve healthcare. Our primary focus is the sales and marketing of our LuViva® Advanced Cervical Scan non-invasive cervical cancer detection device. The underlying technology of LuViva primarily relates to the use of biophotonics for the non-invasive detection of cancers. LuViva is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point of care by scanning the cervix with light, then analyzing the reflected and fluorescent light.

 

LuViva is designed to provide a less invasive and painless alternative to conventional tests for cervical cancer screening and detection. Additionally, LuViva is designed to improve patient well-being not only because it eliminates pain, but also because it is convenient to use and provides rapid results at the point of care. We focus on two primary applications for LuViva: first, as a cancer screening tool in the developing world, where infrastructure to support traditional cancer-screening methods is limited or non-existent, and second, as a triage following traditional screening in the developed world, where a high number of false positive results cause a high rate of unnecessary and ultimately costly follow-up tests.

 

 
40

Table of Contents

  

We are a Delaware corporation, originally incorporated in 1992 under the name “SpectRx, Inc.,” and, on February 22, 2008, changed our name to Guided Therapeutics, Inc. At the same time, we renamed our wholly owned subsidiary, InterScan, which originally had been incorporated as “Guided Therapeutics.”

 

Since our inception, we have raised capital through the public and private sale of debt and equity, funding from collaborative arrangements, and grants.

 

Our prospects must be considered in light of the substantial risks, expenses and difficulties encountered by entrants into the medical device industry. This industry is characterized by an increasing number of participants, intense competition and a high failure rate. We have experienced operating losses since our inception and, as of March 31, 2022, we have an accumulated deficit of approximately $143.4 million. To date, we have engaged primarily in research and development efforts and the early stages of marketing our products. We do not have significant experience in manufacturing, marketing or selling our products. We may not be successful in growing sales for our products. Moreover, required regulatory clearances or approvals may not be obtained in a timely manner, or at all. Our products may not ever gain market acceptance and we may not ever generate significant revenues or achieve profitability. The development and commercialization of our products requires substantial development, regulatory, sales and marketing, manufacturing and other expenditures. We expect our operating losses to continue for the foreseeable future as we continue to expend substantial resources to complete commercialization of our products, obtain regulatory clearances or approvals, build our marketing, sales, manufacturing and finance capabilities, and conduct further research and development.

 

Our product revenues to date have been limited. In 2021, the majority of our revenues were from the sale of LuViva devices and disposables. We expect that the majority of our revenue in 2022 will be derived from revenue from the sale of LuViva devices and disposables.

 

Current Demand for LuViva

 

Based on written agreements and ongoing discussions with our distributors, we currently hold and expect to generate additional purchase orders for approximately $1.0 to $1.5 million in LuViva devices and disposables in 2022 and expect those purchase orders to result in actual sales of $0.5 to $1.0 million in 2022 representing what we view as current demand for our products. We cannot be assured that we will generate all or any of these additional purchase orders, or that existing orders will not be canceled by the distributors or that parts to build product will be available to meet demand, such that existing orders will result in actual sales. Because we have a short history of sales of our products, we cannot confidently predict future sales of our products beyond this time frame and cannot be assured of any particular amount of sales. Accordingly, we have not identified any particular trends with regard to sales of our products. In order to increase demand for LuViva, the Company in 2022 is focused on three primary markets: the United States, China and Europe. In addition, as of November 10, 2021, the Company had filed its initial application for listing on the Nasdaq stock exchange, been assigned a reviewer for its application and received an official review letter from Nasdaq. The goal is to uplist to Nasdaq during 2022, although there can be no assurance that this will happen.

 

In the United States, the Company is actively pursuing FDA approval by initiating a clinical trial protocol involving approximately 400 study participants. The protocol was drafted with input from FDA and three prestigious clinical centers that are expected to participate in enrolling the 400 women at multiple sites within their hospital systems. Clinical trial agreements have been drafted and agreed upon, the budget at one institution has been agreed upon and is under negotiation at the other institution. The third institution is reviewing the protocol and budget. The LuViva devices have been prepared and have passed bench testing in order to begin the study. All requested materials have been submitted for review by the respective hospital institutional review boards (IRBs). Once the IRB’s have approved the study, enrollment may begin, which is expected prior to the end of 2022 and will last approximately eight to nine months; however there can be no assurances that the study will be completed by the end of 2022.

 

In China, the Chinese NMPA (National Medical Products Approval) study has begun at four clinical sites. According to enrollment tracking reports sent to us by our Chinese partner SMI on March 11, 2022, testing of 150 patients has been completed in the ongoing clinical trial for Chinese National Medical Products Administration (NMPA) approval.  The trial is expected to be completed in the second quarter of this year and submitted for approval shortly thereafter, although there can be no assurance that the study will be completed within this time frame.

 

In Europe, the Company attended a meeting in Bucharest, Romania on November 3-4, 2021, hosted by our central Eastern and Russian distribution partner. The LuViva system was demonstrated for doctors at a local clinic and the head Ob-Gyn physician’s hospital has accepted the LuViva device into service and is expected to order additional Cervical Guides to test patients as part of her practice.

 

Critical Accounting Policies

 

Our material accounting policies, which we believe are the most critical to investors understanding of our financial results and condition, are discussed below. Because we are still early in our enterprise development, the number of these policies requiring explanation is limited. As we begin to generate increased revenue from different sources, we expect that the number of applicable policies and complexity of the judgments required will increase.

 

 
41

Table of Contents

  

Revenue Recognition: ASC 606, Revenue from Contracts with Customers establishes a single and comprehensive framework which sets out how much revenue is to be recognized, and when. The core principle is that a vendor should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the vendor expects to be entitled in exchange for those goods or services. Revenue will now be recognized by a vendor when control over the goods or services is transferred to the customer. In contrast, Revenue based revenue recognition around an analysis of the transfer of risks and rewards; this now forms one of a number of criteria that are assessed in determining whether control has been transferred. The application of the core principle in ASC 606 is carried out in five steps:

 

Step 1 - Identify the contract with a customer: a contract is defined as an agreement (including oral and implied), between two or more parties that creates enforceable rights and obligations and sets out the criteria for each of those rights and obligations. The contract needs to have commercial substance and it is probable that the entity will collect the consideration to which it will be entitled.

 

Step 2 - Identify the performance obligations in the contract: a performance obligation in a contract is a promise (including implicit) to transfer a good or service to the customer. Each performance obligation should be capable of being distinct and is separately identifiable in the contract.

 

Step 3 - Determine the transaction price: transaction price is the amount of consideration that the entity can be entitled to, in exchange for transferring the promised goods and services to a customer, excluding amounts collected on behalf of third parties.

 

Step 4 - Allocate the transaction price to the performance obligations in the contract: for a contract that has more than one performance obligation, the entity will allocate the transaction price to each performance obligation separately, in exchange for satisfying each performance obligation. The acceptable methods of allocating the transaction price include adjusted market assessment approach, expected cost plus a margin approach, and the residual approach in limited circumstances. Discounts given should be allocated proportionately to all performance obligations unless certain criteria are met and reallocation of changes in standalone selling prices after inception is not permitted.

 

Step 5 - Recognize revenue as and when the entity satisfies a performance obligation: the entity should recognize revenue at a point in time, except if it meets any of the three criteria, which will require recognition of revenue over time: the entity’s performance creates or enhances an asset controlled by the customer, the customer simultaneously receives and consumes the benefit of the entity’s performance as the entity performs, and the entity does not create an asset that has an alternative use to the entity and the entity has the right to be paid for performance to date.

 

Valuation of Deferred Taxes: We account for income taxes in accordance with the liability method. Under the liability method, we recognize deferred assets and liabilities based upon anticipated future tax consequences attributable to differences between financial statement carrying amounts of assets and liabilities and their respective tax bases. We establish a valuation allowance to the extent that it is more likely than not that deferred tax assets will not be utilized against future taxable income.

 

Valuation of Equity Instruments Granted to Employee, Service Providers and Investors: On the date of issuance, the instruments are recorded at their fair value as determined using either the Black-Scholes valuation model or Monte Carlo Simulation model.

  

Allowance for Accounts Receivable: The Company reviews all outstanding accounts receivable for collectability on a quarterly basis. An allowance for doubtful accounts is recorded for any amounts deemed uncollectable. The allowance is adjusted based on our assessment of the ability of our distributors to make required payments and our review of the financial condition of our distributors.

 

 
42

Table of Contents

  

Inventory Valuation: All inventories are stated at lower of cost or net realizable value, with cost determined substantially on a “first-in, first-out” basis. Selling, general, and administrative expenses are not inventoried, but are charged to expense when incurred.

 

Results of Operations

 

COMPARISON OF THE THREE MONTHS ENDED MARCH 31, 2022 AND 2021

 

Research and Development Expenses: Research and development expenses were $21,000 during the three months ended March 31, 2022, compared to $16,000 during the three months ended March 31, 2021, an increase of $5,000 or 31%. The increase was primarily due to higher research and development clinical costs and payroll-related expenses.

 

Sales and Marketing Expenses: Sales and marketing expenses were $40,000 during the three months ended March 31, 2022, compared to $36,000 during the three months ended March 31, 2021, an increase of $4,000 or 11%. The increase was primarily due to higher travel and payroll-related expenses.

 

General and Administrative Expense: General and administrative expenses were $386,000 for the three months ended March 31, 2022, compared to $771,000 during the three months ended March 31, 2021, a decrease of $385,000 or 50%. The decrease was primarily due to a prior-year charge of $398,000 recorded during the three months ended March 31, 2021 for warrants issued to Mr. Blumberg for consulting services. 

 

Interest Expense: Interest expense during the three months ended March 31, 2022 was $101,000, compared to $141,000 during the three months ended March 31, 2021, a decrease of $40,000, or 28%. The decrease was due a decrease in debt, resulting in lower interest recognized for outstanding notes payable and convertible debt during the three months ended March 31, 2022 versus the same period in the prior year.

 

Loss Due to Change in Fair Value of Derivative Liability: Loss due to change in fair value of the derivative liability during the three months ended March 31, 2022 was $6,000, compared to an $88,000 loss recorded during the three months ended March 31, 2021. The decrease was primarily due to changes to our stock price during each of the three-month periods, which impacted the fair value of the derivative liability.

 

Gain from extinguishment of debt: Gain from extinguishment of debt during the three months ended March 31, 2022 was $41,000, compared to a gain from extinguishment of debt of $87,000 during the three months ended March 31, 2021, a decrease of $46,000, or 53%. The decrease was due to a lower amount of debt forgiven.

 

Change in Fair Value of Warrants: Change in fair value of warrants during the three months ended March 31, 2022 was zero, compared to a $448,000 gain recorded during the three months ended March 31, 2021. The decrease was primarily due to (i) a change in the terms of the warrants during 2021, which resulted in reclassification of the warrant instruments from liabilities to equity and (ii) expiration of the warrants previously outstanding.

 

Preferred Stock Dividends: Expense related to preferred stock dividends during the three months ended March 31, 2022 was $548,000, compared to $55,000 of expense recorded during the three months ended March 31, 2021. The increase was primarily due to payment of a one-time, non-recurring 15% dividends to the Series F and Series F-2 Preferred shareholders, as required by the Series F and Series F-2 Certificate of Designations in the event the Company did not uplist to the NASDAQ stock exchange or file its clinical data intended for FDA approval of LuViva by December 31, 2021.

 

Net Loss: Net loss attributable to common stockholders was $1,055,000 for the three months ended March 31, 2022, compared to net loss of $572,000 for the three months ended March 31, 2021. The reasons for the fluctuation are outlined above.

 

There was no income tax benefit recorded for the three months ended March 31, 2022 and 2021, due to recurring net operating losses. A full valuation allowance has been recorded related the deferred tax assets generated from the net operating losses.

 

 
43

Table of Contents

 

COMPARISON OF THE YEARS ENDED DECEMBER 31, 2021 AND 2020

  

Sales Revenue, Cost of Sales and Gross Profit from Devices and Disposables: Revenues from the sale of LuViva devices for the year ended December 31, 2021 were $81,000, compared to $102,000 for the year ended December 31, 2020, a decrease of $21,000 or 21%. Cost of goods sold was $61,000 during the year ended December 31, 2021, compared to cost of goods recovered of $41,000 during the year ended December 31, 2020. Cost of goods recovered in 2020 was the result of the buy-back of parts from one customer that were then sold, resulting in a revaluation of the inventory reserve. Cost of goods sold increased during the year ended December 31, 2021 due to inventory write-offs of slow-moving inventory. This resulted in gross profit of $20,000 on the sales of devices and disposals for the year ended December 31, 2021, compared to gross profit of $143,000 for the same period in 2020. 

 

Research and Development Expenses: Research and development expenses for the year ended December 31, 2021 decreased to $69,000 from $143,000 during the same period in 2020. The decrease of $74,000 or 52% was primarily due to a reduction in research and development clinical costs and payroll expenses.

 

Sales and Marketing Expenses: Sales and marketing expenses for the year ended December 31, 2021 remained consistent with the year ended December 31, 2020.

 

General and Administrative Expense: General and administrative expenses for the year ended December 31, 2021 increased to approximately $2,172,000 compared to $913,000 during the same period in 2020. The increase of approximately $1,259,000, or 138%, was primarily due to a charge of $556,000 for warrants issued to Mr. Blumberg for consulting services and consulting expenses of $228,000 for warrants issued to finders in the capital raises. Additionally, during the year ended December 31, 2020, the Company reversed $292,000 of a reserve taken for a deposit made for inventory parts for its devices, which lowered general and administrative expenses in the prior period. The remaining increase in current period general and administrative expenses was due to minimal increases in rent expense, payroll-related expenses, and miscellaneous other expenses.

 

Other Income: Other income during the year ended December 31, 2021 was $507,000, compared to $271,000 during the same period in 2020. The increase of $236,000, or 87%, was primarily due to the write-off of a $350,000 subscription receivable liability during 2021. The increase was offset by additional income recorded for recovery of employment expenses and aged payables with had exceeded their statute of limitations on collectability during 2020.

 

Interest Expense: Interest expense for the year ended December 31, 2021 increased to approximately $1,150,000, compared to $1,056,000 during the same period in 2020. The increase of approximately $94,000, or 9%, was primarily due to a $350,000 prepayment penalty incurred on short-term convertible notes payable, offset by lower interest incurred for outstanding notes payable and convertible debt during the year ended December 31, 2021.

 

Gain (Loss) from extinguishment of debt: During the year ended December 31, 2021, the Company recognized a gain on extinguishment of debt of $578,000, compared to a loss on extinguishment of debt of $296,000 during the same period in 2020. The gain from debt extinguished in 2021 was primarily due to forgiveness of debt principal and accrued interest totaling $578,000 during 2021. The loss of $296,000 recognized in the prior period was related to debt eliminated from debt exchange agreements.

 

Change in Fair Value of Warrants: The gain recorded due to change in fair value of warrants was $448,000 during the year ended December 31, 2021, compared to $1,879,000 during the same period in 2020. The decrease of $1,431,000, or 76%, was primarily due to an exchange agreement signed with GPB Debt Holdings II LLC (“GPB”), which resulted changes to the terms of the warrants and reclassification of the warrants from liabilities to equity.

 

Change in Fair Value of Derivative Liability: Loss from the change in the fair value of the derivative liability was $91,000 during the year ended December 31, 2021, compared to $25,000 during the same period in 2020. The increase in the loss of $66,000, or 264%, was due to changes in the fair value of the associated derivative liability and extinguishment due to a $700,000 payoff of the associated loan.

 

Net Loss: Net loss attributable to common stockholders was $2,431,000 during the year ended December 31, 2021, compared to $401,000 during the same period in the prior year. The increase in net loss of $2,030,000 or 506% was due to the reasons described above.

 

There was no income tax benefit recorded for the years ended December 31, 2021 or 2020, due to recurring net operating losses.

 

 
44

Table of Contents

  

Liquidity And Capital Resources

 

Since our inception, we have raised capital through the public and private sale of debt and equity, funding from collaborative arrangements, and grants. As of March 31, 2022, we had cash of approximately $725,000 and negative working capital of $3,662,000.

 

Our major cash flows for the three months ended March 31, 2022 consisted of cash used by operating activities of $179,000, cash used for investing activities of $14,000, and net cash provided by financing activities of $275,000, which primarily represented the proceeds received from warrant exercises.

 

Capital Resources For 2021

 

During 2021, the Company received $1,130,000 of cash from the sale of 10% debenture unit investments and incurred transactional fees of $86,400. The Company issued the finders 413,600 warrants for the Company’s common stock shares. The investors received a total of 1,130,000 warrants for common stock shares. The debentures are convertible into 2,260,000 of the Company’s common stock shares.

 

During 2021, the Company received $2,114,000 of cash from the sale of equity securities and incurred transactional fees of $139,000. The Company also issued the finders 98,000 of the Company’s common stock shares and 643,700 warrants for the Company’s common stock shares. The investors received a total of 1,436 and 3,237 shares of Series F and Series F-2 preferred stock, respectively. Each share of Series F or Series F-2 preferred stock is convertible into 4,000 shares of the Company’s common stock, at the election of the investor.

 

During 2021, the Company finalized an investment by Power Up Lending Group Ltd (“Power Up”). Power Up invested $132,000 (of which the Company received $125,000 net of costs) for 153,000 shares of Series G preferred stock. As of December 31, 2021, all Series G preferred shares were redeemed.

 

During 2021, the Company entered into an exchange agreement with Richard Fowler. As of December 31, 2020, the Company owed Mr. Fowler $546,214 ($412,624 in deferred salary and $133,590 in accrued interest). Mr. Fowler exchanged $50,000 of the amount owed of $546,214 for 50 shares of Series F-2 Preferred Shares (convertible into 200,000 shares of common stock) and a $150,000 unsecured note. The note accrues interest at the rate of 6.0% (18.0% in the event of default) beginning on March 1, 2022 and is payable in monthly installments of $3,600 for four years, with the first payment being due on March 15, 2022. The effective interest rate of the note is 6.18%. Mr. Fowler forgave $86,554 and may forgive up to $259,661 of debt if the Company complies with the repayment plan described above.

 

Capital Resources For 2020

 

During 2020, we received equity investments in the amount of $1,735,500. These investors received a total of 1,735.5 shares of Series E preferred stock (if the Investor elects to convert their Series E preferred stock, each share of Series E preferred stock converts into 4,000 shares of our common stock).

 

During January and April 2020, we received equity investments in the amount of $128,000. These investors received a total of 256,000 shares of common stock and 256,000 warrants issued to purchase shares of common stock at a strike price of $0.25, 256,000 warrants to purchase shares of common stock at a strike price of $0.75 and 128 shares of Series D preferred stock (if the Investor elects to convert their Series D preferred stock, each share of Series D preferred stock converts into 3,000 shares of our common stock shares). Of the amount invested $38,000 was from related parties.

 

 
45

Table of Contents

  

On January 6, 2020, we entered into an exchange agreement with Jones Day. Upon making a payment of $175,000, which had not yet occurred, we will exchange $1,744,768 of debt outstanding for: $175,000, an unsecured promissory note in the amount of $550,000; due 13 months form the date of issuance, that may be called at any time prior to maturity upon a payment of $150,000; and an unsecured promissory note in the principal amount of $444,768, bearing an annualized interest rate of 6.0% and due in four equal annual installments beginning on the second anniversary of the date of issuance.

 

On January 8, 2020, we exchanged $2,064,366 in debt for several equity instruments (noted below) that were determined to have a total fair value of $2,065,548, resulting in a loss on extinguishment of debt of $1,183 which is recorded in other income (expense) on the accompanying consolidated statements of operations. We also issued 6,957,013 warrants to purchase shares of common stock; with exercise prices of $0.25, $0.75 and $0.20.

 

On June 3, 2020, we exchanged $328,422 in debt from Auctus, (summarized in footnote 10: Convertible Notes), for 500,000 shares of common stock and 700,000 warrants to purchase shares of common stock. The fair value of the shares of common stock was $250,000 (based on a $0.50 fair value for our stock) and of the warrants to purchase shares of common stock was $196,818 (based on a $0.281 black scholes fair valuation). This resulted in a net loss on extinguishment of debt of $118,396 ($446,818 fair value less the $328,422 of exchanged debt).

 

On June 30, 2020, we exchanged $125,000 in debt (during June 2020, $125,000 in payables had been converted into short-term debt) from Mr. James Clavijo, for 500,000 shares of common stock and 250,000 warrants to purchase shares of common stock. The fair value of the shares of common stock was $250,000 (based on a $0.50 fair value for our stock) and of the warrants to purchase shares of common stock was $99,963 (based on a $0.40 black scholes fair valuation). This resulted in a net loss on extinguishment of debt of $224,963 ($349,963 fair value less the $125,000 of exchanged debt). After the exchange transaction a balance was due Mr. Clavijo of $10,213 which was paid.

 

On July 9, 2020, we entered into an exchange agreement with Mr. Bill Wells (one of its former employees). In lieu of agreeing to dismiss approximately half of what is owed or

$220,000, Mr. Wells will receive the following: (i) cash payments of $20,000 within 60 days of the signing of the agreement; cash payments over time in the amount of $90,000 in the form of an unsecured note to be executed within 30 days of a new financing(s) totaling at least $3.0 million. The note shall bear interest of 6.0% and mature over 18 months; (iii) 66,000 common share stock options that vest at a rate of 3,667 per month and have a $0.49 exercise price (if two consecutive payments in (ii) are not made the stock options will be canceled and a cash payment will be required; and (iv) the total amount of forgiveness by creditor of approximately $110,000 shall be prorated according to amount paid.

 

The following table summarizes the debt exchanges:

 

 

 

 

Total Debt

and Accrued

Interest

 

 

Total

Debt

 

 

Total

Accrued

Interest

 

 

Common

Stock

Shares

 

 

Warrants

(Exercise

$0.25)

 

 

Warrants

(Exercise

$0.75)

 

 

Warrants

(Exercise

$0.20)

 

 

Warrants

(Exercise

$0.15)

 

 

Warrants

(Exercise

$0.50)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Aquarius

 

$ 145,544

 

 

$ 107,500

 

 

$ 38,044

 

 

 

291,088

 

 

 

145,544

 

 

 

145,544

 

 

 

-

 

 

 

-

 

 

 

-

 

K2 Medical (Shenghuo) (3)

 

 

803,653

 

 

 

771,927

 

 

 

31,726

 

 

 

1,905,270

 

 

 

704,334

 

 

 

704,334

 

 

 

496,602

 

 

 

-

 

 

 

-

 

Mr. Blumberg

 

 

305,320

 

 

 

292,290

 

 

 

13,030

 

 

 

1,167,630

 

 

 

119,656

 

 

 

119,656

 

 

 

928,318

 

 

 

-

 

 

 

-

 

Mr. Case

 

 

179,291

 

 

 

150,000

 

 

 

29,291

 

 

 

896,456

 

 

 

-

 

 

 

-

 

 

 

896,456

 

 

 

-

 

 

 

-

 

Mr. Grimm

 

 

51,110

 

 

 

50,000

 

 

 

1,110

 

 

 

255,548

 

 

 

-

 

 

 

-

 

 

 

255,548

 

 

 

-

 

 

 

-

 

Mr. Gould

 

 

111,227

 

 

 

100,000

 

 

 

11,227

 

 

 

556,136

 

 

 

-

 

 

 

-

 

 

 

556,136

 

 

 

-

 

 

 

-

 

Mr. Mamula

 

 

15,577

 

 

 

15,000

 

 

 

577

 

 

 

77,885

 

 

 

-

 

 

 

-

 

 

 

77,885

 

 

 

-

 

 

 

-

 

Dr. Imhoff2

 

 

400,417

 

 

 

363,480

 

 

 

36,937

 

 

 

1,699,255

 

 

 

100,944

 

 

 

100,944

 

 

 

1,497,367

 

 

 

-

 

 

 

-

 

Ms. Rosenstock (1)

 

 

50,000

 

 

 

50,000

 

 

 

-

 

 

 

100,000

 

 

 

50,000

 

 

 

50,000

 

 

 

-

 

 

 

-

 

 

 

-

 

Mr. James (2)

 

 

2,286

 

 

 

2,000

 

 

 

286

 

 

 

7,745

 

 

 

1,227

 

 

 

1,227

 

 

 

5,291

 

 

 

-

 

 

 

-

 

Auctus

 

 

328,422

 

 

 

249,119

 

 

 

79,303

 

 

 

500,000

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

700,000

 

 

 

-

 

Mr. Clavijo

 

 

125,000

 

 

 

125,000

 

 

 

-

 

 

 

500,000

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

250,000

 

Mr. Wells (4)

 

 

220,000

 

 

 

220,000

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Total

 

 

2,737,847

 

 

 

2,496,316

 

 

 

241,531

 

 

 

7,957,013

 

 

 

1,121,705

 

 

 

1,121,705

 

 

 

4,713,603

 

 

 

700,000

 

 

 

250,000

 

 

1.

Ms. Rosenstock also forgave $28,986 in debt.

2.

Mr. Imhoff and Mr. James are members of the board of directors and therefore related parties.

3.

Our COO and director, Mark Faupel, is a shareholder of Shenghuo, and another current director, Richard Blumberg, also is a managing member of Shenghuo.

4.

Mr. Wells will also receive 66,000 common share stock options; the details of which are explained above.

   

 
46

Table of Contents

  

On January 16, 2020, we entered into an exchange agreement with GPB. Under the terms of this exchange agreement, we will exchange $3,360,811 of debt outstanding as of December 12, 2019 for the following: (1) a cash payment of $1,500,000, (2) 7,185,000 warrants to purchase common stock, previously outstanding, would be exchanged for new warrants to purchase shares of common stock at a strike price of $0.20 and (3) a certain number of shares of preferred stock s for the remaining balance outstanding upon the final exchange date. On January 8, 2021, we made the final payment of $750,000 out of the total $1,500,000 as required by this exchange agreement with GPB. On June 30, 2021, we issued 2,236 shares of series F-2 preferred stock in accordance with the terms of the agreement.

 

On March 31, 2020, we entered into a securities purchase agreement with Auctus Fund, LLC for the issuance and sale to Auctus of $112,750 in aggregate principal amount of a 12% convertible promissory note. On March 31, 2020, we issued the note to Auctus and issued 250,000 five-year common stock warrants at an exercise price of $0.16. On April 3, 2020, we received net proceeds of $100,000. The note matured on January 26, 2021 and accrues interest at a rate of 12% per year. As December 31, 2021, the note is in default and accrues default interest of 24% per year.

 

On May 4, 2020, we received a loan from the Small Business Administration (SBA) pursuant to the Paycheck Protection Program (PPP) as part of the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) in the amount of $50,184. We were notified that the application for loan forgiveness was approved in the amount of $23,742 in principal and $234 in interest. We are planning on appealing the amount forgiven.

 

On May 20, 2020, we received a $70,000 loan from Mr. Blumberg, which was paid off in June 2020.

 

On May 22, 2020, we entered into an exchange agreement with Auctus. Based on this agreement we exchanged three outstanding notes, in the amounts of $150,000, $89,250, and $65,000 for a total amount $304,250 of debt outstanding, as well as any accrued interest and default penalty, for: $160,000 in cash payments (payable in monthly payments of $20,000), converted a portion of the notes pursuant to original terms of the notes into 500,000 restricted shares of common stock (shares were issued on June 3, 2020); and 700,000 warrants issued to purchase shares of common stock with an exercise price of $0.15. The fair value of the shares of common stock was $250,000 (based on a $0.50 fair value for our stock) and of the warrants to purchase shares of common stock was $196,818 (based on a $0.281 black scholes fair valuation). This resulted in a net loss on extinguishment of debt of $118,396 ($446,818 fair value less the $328,422 of exchanged debt). The notes were no longer outstanding as of December 31, 2021.

 

On May 27, 2020, we received the second tranche in the amount of $400,000, from the December 17, 2019, securities purchase agreement and convertible note with Auctus. The net amount paid to us was $313,000 This second tranche is part of the convertible note issued to Auctus for a total of $2.4 million of which $700,000 has already been provided by Auctus. The note matures on May 27, 2022 and accrues interest at a rate of ten percent (10% per annum). This note is subject to the exchange agreement dated February 1, 2022 discussed below.

 

Auctus Exchange

 

On June 2, 2021, we entered into an initial exchange agreement Auctus. On February 1, 2022, we entered into a second exchange agreement with Auctus. Pursuant to this second agreement, Auctus agreed to exchange an aggregate of $668,290 of outstanding notes (the "Notes"), including accrued interest, and the associated warrants issued in connection with the Notes (which warrants, for the purpose of the exchange, are valued at, in the aggregate, $1,681,707) into unregistered units of our common stock, warrants and prefunded warrants otherwise in the form and ratios issued in this offering. The exchange price will be on a $1 for $1 basis such that Auctus will receive $2,349,997 of units consisting of common stock, warrants and prefunded warrants. The units being issued in the exchange with Auctus are not registered on this Registration Statement and are being issued pursuant to Section 4(a)(2) under the Securities Act of 1933, as amended. Additionally, the units and the common stock underlying the units will be subject to a lock up agreement with the underwriters until the earlier of 120 days after this offering and the date that the daily volume weighted average price of the common stock exceeds 200% of the public offering price for at least five consecutive trading days. Further, the termination date of the June 2, 2021 agreement was extended to April 15, 2022. The $350,000 related to default penalties will be exchanged into $350,000 of securities offered in the Nasdaq uplist offering. On April 14, 2022, we entered into an agreement with Auctus that extended the April 15, 2022 deadline to May 15, 2022. On June 1, 2022, we entered into a third exchange agreement with Auctus. As of the date of the agreement, Auctus was owed $692,114 of Notes and accrued interest. Pursuant to this third agreement, as long as we complete the Nasdaq Offering prior to July 15, 2022, the total amount owed to Auctus will be payable in cash 13 months subsequent to the consummation of the Offering.

 

GPB Warrant Exchange Agreement

 

On December 21, 2021, we entered into a warrant exchange agreement with GPB Holdings LLC. Pursuant to this agreement, upon an equity financing of net proceeds of at least $4.0 million, GPB will exchange 7,185,000 pre-split warrants at an exercise price of $0.20, with no anti-dilution provisions and no cashless exercise provision, for a cash payment of $350,000 and new warrants under the same terms as warrants granted in the aforementioned financing. The warrants will vest six months from the closing date of the equity financing. The investor agreed to restrict its holding of Company’s common stock to less than 4.99% of the total number of the Company’s outstanding common shares at any one point in time.

 

Other Warrant Exchange Agreements

 

During the year ended December 31, 2021, the Company entered into various agreements with holders of the Company’s $0.20 strike price warrants, pursuant to which each holder separately agreed to exchange 4,713,603 common stock warrants with a strike price of $0.20 for 4,477,923 common stock warrants with a strike price of $0.16 and a contractual term of 15 days. The Company received approximately $365,492 from the holders for the exercises of the warrants.

 

Contingencies

 

Based on the current outbreak of the Coronavirus SARS-CoV-2, the pathogen responsible for COVID-19, which has already had an impact on financial markets, there could be additional repercussions in our operating business, including but not limited to, the sourcing of materials for product candidates, manufacture of supplies for preclinical and/or clinical studies, delays in clinical operations, which may include the availability or the continued availability of patients for trials due to such things as quarantines,  conduct of  patient monitoring and clinical trial data retrieval at investigational study sites.

 

 
47

Table of Contents

  

The future impact of the outbreak is highly uncertain and cannot be predicted, and we cannot provide any assurance that the outbreak will not have a material adverse impact on our operations or future results or filings with regulatory health authorities. The extent of the impact, if any, we will depend on future developments, including actions taken to contain the coronavirus.

 

The conflict in Ukraine, which has already had an impact on financial markets, could result in additional repercussions in our operating business, including delays in obtaining regulatory approval to market our products in Russia. The future impact of the conflict is highly uncertain and cannot be predicted, and we cannot provide any assurance that the conflict will not have a material adverse impact on our operations or future results or filings with regulatory health authorities.

 

Off-Balance Sheet Arrangements

 

We have no material off-balance sheet arrangements, no special purpose entities, and no activities that include non-exchange-traded contracts accounted for at fair value.

 

BUSINESS

 

Overview

 

We are a medical technology company focused on developing innovative medical devices that have the potential to improve healthcare. Our primary focus is the sales and marketing of our LuViva® Advanced Cervical Scan non-invasive cervical cancer detection device. The underlying technology of LuViva primarily relates to the use of biophotonics for the non-invasive detection of cancers. LuViva is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point of care by scanning the cervix with light, then analyzing the reflected and fluorescent light.

 

LuViva is designed to provide a less invasive and painless alternative to conventional tests for cervical cancer screening and detection. Additionally, LuViva is designed to improve patient well-being not only because it eliminates pain, but also because it is convenient to use and provides rapid results at the point of care. We focus on two primary applications for LuViva: first, as a cancer screening tool in the developing world, where infrastructure to support traditional cancer-screening methods is limited or non-existent, and second, as a triage following traditional screening in the developed world, where a high number of false positive results cause a high rate of unnecessary and ultimately costly follow-up tests.

 

Screening for cervical cancer represents one of the most significant demands on the practice of diagnostic medicine. As cervical cancer is linked to a sexually transmitted disease -the human papillomavirus (HPV)-every woman essentially becomes “at risk” for cervical cancer simply after becoming sexually active. In the developing world, there are approximately 2.0 billion women aged 15 and older who are potentially eligible for screening with LuViva. Guidelines for screening intervals vary across the world, but U.S. guidelines call for screening every three years. Traditionally, the Pap smear screening test, or Pap test, is the primary cervical cancer screening methodology in the developed world. However, in developing countries, cancer screening using Pap tests is expensive and requires infrastructure and skill not currently existing, and not likely to be developed in the near future, in these countries.

 

We believe LuViva is the answer to the developing world’s cervical cancer screening needs. Screening for cervical cancer in the developing world often requires working directly with foreign governments or non-governmental agencies (NGOs). By partnering with governments or NGOs, we can provide immediate access to cervical cancer detection to large segments of a nation’s population as part of national or regional governmental healthcare programs, eliminating the need to develop expensive and resource-intensive infrastructures.

 

In the developed world, we believe LuViva offers a more accurate and ultimately cost-effective triage medical device, to be used once a traditional Pap test or HPV test indicates the possibility of cervical cancer. Due to the high number of false positive results from Pap tests, traditional follow-on tests entail increased medical treatment costs. We believe these costs can be minimized by utilizing LuViva as a triage to determine whether and to what degree follow-on tests are warranted.

 

 
48

Table of Contents

  

We believe our non-invasive cervical cancer detection technology can be applied to the early detection of other cancers as well. For example, we have developed prototypes and conducted limited clinical studies using our biophotonic technology for the detection of esophageal cancer. The Company believes that skin cancer detection also is a promising target for our technology, but currently we are focused primarily on the large-scale commercialization of LuViva.

 

Cancer

 

Cancer is a group of many related diseases. All forms of cancer involve the out-of-control growth and spread of abnormal cells. Normal cells grow, divide, and die in an orderly fashion. Cancer cells, however, continue to grow and divide and can spread to other parts of the body. As reported in 2015, in the United States, one in every two women and one in every three men will develop cancer in their lifetimes. According to the American Cancer Society, the sooner a cancer is found and treatment begins, the better a patient’s chances are of being cured. We began investigating the applications of our biophotonic technology to cancer detection before 1997, when we initiated a preliminary market analysis. We concluded that our biophotonic technology had applications for the detection of a variety of cancers through the exposure of tissue to light. We selected detection of cervical cancer and skin cancer from a list of the ten most promising applications to pursue initially, and ultimately focused primarily on our LuViva cervical cancer detection device.

 

Cervical cancer is a cancer that begins in the lining of the cervix (which is located in the lower part of the uterus). Cervical cancer forms over time and may spread to other parts of the body if left untreated. There is generally a gradual change from a normal cervix to a cervix with precancerous cells to cervical cancer. For some women, precancerous changes may go away without any treatment. While the majority of precancerous changes in the cervix do not advance to cancer, if precancers are treated, the risk that they will become cancers can be greatly reduced.

 

The Developing World

 

According to the most recent data published by the WHO, cervical cancer is the fourth most frequent cancer in women worldwide, with an estimated 570,000 new cases in 2018, an increase of 40,000 cases from 2012. For women living in less developed regions, however, cervical cancer is the second most common cancer, and 9 out of 10 women who die from cervical cancer reside in low- and middle-income countries. In 2018, GLOBOCAN, the international cancer tracking agency, estimated that approximately 311,000 women died from cervical cancer, with 85% of these deaths occurring in low- and middle-income countries.

 

As noted by the WHO, in developed countries, programs are in place that enable women to get screened, making most pre-cancerous lesions identifiable at stages when they can easily be treated. Early treatment prevents up to 80% of cervical cancers in these countries. In developing countries, however, limited access to effective screening means that the disease is often not identified until it is further advanced and symptoms develop. In addition, prospects for treatment of such late-stage disease may be poor, resulting in a higher rate of death from cervical cancer in these countries.

 

We believe that the greatest need and market opportunity for LuViva lies in screening for cervical cancer in developing countries where the infrastructure for traditional screening may be limited or non-existent.

 

In addition to private care markets, we are actively working with distributors in the following countries to implement government-sponsored screening programs: Turkey, Indonesia and several countries in Eastern Europe. The number of screening candidates in those countries is approximately 155 million.

 

 
49

Table of Contents

  

The Developed World

 

The Pap test, which involves a sample of cervical tissue being placed on a slide and observed in a laboratory, is currently the most common form of cervical cancer screening. Since the introduction of screening and diagnostic methods, the number of cervical cancer deaths in the developed world has declined dramatically, due mainly to the increased use of the Pap test. However, the Pap test has a wide variation in sensitivity, which is the ability to detect the disease, and specificity, which is the ability to exclude false positives. A study by Duke University for the U.S. Agency for Health Care Policy and Research published in 1999 showed Pap test performance ranging from a 22%-95% sensitivity and 78%-10% specificity, although new technologies improving the sensitivity and specificity of the Pap test have recently been introduced and are finding acceptance in the marketplace. About 60 million Pap tests are given annually in the United States, and combined with a pelvic exam as the standard of care, has an average price of approximately $380 per exam.

 

After a Pap test returns a positive result for cervical cancer, accepted protocol calls for a visual examination of the cervix using a colposcope, usually followed by a biopsy, or tissue sampling, at one or more locations on the cervix. This method looks for visual changes attributable to cancer. There are about two million colposcope examinations annually in the United States and Europe. According to industry reports by MD Save and Costhelper Health, leading online medical service providers, the average cost of a colposcopy examination with biopsy in the United States is currently $943.

 

Given this landscape, we believe that there is a material need and market opportunity for LuViva as a triage device in the developed world where LuViva represents a more cost- effective method of verifying a positive Pap test than the alternatives.

 

The LuViva Advanced Cervical Scan

 

LuViva is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point of care by scanning the cervix with light, then analyzing the light reflected from the cervix. The information presented by the light would be used to indicate the likelihood of cervical cancer or precancers. Our product, in addition to detecting the structural changes attributed to cervical cancer, is also designed to detect the biochemical changes that precede the development of visual lesions. In this way, cervical cancer may be detected earlier in its development, which should increase the chances of effective treatment. In addition to the device itself, operation of LuViva requires employment of our single-use, disposable calibration and alignment cervical guide.

 

To date, thousands of women in multiple international clinical settings have been tested with LuViva. As a result, more than 25 papers and presentations have been published regarding LuViva in a clinical setting, including at the International Federation of Gynecology and Obstetrics Congress in London in 2015 and at the Indonesian National Obstetrics and Gynecology (POGI) Meeting in Solo in 2016.

 

Internationally, we contract with country-specific or regional distributors. We believe that the international market will be significantly larger than the U.S. market due to the international demand for cervical cancer screening. We have executed formal distribution agreements covering over 40 countries, some of which have since expired. We still have active contracts in place for countries including China and Southeast Asia (including Indonesia), Eastern Europe and Russia. In 2022, we intend to focus on other large markets such as those in the European Union, India, and certain Latin American countries, such as Mexico.

 

We have previously obtained regulatory approval to sell LuViva in Europe under our Edition 3 CE Mark. Additionally, LuViva has also previously obtained marketing approval from Health Canada, COFEPRIS in Mexico, Ministry of Health in Kenya, which have all expired. Presently, we have marketing approval from India and the Singapore Health Sciences Authority. In addition, in 2018, we were approved for sales and marketing in India. We currently are seeking regulatory approval to market LuViva in the United States but have not yet received approval from the U.S. Food and Drug Administration (FDA). As of December 31, 2021, we have sold 144 LuViva devices and approximately 76,980 single-use-disposable cervical guides to international distributors.

 

We believe our non-invasive cervical cancer detection technology can be applied to the early detection of other cancers as well. From 2008 to early 2013, we worked with Konica Minolta to explore the feasibility of adapting our microporation and biophotonic cancer detection technology to other areas of medicine and to determine potential markets for these products in anticipation of a development agreement. In February 2013, we replaced our existing agreements with Konica Minolta with a new agreement, pursuant to which, subject to the payment of a nominal license fee due upon FDA approval, Konica Minolta has granted us a five-year, world-wide, non-transferable and non-exclusive right and license to manufacture and to develop a non-invasive esophageal cancer detection product from Konica Minolta and based on our biophotonic technology platform. The license permitted us to use certain related intellectual property of Konica Minolta. In return for the license, we agreed to pay Konica Minolta a royalty for each licensed product we sell that includes their intellectual property. To date, we have not achieved any sales of products that include the intellectual property of Konica Minolta. As we develop LuViva as a commercial product, we will continue to seek new collaborative partners focused especially on marketing and sales.

 

 
50

Table of Contents

  

Our Strengths

 

Currently, we are the only commercial stage company with a biophotonic technology that potentially addresses a large primary screening market and a potential R&D pipeline that could improve the early detection of numerous cancers that afflict men and women. Key strengths include:

 

 

·

The engineering and production risks have been largely addressed as we have sold over 100 working systems worldwide.

 

 

 

 

·

Regulatory approvals have been granted covering over 40 countries.

 

 

 

 

·

We have legitimate pathways for securing marketing approvals in the two largest medical markets - the US and China, within a 2-3 year period.

 

 

 

 

·

The clinical results of our technology have been published in leading peer-reviewed journals by world-famous, thought leading physicians.

 

Our Business Strategy

 

Our near term goals are to accomplish the following over the next two years by pursuing the following strategies:

 

 

·

Seek US FDA approval by completing a clinical trial.

 

 

 

 

·

Contingent upon FDA approval, discuss opportunities to partner with a larger U.S. based company for distribution in the U.S. At the same time, we intend to build a small dedicated sales force based near major metropolitan centers and focused on generating sales at large centralized Ob-Gyn practices.

 

 

 

 

·

Seek Chinese FDA approval working with our existing partner in China, Shandong Medical Instrumentation Co. Ltd.

 

 

 

 

·

Pursue regulatory approval in Russia and work with our partner in Eastern Europe, Newmars Technology, Inc. to generate sales in Europe.

 

 

 

 

·

Continue to selectively support sales through our distributors in large countries such as Indonesia.

 

While we plan to pursue regulatory approval in Russia, the ongoing conflict in Ukraine may delay filing and approval to market LuViva in Russia.  It does not affect any existing contracts with our distribution partner for Eastern Europe and Russia as they are focused more on countries less affected by the conflict in Ukraine.

 

Manufacturing, Sales Marketing and Distribution

 

We manufacture LuViva at our Norcross, Georgia facility and our contract manufacturer, Newmars Technology, Inc, located near Budapest, Hungary. Most of the operational components of LuViva are custom made for us by third-party manufacturers. We adhere to ISO 13485:2003 quality standards in our manufacturing processes. Our single-use cervical guides are manufactured by a vendor that specializes in injection molding of plastic medical products. On January 22, 2017, we entered into a license agreement with SMI, as amended on March 28, 2017, pursuant to which we granted SMI an exclusive global license to manufacture the LuViva device and related disposables (subject to a carve-out for manufacture in Turkey). On December 18, 2018, we entered into a co-development agreement with NTI, whereby NTI will perform final assembly of the LuViva device for its contracted distribution countries in Eastern Europe and Russia at its ISO 13485 facility in Hungary. This additional carve out has been agreed to by SMI. On August 12, 2021 the Company entered into a second amendment with SMI pursuant to which the Company has continued to grant SMI exclusive distribution, sales and manufacturing rights of the LuViva for China, Taiwan, Hong Kong and Macau.

 

 
51

Table of Contents

  

We rely on distributors to sell our products. Distributors can be country exclusive or cover multiple countries in a region. We manage these distributors, provide them marketing materials and train them to demonstrate and operate LuViva. We seek distributors that have experience in gynecology and in introducing new technology into their assigned territories. Currently, we rely on SMI in distributing our products in the People's Republic of China, Macau, Hong Kong and Taiwan; we rely on NTI in distributing our products in Eastern Europe and Russia.

 

We have only limited experience in the production planning, quality system management, facility development, and production scaling that will be needed to bring production to increased sustained commercial levels. We will likely need to develop additional expertise in order to successfully manufacture, market, and distribute any future products.

 

Patents

 

We have pursued a course of developing and acquiring patents and patent rights and licensing technology. Our success depends in large part on our ability to establish and maintain the proprietary nature of our technology through the patent process and to license from other’s patents and patent applications necessary to develop our products. As of March 31, 2022, we have 41 granted U.S. and foreign patents, collectively, relating to our biophotonic cancer detection technology that were developed in-house and are owned by the Company. 10 patents are still currently active and 31 have since expired. Currently, we do not own third party patents nor do we make any outside payments for patents.

 

Patents can be extended up to an additional five (5) years. However, patent term extension under the Hatch-Waxman Act does not occur automatically and the patent owner must file an application with the USPTO requesting term extension within 60 days of obtaining FDA marketing approval.

 

Patent No.

Title

Country

Grant Date

Expiration Date

6,792,982

Vacuum Source For Harvesting Substances

US

9/21/2004

7/23/2023

7,174,927

Vacuum Source For Harvesting Substances

US

2/13/2007

9/3/2024

7,301,629

Apparatus and Method for Determining Tissue Characteristics

US

11/27/2007

7/3/2023

7,335,166

System And Methods For Fluid Extractions And Monitoring

US

2/26/2008

5/22/2023

8,644,912

Method and Apparatus For Determining Tissue Characteristics

US

2/4/2014

8/22/2031

8,781,560

Method and Apparatus For Rapid Detection and Diagnosis of Tissue Abnormalities

US

7/15/2014

9/09/2031

9,561,003

Method and Apparatus For Rapid Detection and Diagnosis of Tissue Abnormalities

US

2/7/2017

3/5/2034

D714453

Mobile Cart and Hand Held Unit for Diagnostics of Measurement

US

9/30/2014

9/30/2028

D724199

Medical Diagnostic Stand Off Tube

US

3/10/2015

3/10/2029

D746475

Mobile Cart and Hand Held Unit for Diagnostics or Measurement

US

12/29/2015

12/29/2029

 

 
52

Table of Contents

  

The Company has applied for two additional US patents, although there is no assurance that these patents will be granted. The Company’s strategy is to continue improving its products and filing new patents to protect those improvements.

 

In the United States, additional years of patent protection may be added (on a case-by-case basis) beyond the standard patent terms under the 1984 Drug Price Competition and Patent Term Restoration Act, also known as the Hatch-Waxman Act. The Hatch-Waxman act includes Section 156, which provides for the extension of the term of a granted patent (PTE) under certain circumstances. The intent behind Section 156 is to extend patent life to compensate patent holders for patent term lost while developing their product and awaiting FDA approval. The Company’s patents qualify under Section 156 because LuViva has not yet been commercialized in the United States and it is being regulated by FDA as a Class III Medical Device.

 

Research, Development and Engineering

 

We have been engaged primarily in the research, development and testing of our LuViva non-invasive cervical cancer detection product and our core biophotonic technology. Since 2013, we have incurred approximately $8.1 million in research and development expenses, net of about $927,000 reimbursed through collaborative arrangements and government grants. Research and development costs were approximately $0.1 million in the years ended December 31, 2021 and 2020 and were not material during the three months ended March 31, 2022.

  

Since 2013, we have focused our research and development and our engineering resources almost exclusively on development of our biophotonic technology, with only limited support of other programs funded through government contracts or third-party funding. Because our research and clinical development programs for other cancers are at a very early stage, substantial additional research and development and clinical trials will be necessary before we can produce commercial prototypes of other cancer detection products.

 

Several of the components used in LuViva currently are available from only one supplier, and substitutes for these components could not be obtained easily or would require substantial modifications to our products.

 

Competition

 

The medical device industry in general and the markets for cervical cancer detection in particular, are intensely competitive. If successful in our product development, we will compete with other providers of cervical cancer detection and prevention products.

 

Current cervical cancer screening and diagnostic tests, primarily the Pap test, HPV test, and colposcopy, are well established and pervasive. Improvements and new technologies for cervical cancer detection and prevention, such as Thin-Prep from Hologic and HPV testing from Qiagen, have led to other new competitors. In addition, there are other companies attempting to develop products using forms of biophotonic technologies in cervical cancer detection, such as Spectrascience, which has a very limited U.S. FDA approval to market its device for detection of cervical cancers, but has not yet entered the market. The approval limits use of the Spectrascience device only after a colposcopy, as an adjunct. In addition to the Spectrascience device, there are other technologies that are seeking to enter the market as adjuncts to colposcopy, including devices from Dysis and Zedco. While these technologies are not direct competitors to LuViva, modifications to them or other new technologies will require us to develop devices that are more accurate, easier to use or less costly to administer so that our products have a competitive advantage.

 

In April 2014, the U.S. FDA approved the use of the Roche cobas HPV test as a primary screener for cervical cancer. Using a sample of cervical cells, the cobas HPV test detects DNA from 14 high-risk HPV types. The test specifically identifies HPV 16 and HPV 18, while concurrently detecting 12 other types of high-risk HPVs. This could make HPV testing a competitor to the Pap test. However, due to its lower specificity, we believe that screening with HPV will increase the number of false positive results if widely adopted.

 

In June 2006, the U.S. FDA approved the HPV vaccine Gardasil from drug maker Merck. Gardasil is a prophylactic HPV vaccine, meaning that it is designed to prevent the initial establishment of HPV infections. For maximum efficacy, it is recommended that girls receive the vaccine prior to becoming sexually active. Since Gardasil will not block infection with all of the HPV types that can cause cervical cancer, the vaccine should not be considered a substitute for routine Pap tests. On October 16, 2009, GlaxoSmithKline PLC was granted approval in the United States for a similar preventive HPV vaccine, known as Cervarix. Due to the limited availability and lack of 100% protection against all potentially cancer-causing strains of HPV, we believe that the vaccines will have a limited impact on the cervical cancer screening and diagnostic market for many years.

 

 
53

Table of Contents

  

Government Regulation

 

The medical devices that we manufacture are subject to regulation by numerous regulatory bodies, including the Chinese FDA (recently renamed the Chinese National Medical Product Administration (NMPA), the U.S. FDA, and comparable international regulatory agencies. These agencies require manufacturers of medical devices to comply with applicable laws and regulations governing the development, testing, manufacturing, labeling, marketing and distribution of medical devices. Devices are generally subject to varying levels of regulatory control, the most comprehensive of which requires that a clinical evaluation program be conducted before a device receives approval for commercial distribution.

 

In the European Union, medical devices are required to comply with the Medical Devices Directive and obtain CE Mark certification in order to market medical devices. The CE Mark certification, granted following approval from an independent “Notified Body,” is an international symbol of adherence to quality assurance standards and compliance with applicable European Medical Devices Directives. From 2017 through 2019, we were unable to pay the annual registration fees to maintain our ISO 13485:2003 certification and our CE Mark. On December 21, 2018 we executed an agreement with Newmars, described above, for final assembly of LuViva at their ISO 13485:2016 accredited facility. This allowed LuViva to be granted to CE Mark through the facility at Newmars, which was achieved in 2021, and both the ISO and CE Mark accreditations for LuViva are currently active. Thus, LuViva can be marketed in the European Union and other countries that honor the CE Mark.

 

China has a regulatory regime similar to that of the European Union, but due to interaction with the U.S. regulatory regime, the CFDA also shares some similarities with its U.S. counterpart. Devices are classified by the CFDA’s Center for Medical Device Evaluation (CMDE) into three categories based on medical risk, with the level of regulatory oversight determined by degree of risk and invasiveness. CMDE’s device classifications and definitions are as follows:

 

 

·

Class I device: The safety and effectiveness of the device can be ensured through routine administration.

 

 

 

 

·

Class II device: Further control is required to ensure the safety and effectiveness of the device.

 

 

 

 

·

Class III device: The device is implanted into the human body; used for life support or sustenance; or poses potential risk to the human body, and thus must be strictly controlled in respect to safety and effectiveness.

 

Based on the above definitions and several discussions with regulatory consultants and potential partners, we believe that LuViva is most likely to be classified as a Class II device, however, this is not certain and the CFDA may determine that LuViva requires a Class III registration. Class III registrations are granted by the national CFDA office while Class I and II registrations occur at the provincial level. Typically, registration granted at the provincial level allows a medical device to be marketed in all of China’s provinces.

 

While Class I devices usually do not require clinical trial data from Chinese patients and Class III devices almost always do, Class II medical devices sometimes do and sometimes do not require Chinese clinical trials, and this determination may depend on the claim for the device and quality of clinical trials conducted outside of China. If clinical trials conducted in China are required, they usually are less burdensome for Class II devices than Class III devices.

 

CFDA labs also conduct electrical, mechanical and electromagnetic emission safety testing for medical devices similar to those required for the CE Mark. As is the case with the

U.S. FDA, manufacturers in China undergo periodic inspections and must comply with international quality standards such as ISO 13485 for medical devices. As part of our agreement with SMI, SMI will underwrite the cost of securing approval of LuViva with the CFDA. As of the date of this Prospectus, SMI has informed us in writing that LuViva has passed electrical, mechanical and electromagnetic emission safety testing for medical devices, which allows clinical trials to commence.

 

In the United States, permission to distribute a new device generally can be met in one of two ways. The first process requires that a pre-market notification (510(k) Submission) be made to the U.S. FDA to demonstrate that the device is as safe and effective as, or substantially equivalent to, a legally marketed device that is not subject to premarket approval (PMA). A legally marketed device is a device that (1) was legally marketed prior to May 28, 1976, (2) has been reclassified from Class III to Class II or I, or (3) has been found to be substantially equivalent to another legally marketed device following a 510(k) Submission. The legally marketed device to which equivalence is drawn is known as the “predicate” device. Applicants must submit descriptive data and, when necessary, performance data to establish that the device is substantially equivalent to a predicate device. In some instances, data from human clinical studies must also be submitted in support of a 510(k) Submission. If so, these data must be collected in a manner that conforms with specific requirements in accordance with federal regulations. The U.S. FDA must issue an order finding substantial equivalence before commercial distribution can occur. Changes to existing devices covered by a 510(k) Submission which do not significantly affect safety or effectiveness can generally be made by us without additional 510(k) Submissions.

 

 
54

Table of Contents

  

The second process requires that an application for premarket approval (PMA) be made to the U.S. FDA to demonstrate that the device is safe and effective for its intended use as manufactured. This approval process applies to most Class III devices, including LuViva. In this case, two steps of U.S. FDA approval are generally required before marketing in the United States can begin. First, investigational device exemption (IDE) regulations must be complied with in connection with any human clinical investigation of the device in the United States. Second, the U.S. FDA must review the PMA application, which contains, among other things, clinical information acquired under the IDE. The U.S. FDA will approve the PMA application if it finds that there is a reasonable assurance that the device is safe and effective for its intended purpose.

 

We completed enrollment in our U.S. FDA pivotal trial of LuViva in 2008 and, after the U.S. FDA requested two-years of follow-up data for patients enrolled in the study, the

U.S. FDA accepted our completed PMA application on November 18, 2010, effective September 23, 2010, for substantive review. On March 7, 2011, we announced that the U.S. FDA had inspected two clinical trial sites and audited our clinical trial data base systems as part of its review process and raised no formal compliance issues. On January 20, 2012, we announced our intent to seek an independent panel review of our PMA application after receiving a “not-approvable” letter from the U.S. FDA. On November 14, 2012 we filed an amended PMA with the U.S. FDA. On September 6, 2013, we received a letter from the U.S. FDA with additional questions and met with the U.S. FDA on May 8, 2014 to discuss our response. On July 25, 2014, we announced that we had responded to the U.S. FDA’s most recent questions.

 

We received a “not-approvable” letter from the U.S. FDA on May 15, 2015. We had a follow up meeting with the U.S. FDA to discuss a path forward on November 30, 2015, at which we agreed to submit a detailed clinical protocol for U.S. FDA review so that additional studies can be completed. We held a follow up teleconference with FDA on January 28, 2020 and filed a pre-submission document to the Agency on February 17, 2020 that summarized the clinical protocol to be submitted for FDA review. We agreed with the FDA on the study protocol during the second quarter of 2021 and are recruiting clinical sites for the study. These studies may not be completed in 2022, although we intend to pursue FDA approval and start studies in 2022 once funds are available. We remain committed to obtaining U.S. FDA approval, but at the same time we are focused on international sales growth, where we believe the commercial opportunities are larger and the clinical need is more significant.

 

The process of obtaining clearance to market products is costly and time-consuming in virtually all of the major markets in which we sell, or expect to sell, our products and may delay the marketing and sale of our products. Countries around the world have recently adopted more stringent regulatory requirements, which are expected to add to the delays and uncertainties associated with new product releases, as well as the clinical and regulatory costs of supporting those releases. No assurance can be given that our products will be approved on a timely basis in any particular jurisdiction, if at all. In addition, regulations regarding the development, manufacture and sale of medical devices are subject to future change. We cannot predict what impact, if any, those changes might have on our business. Failure to comply with regulatory requirements could have a material adverse effect on our business, financial condition and results of operations.

 

Noncompliance with applicable requirements can result in import detentions, fines, civil penalties, injunctions, suspensions or losses of regulatory approvals or clearances, recall or seizure of products, operating restrictions, denial of export applications, governmental prohibitions on entering into supply contracts, and criminal prosecution. Failure to obtain regulatory approvals or the restriction, suspension or revocation of regulatory approvals or clearances, as well as any other failure to comply with regulatory requirements, would have a material adverse effect on our business, financial condition and results of operations.

 

Regulatory approvals and clearances, if granted, may include significant labeling limitations and limitations on the indicated uses for which the product may be marketed. In addition, to obtain regulatory approvals and clearances, the U.S. FDA and some foreign regulatory authorities impose numerous other requirements with which medical device manufacturers must comply. U.S. FDA enforcement policy strictly prohibits the marketing of approved medical devices for unapproved uses. Any products we manufacture or distribute under U.S. FDA clearances or approvals are subject to pervasive and continuing regulation by the U.S. FDA. The U.S. FDA also requires us to provide it with information on death and serious injuries alleged to have been associated with the use of our products, as well as any malfunctions that would likely cause or contribute to death or serious injury.

 

 
55

Table of Contents

  

The U.S. FDA requires us to register as a medical device manufacturer and list our products. We are also subject to inspections by the U.S. FDA and state agencies acting under contract with the U.S. FDA to confirm compliance with good manufacturing practice. These regulations require that we manufacture our products and maintain documents in a prescribed manner with respect to manufacturing, testing, quality assurance and quality control activities. The U.S. FDA also has promulgated final regulatory changes to these regulations that require, among other things, design controls and maintenance of service records. These changes will increase the cost of complying with good manufacturing practice requirements.

 

Distributors of medical devices may also be required to comply with other foreign regulatory agencies, and we or our distributors currently have marketing approval for LuViva from Health Canada, COFEPRIS in Mexico, the Ministry of Health in Kenya, and the Singapore Health Sciences Authority. The time required to obtain these foreign approvals to market our products may be longer or shorter than that required in China or the United States, and requirements for those approvals may differ from those required by the CFDA or the U.S. FDA.

 

We are also subject to a variety of other controls that affect our business. Labeling and promotional activities are subject to scrutiny by the U.S. FDA and, in some instances, by the U.S. Federal Trade Commission. The U.S. FDA actively enforces regulations prohibiting marketing of products for unapproved users. We are also subject, as are our products, to a variety of state and local laws and regulations in those states and localities where our products are or will be marketed. Any applicable state or local regulations may hinder our ability to market our products in those regions. Manufacturers are also subject to numerous federal, state and local laws relating to matters such as safe working conditions, manufacturing practices, environmental protection, fire hazard control and disposal of hazardous or potentially hazardous substances. We may be required to incur significant costs to comply with these laws and regulations now or in the future. These laws or regulations may have a material adverse effect on our ability to do business.

 

Although our marketing and distribution partners around the world assist in the regulatory approval process, ultimately, we are be responsible for obtaining and maintaining regulatory approvals for our products. The inability or failure to comply with the varying regulations or the imposition of new regulations would materially adversely affect our business, financial condition and results of operations.

 

 
56

Table of Contents

  

REGULATORY OVERVIEW

 

The development of innovative new drugs and medical devices is a time-consuming, expensive, and risky process. Despite these challenges, the pharmaceutical and medical device industries have been remarkably successful in developing a broad range of important new medicines and devices. It is also a heavily regulated industry. Drugs and medical devices are evaluated for safety, efficacy, and manufacturing quality as a condition of market access, and promotional messages must adhere to approved product characteristics. Drug and medical device prices also are regulated in most countries with national health insurance systems. Regulation of market access and promotion derives from uncertainty about drug and medical device safety and efficacy. These product characteristics can only be determined from accumulated experience over large numbers of patients in carefully designed trials or observational studies. The 1962 and 1976 (for medical device) Amendments to the United States Food and Drug Agency Act extended the powers of the FDA to review safety, efficacy, manufacturing quality and promotion. Subsequent studies concluded that the safety and efficacy requirements added to the intrinsically high cost of research and development, led to launch delay of new drugs and favored large over small firms.

 

However, more recently the biotechnology revolution has transformed the nature of drug discovery and the structure of the industry. Increasingly, new drugs originate in small firms, which often license out their products to more experienced firms for later stage drug development, regulatory review, and commercialization. In any given year, the biotechnology industry may comprise a couple of thousand firms, but the identities of these firms change as new start-ups are formed and established firms grow, merge, or are acquired by other established companies.

 

Government Regulation and Product Approval

 

United States Government Regulation

 

Government authorities in the United States, at the federal, state and local level, and in other countries extensively regulate, among other things, the research, development, testing, manufacture, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, import and export of the medical devices such as those we are developing. The processes for obtaining regulatory approvals in the United States and in foreign countries, along with subsequent compliance with applicable statutes and regulations, require the expenditure of substantial time and financial resources.

 

In the United States, the FDA regulates drugs and medical devices under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable United States requirements at any time during the product development process, approval process or after approval, may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA’s refusal to approve pending new drug applications, or NDAs, withdrawal of an approval, imposition of a clinical hold, issuance of warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties.

 

European Union Regulation

 

In the European Union, medical devices are required to comply with the Medical Devices Directive and obtain CE Mark certification in order to market medical devices. The CE Mark certification, granted following approval from an independent “Notified Body,” is an international symbol of adherence to quality assurance standards and compliance with applicable European Medical Devices Directives. From 2017 through 2019, we were unable to pay the annual registration fees to maintain our ISO 13485:2003 certification and our CE Mark. Once our financing is completed, we will make the required payments and reobtain both certifications. In addition, our December 21, 2018 agreement with NTI, described above, will allow final assembly at their ISO 13485:2016 accredited facility. Once all inspections have been passed for LuViva, this will allow an alternative path for obtaining the CE Mark.

 

 
57

Table of Contents

  

MANAGEMENT

 

The following table provides information regarding our executive officers and directors as of the date hereof:

 

Gene S. Cartwright, Ph.D.

67

Chief Executive Officer, President, Acting Chief Financial Officer and Director

Mark Faupel, Ph.D.

66

Chief Operating Officer and Director

Richard P. Blumberg

65

Director

Michael C. James

63

Chairman and Director

John E. Imhoff, M.D.

72

Director

 

Except as set forth below, all of the executive officers have been associated with us in their present or other capacities for more than the past five years. Officers are elected annually by the board of directors and serve at the discretion of the board. There are no family relationships among any of our executive officers and directors.

 

The following is a biographical summary of the experience of our executive officers, other senior management and directors. There are no family relationships among any of our executive officers, other senior management or directors.

 

Gene S. Cartwright, Ph.D - President, Chief Executive Officer, President, Acting Chief Financial Officer and Director

 

Gene S. Cartwright, Ph.D. joined us in January 2014 as the President, Chief Executive Officer and Acting Chief Financial Officer. He was elected as a director on January 11, 2014. His most recent position was with Omnyx, LLC, a Joint Venture between GE Healthcare and the University of Pittsburgh Medical Center, where, as CEO for over four years he founded and managed the successful development of products for the field of Digital Pathology. Prior to his work with Omnyx, LLC, he was President of Molecular Diagnostics for GE Healthcare. Prior to GE, Dr. Cartwright was Divisional Vice President/General Manager for Abbott Diagnostics’ Molecular Diagnostics business. In his 24-year career at Abbott, he also served as Divisional Vice President for U.S. Marketing for five years. He received a Master of Management degree from Northwestern’s Kellogg School of Management and also holds a Ph.D. in chemistry from Stanford University and an AB from Dartmouth College.

 

Dr. Cartwright brings over 30 years of experience working in the IVD diagnostics industry. He has great experience in the diagnostics market both in the development and introduction of new diagnostics technologies, as well as extensive successful commercial experience with global businesses. With his background and experience, Dr. Cartwright, as President and Chief Executive Officer, as well as Acting Chief Financial Officer, works with and advises the board as to how we can successfully market and build LuViva international sales.

 

Mark Faupel, Ph.D., - Chief Operating Officer and Director

 

Mark Faupel, Ph.D., rejoined us as Chief Operating Officer and director on December 8, 2016. He previously served on our board of directors through 2013 and has more than 30 years of experience in developing non-invasive alternatives to surgical biopsies and blood tests, especially in the area of cancer screening and diagnostics. Dr. Faupel was one of our co- founders and also served as our Chief Executive Officer from May 2007 through 2013. Prior thereto was our Chief Technical Officer from April 2001 to May 2007. Dr. Faupel has served as a National Institutes of Health reviewer, is the inventor on 32 U.S. patents and has authored numerous scientific publications and presentations, appearing in such peer-reviewed journals as The Lancet. Dr. Faupel earned his Ph.D. in neuroanatomy and physiology from the University of Georgia. Dr. Faupel is also a stockholder of Shenghuo Medical, LLC. See Item 13, Certain Relationships and Related Transactions and Director Independence.

 

Richard P. Blumberg - Director

 

Richard P. Blumberg was appointed to the Board of Directors on November 10, 2016 and resigned on March 27, 2019, but was reappointed on September 1, 2020. Mr. Blumberg has been a long-time investor in the Company. Since 1978, Mr. Blumberg has been a Principal at Webster, Mrak & Blumberg, a medical-legal and class action labor litigation firm. He is also currently a Managing Member of K2 Medical, LLC formerly known as Shenghuo Medical, LLC (“Shenghuo”), a company with licensing rights in several Asian countries for the Company’s LuViva Advanced Cervical Scan, and is a Managing Member of Elysian Medical, LLC, a company with world-wide rights for certain breast cancer detection technology. He served from 2004 to 2007 as Chief Executive Officer of Energy Logics, a wind power company that developed projects in Alberta, Canada and Montana. Mr. Blumberg holds a B.S. in Electrical Engineering and Computer Science from the University of Illinois and received a J. D. from Stanford University. He also brings extensive experience as a venture capitalist specializing in high-tech and life science companies.

 

 
58

Table of Contents

  

Michael C. James - Chairman and Director

 

Michael C. James has served as a member of our Board of Directors since March 2007 and as Chairman of the Board since October 2013. Mr. James is also the Managing Partner of Kuekenhof Capital Management, LLC, a private investment management company, Chief Executive Officer and the Chief Financial Officer of Inergetics, Inc., a nutraceutical supplements company and formerly was the Chief Financial Officer of Terra Tech Corporation, which is a hydroponic and agricultural company. He also holds the position of Managing Director of Kuekenhof Equity Fund, L.P. and Kuekenhof Partners, L.P. Mr. James currently sits on the Board of Directors of Inergetics; Inc. Mr. James was Chief Executive Officer of Nestor, Inc. from January 2009 to September 2009 and served on their Board of Directors from July 2006 to June 2009. He was employed by Moore Capital Management, Inc., a private investment management company from 1995 to 1999 and held position of Partner. He was employed by Buffalo Partners, L.P., a private investment management company from 1991 to 1994 and held the position of Chief Financial and Administrative Officer. He began his career in 1980 as a staff accountant with Eisner LLP. Mr. James received a B.S. degree in Accounting from Farleigh Dickinson University in 1980.

 

Mr. James has experience both in the areas of company finance and accounting, which is invaluable to us during financial audits and offerings. Mr. James has extensive experience in the management of both small and large companies and his entrepreneurial background is relevant as we develop as a company.

 

John E. Imhoff, M.D. - Director

 

John E. Imhoff, M.D. has served as a member of our Board of Directors since April 2006. Dr. Imhoff is an ophthalmic surgeon who specializes in cataract and refractive surgery. He is one of our principal stockholders and invests in many other private and public companies. He has a B.S. in Industrial Engineering from Oklahoma State University, an M.D. from the University of Oklahoma and completed his ophthalmic residency at the Dean A. McGee Eye Institute. He has worked as an ophthalmic surgeon and owner of Southeast Eye Center since 1983.

 

Dr. Imhoff has experience in clinical trials and in other technical aspects of a medical device company. His background in industrial engineering is especially helpful to us, especially as Dr. Imhoff can combine this knowledge with clinical applications. His experience in the investment community is invaluable to a public company often undertaking capital raising efforts.

 

 
59

Table of Contents

  

EXECUTIVE COMPENSATION

 

Summary Compensation Table

 

The following table lists specified compensation we paid or accrued during each of the fiscal years ended December 31, 2021 and 2020 to the Chief Executive Officer and our two other most highly compensated executive officers, collectively referred to as the “named executive officers,” in 2021:

 

Name and Principal Position

 

Year

 

Salary ($) (3)

 

 

Bonus ($)

 

 

Option Awards ($) (1)

 

 

Other ($) (4)

 

 

Total ($)

 

Gene S. Cartwright, Ph.D. - President,

 

2021

 

 

12,000

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

12,000

 

CEO, Acting CFO and Director (2)

 

2020

 

 

12,000

 

 

 

-

 

 

 

193,200

 

 

 

-

 

 

 

205,200

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Mark Faupel, Ph.D. - COO

 

2021

 

 

12,000

 

 

 

-

 

 

 

-

 

 

 

29,370

 

 

 

41,370

 

and Director (2)

 

2020

 

 

12,000

 

 

 

-

 

 

 

193,200

 

 

 

14,000

 

 

 

219,200

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Richard Fowler - Senior Vice President of Engineering (2) (6)

 

2021

 

 

-

 

 

 

-

 

 

 

-

 

 

 

7,497

 

 

 

7,497

 

 

 

2020

 

 

-

 

 

 

-

 

 

 

-

 

 

 

21,000

 

 

 

21,000

 

___________

(1) Option awards figure includes the value of Common Stock option awards at grant date as calculated under FASB ASC 718.    

(2) All amounts reported as accrued. Dr. Cartwright, Dr. Faupel, and Mr. Fowler have elected not to get paid a salary, due to our cash position.   

(3) Dr. Cartwright and Dr. Faupel accrued $1,000 per month as compensation; the amounts have not been paid.  

(4) Other expenses are related to the Company health insurance plan 

(6) During 2021, Mr. Fowler was no longer an executive of the Company. Mr. Fowler provided consulting services to the Company during 2021. 

 

Outstanding Equity Awards to Officers at December 31, 2021

 

 

 

Number of Securities Underlying Vested Options

 

 

Number of Securities Underlying Unvested Options

 

 

Weighted-Average Exercise Price ($)

 

 

Weighted-Average Expiration Date

 

Name and Principal Position

 

 

 

 

 

 

 

 

 

 

 

 

Gene S. Cartwright, Ph.D. - President, CEO, Acting CFO and Director

 

 

236,364

 

 

 

163,636

 

 

 

0.49

 

 

07/12/30

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Mark Faupel, Ph.D. - COO and Director

 

 

236,364

 

 

 

163,636

 

 

 

0.49

 

 

07/12/30

 

 

Outstanding Equity Awards to Directors at December 31, 2021

 

 

 

Number of Securities Underlying Vested Options

 

 

Number of Securities Underlying Unvested Options

 

 

Weighted-Average Exercise Price ($)

 

 

Weighted-Average Expiration Date

 

Name and Principal Position

 

 

 

 

 

 

 

 

 

 

 

 

Michael C. James, Chairman and Director

 

 

50,000

 

 

 

-

 

 

 

0.49

 

 

07/12/30

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

John E. Imhoff, M.D., Director

 

 

50,000

 

 

 

-

 

 

 

0.49

 

 

07/12/30

 

 

 
60

Table of Contents

  

Stock Options

 

Our 1995 Stock Plan (the “Plan”) has expired pursuant to its terms, so zero shares remained available for issuance at December 31, 2019 and 2018. The Plan allowed for the issuance of incentive stock options, nonqualified stock options, and stock purchase rights. The exercise price of options was determined by the our board of directors, but incentive stock options were granted at an exercise price equal to the fair market value of our common stock as of the grant date. Options historically granted have generally become exercisable over four years and expire ten years from the date of grant. As of December 31, 2021, and 2020, there were no stock options outstanding and exercisable.

 

The 1:800 reverse stock split of all of our issued and outstanding common stock was implemented on March 29, 2019. As a result of the reverse stock split, every 800 shares of issued and outstanding common stock were converted into 1 share of common stock. This resulted in the number of stock options outstanding to be zero.

 

2018 Stock Option Plan

 

Overview: Our stockholders approved and adopted the Guided Therapeutics, Inc. 2018 Stock Option Plan (the “Plan”) and the material terms thereunder at the annual meeting of our stockholders in 2018. A total of 325,470 shares of common stock are reserved for issuance under the Plan.

 

Administration: Our Board or a committee of at least two people as our Board may appoint (the “Committee”) administer the Plan. The Committee has the authority to determine the terms and conditions of any agreements evidencing any awards granted under the Plan and to adopt, alter and repeal rules, guidelines and practices relating to the Plan. The Committee has full discretion to administer and interpret the Plan and to adopt such rules, regulations and procedures as it deems necessary or advisable and to determine, among other things, the time or times at which the awards may be exercised and whether and under what circumstances an award may be exercised.

 

Eligibility: Employees, directors, officers, advisors or consultants of our company or our affiliates are eligible to participate in the Plan. The Committee has the sole and complete authority to determine who will be granted an award under the Plan, however, it may delegate such authority to one or more officers of the Company under the circumstances set forth in the Plan.

 

Number of Shares Authorized: The Plan provides for an aggregate of 325,470 shares of common stock to be available for awards. If an award is forfeited or if any option terminates, expires or lapses without being exercised, the shares of our common stock subject to such award will again be made available for future grant. Shares that are used to pay the exercise price of an option or that are withheld to satisfy the plan participant’s tax withholding obligation will not be available for re-grant under the Plan. If there is any change in our corporate capitalization, the Committee in its sole discretion may make substitutions or adjustments to the number of shares reserved for issuance under the Plan, the number of shares covered by awards then outstanding under the Plan, the limitations on awards under the Plan, the exercise price of outstanding options and such other equitable substitution or adjustments as it may determine appropriate.

 

Term: The Plan has a term of ten years and no further awards may be granted under the Plan after that date.

 

Awards Available for Grant: The Committee may grant awards of Non-Qualified Stock Options, Incentive (qualified) Stock Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units, Stock Bonus Awards or any combination of the foregoing; provided, that the Committee may not grant to any one person in any one calendar year Awards (i) for more than 500,000 shares of common stock in the aggregate or (ii) payable in cash in an amount to exceed $25,000 in the aggregate.

 

 
61

Table of Contents

  

The new Stock Plan (the “Plan”) allows for the issuance of incentive stock options, nonqualified stock options, and stock purchase rights. The exercise price of options was determined by the Company’s board of directors, but incentive stock options were granted at an exercise price equal to the fair market value of the Company’s common stock as of the grant date. Options historically granted have generally become exercisable over four years and expire ten years from the date of grant. The Plan provides for stock options to be granted up to 10% of the outstanding shares of common stock shares. During the years ended December 31, 2021 and 2020, the Company granted 1,250 and 90,000 stock options to employees and consultants, respectively. The fair value of options issued during the years ended December 31, 2021 and 2020 was estimated using the Black-Scholes option-pricing model and the following assumptions:

 

 

·

a dividend yield of 0%;

 

·

an expected life of 10 years;

 

·

volatility of 153.1%; and

 

·

risk-free interest rate of 0.98%.

 

The fair value of each option grant made during 2021 and 2020 was estimated on the date of each grant using the Black-Scholes option pricing model and recognized as stock-based compensation ratably over the option vesting periods, which approximates the service period. There were no additional options granted during the three months ended March 31, 2022.

 

Risk Oversight

 

Our board as a whole has responsibility for risk oversight, with reviews of certain areas being conducted by the relevant board committees that report on their deliberations to the full board, as further described below. Given the small size of the board, the board feels that this structure for risk oversight is appropriate (except for those risks that require risk oversight by independent directors only). The audit committee is specifically charged with discussing risk management (primarily financial and internal control risk), and receives regular reports from management and independent auditors on risks related to, among others, our financial controls and reporting. The compensation committee reviews risks related to compensation and makes recommendations to the board with respect to whether the Company’s compensation policies are properly aligned to discourage inappropriate risk-taking, and is regularly advised by management. In addition, the Company’s management regularly communicates with the board to discuss important risks for their review and oversight, including regulatory risk, and risks stemming from periodic litigation or other legal matters in which we are involved.

 

 
62

Table of Contents

  

CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS

 

Our Board recognizes that related person transactions present a heightened risk of conflicts of interest. The audit committee has the authority to review and approve all related party transactions involving our directors or executive officers.

 

Under the policy, when management becomes aware of a related person transaction, management reports the transaction to the audit committee and requests approval or ratification of the transaction. Generally, the audit committee will approve only related party transactions that are on terms comparable to those that could be obtained in arm’s length dealings with an unrelated third person. The audit committee will report to the full board all related person transactions presented to it. Based on the definition of independence of Nasdaq, the board has determined that Mr. James and Dr. Imhoff are independent directors.

 

Long-Term Debt - Related Parties.

 

On July 14, 2018, the Company entered into an exchange agreement with Dr. Faupel, whereby Dr. Faupel agreed to exchange outstanding amounts due to him for loans, interest, bonus, salary and vacation pay in the amount of $660,895 for a $207,111 promissory note dated September 4, 2018. On July 20, 2018, the Company entered into an exchange agreement with Dr. Cartwright, whereby Dr. Cartwright agreed to exchange outstanding amounts due to him for loans, interest, bonus, salary and vacation pay in the amount of $1,621,499 for a $319,000 promissory note dated September 4, 2018 that incurs interest at a rate of 6% per annum.

 

On July 24, 2019, Dr. Faupel and Mr. Cartwright agreed to an addendum to the debt restructuring exchange agreement and to modify the terms of the original exchange agreement. Under this modification Dr. Faupel and Mr. Cartwright agreed to extend the note to be due in full on the third anniversary of that agreement.

 

On February 19, 2021, the Company entered into new promissory notes replacing the original notes from September 4, 2018, with Mark Faupel and Gene Cartwright. For Dr. Cartwright the principal amount on the new note was $267,085, matures on February 18, 2023, and will accrue interest at a rate of 6.0%. For Dr. Faupel the principal amount on the new note was $153,178, matures on February 18, 2023, and will accrue interest at a rate of 6.0%. The modifications extended the maturity date on both of the notes.

 

On February 19, 2021, the Company exchanged $100,000 and $85,000 of long-term debt for Dr. Cartwright and Dr. Faupel in exchange for 100 and 85 shares of Series F-2 Preferred Stock, respectively.  

 

The table below summarizes the details of the exchange agreement (in thousands):

 

For Dr. Faupel:

 

 

 

 

 

 

 

Salary

 

$ 134

 

Bonus

 

 

20

 

Vacation

 

 

95

 

Interest on compensation

 

 

67

 

Loans to Company

 

 

196

 

Interest on loans

 

 

149

 

Total outstanding prior to exchange

 

 

661

 

 

 

 

 

 

Amount forgiven in prior years

 

 

(454 )

Amount exchanged for Series F-2 Preferred Stock

 

 

(85 )

Total interest accrued through December 31, 2021

 

 

39

 

Balance outstanding at December 31, 2021

 

$ 161

 

 

 

 

 

 

Interest accrued through March 31, 2022

 

 

2

 

Balance outstanding at March 31, 2022

 

$ 163

 

 

For Dr.Cartwright

 

 

 

 

 

 

 

Salary

 

$ 337

 

Bonus

 

 

675

 

Loans to Company

 

 

528

 

Interest on loans

 

 

81

 

Total outstanding prior to exchange

 

 

1,621

 

 

 

 

 

 

Amount forgiven in prior years

 

 

(1,302 )

Amount exchanged for Series F-2 Preferred Stock

 

 

(100 )

Total interest accrued through December 31, 2021

 

 

62

 

Balance outstanding at December 31, 2021

 

$ 281

 

 

 

 

 

 

Interest accrued through March 31, 2022

 

 

4

 

Balance outstanding at March 31, 2022

 

$ 285

 

   

Consulting Agreement - Richard Blumberg

 

On March 10, 2021, the Company entered into a consulting agreement with Richard Blumberg. As a result of the consulting agreement Mr. Blumberg provided $350,000, which was recorded as a subscription receivable, to the Company in exchange for the following: (1) on September 26, 2021, 45,000 3-year warrants with an exercise price of $6.00 and 20,000 common stock shares; (2) on March 26, 2022, 45,000 3-year warrants with an exercise price of $8.00 and 20,000 common stock shares; (3) on September 26, 2022, 45,000 3-year warrants with an exercise price of $10.00 and 20,000 common stock shares; and (4) on March 26, 2023, 45,000 3-year warrants with an exercise price of $12.00 and 20,000 common stock shares.

 

During the year ended December 31, 2021, the consulting agreement was amended to clarify that $350,000 is not intended to be debt and will not be required to be repaid in cash. Additionally, issuance of the warrants is now predicated on the Company receiving funding receipts of $1,000,000, whether from a financing, series of financing, or gross sales. The amended agreement clarified that the warrants issued to Mr. Blumberg are compensation for services, which involve obtaining financing. The Company will recognize expense for the services equal to the fair value of the warrants issued to Mr. Blumberg as the services are provided, which will coincide with the successful execution of a financing agreement over $1,000,000. The Company concluded that as of September 30,2021, there was no longer a liability due to Mr. Blumberg of $350,000. The liability was written off in the third quarter of 2021 and a gain of $350,000 was recognized in non-operating income.

 

 
63

Table of Contents

  

PRINCIPAL STOCKHOLDERS

 

The following table lists information regarding the beneficial ownership of our equity securities as of June 17, 2022 by (1) each person whom we know to beneficially own more than 5% of the outstanding shares of our common stock, (2) each director, (3) each officer named in the summary compensation table below, and (4) all directors and executive officers as a group. Unless otherwise indicated, the address of each officer and director is 5835 Peachtree Corners East, Suite B, Norcross, Georgia 30092.

 

 

 

Common Stock

Beneficially Owned (2)

 

 

Common Stock Directly Held

 

 

Series C Preferred Stock (3)

 

Name and Address of Beneficial Owner (1)

 

Number of Shares

 

 

Percentage

 

 

Number of Shares

 

 

Percentage

 

 

Number of Shares

 

 

Percentage

 

Blumberg, Richard P. (10)

 

 

81,320

 

 

 

5.78 %

 

 

51,754

 

 

 

3.75 %

 

 

-

 

 

 

-

 

Cartwright, Gene (11)

 

 

67,101

 

 

 

4.67 %

 

 

7,601

 

 

 

0.55 %

 

 

-

 

 

 

-

 

Case, Flynn (12)

 

 

87,404

 

 

 

6.34 %

 

 

87,404

 

 

 

6.34 %

 

 

-

 

 

 

-

 

Faupel, Mark (13)

 

 

88,597

 

 

 

6.06 %

 

 

5,971

 

 

 

0.43 %

 

 

-

 

 

 

-

 

Fieldhouse Pro Funds (14)

 

 

121,412

 

 

 

8.70 %

 

 

105,971

 

 

 

7.69 %

 

 

-

 

 

 

-

 

Imhoff, John E. (15)

 

 

551,929

 

 

 

31.76 %

 

 

192,259

 

 

 

13.95 %

 

 

-

 

 

 

-

 

James, Michael C. (16)

 

 

3,262

 

 

 

0.24 %

 

 

639

 

 

 

0.05 %

 

 

-

 

 

 

-

 

K2 Medical (17)

 

 

96,286

 

 

 

6.65 %

 

 

25,852

 

 

 

1.88 %

 

 

-

 

 

 

-

 

Maloof, Dolores (18)

 

 

85,092

 

 

 

5.84 %

 

 

6,367

 

 

 

0.46 %

 

 

-

 

 

 

-

 

Narbut, Laurence (19)

 

 

82,903

 

 

 

5.84 %

 

 

42,903

 

 

 

3.11 %

 

 

-

 

 

 

-

 

Rosalind Master Fund (20)

 

 

142,975

 

 

 

9.83 %

 

 

67,975

 

 

 

4.92 %

 

 

-

 

 

 

-

 

Wells Plus 6ix Multi Strategy (21)

 

 

106,153

 

 

 

7.42 %

 

 

59,830

 

 

 

4.33 %

 

 

-

 

 

 

-

 

All directors and executive officers as a group (5 persons) (22)

 

 

792,208

 

 

 

36.50 %

 

 

258,224

 

 

 

18.73 %

 

 

-

 

 

 

-

 

 

 

 

Series C1 Preferred Stock (4)

 

 

Series C2 Preferred Stock (5)

 

 

 

Number of Shares

 

 

Percentage

 

 

Number of Shares

 

 

Percentage

 

Name and Address of Beneficial Owner (1)

 

 

 

 

Blumberg, Richard P. (10)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Cartwright, Gene (11)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Case, Flynn (12)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Faupel, Mark (13)

 

 

-

 

 

 

-

 

 

 

299.25

 

 

 

9.17 %
Fieldhouse Pro Funds (14)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Imhoff, John E. (15)

 

 

-

 

 

 

-

 

 

 

2,400.75

 

 

 

73.59 %
James, Michael C. (16)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

K2 Medical (17)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Maloof, Dolores (18)

 

 

-

 

 

 

-

 

 

 

562.25

 

 

 

17.24 %
Narbut, Laurence (19)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Rosalind Master Fund (20)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Wells Plus 6ix Multi Strategy (21)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

All directors and executive officers as a group (5 persons) (22)

 

 

-

 

 

 

-

 

 

 

2,700.00

 

 

 

82.76 %

  

 

 

Series D Preferred Stock (6)

 

 

Series E Preferred Stock (7)

 

Name and Address of Beneficial Owner (1)

 

Number of Shares

 

 

Percentage

 

 

Number of Shares

 

 

Percentage

 

Blumberg, Richard P. (10)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Cartwright, Gene (11)

 

 

50.00

 

 

 

11.42 %

 

 

-

 

 

 

-

 

Case, Flynn (12)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Faupel, Mark (13)

 

 

38.00

 

 

 

8.68 %

 

 

-

 

 

 

-

 

Fieldhouse Pro Funds (14)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Imhoff, John E. (15)

 

 

300.00

 

 

 

68.49 %

 

 

-

 

 

 

-

 

James, Michael C. (16)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

K2 Medical (17)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Maloof, Dolores (18)

 

 

50.00

 

 

 

11.42 %

 

 

-

 

 

 

-

 

Narbut, Laurence (19)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Rosalind Master Fund (20)

 

 

-

 

 

 

-

 

 

 

250.00

 

 

 

28.15 %
Wells Plus 6ix Multi Strategy (21)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

All directors and executive officers as a group (5 persons) (22)

 

 

388.00

 

 

 

88.58 %

 

 

-

 

 

 

-

 

 

 

 

Series F Preferred Stock (8)

 

 

Series F-2 Preferred Stock (9)

 

Name and Address of Beneficial Owner (1)

 

Number of Shares

 

 

Percentage

 

 

Number of Shares

 

 

Percentage

 

Blumberg, Richard P. (10)

 

 

-

 

 

 

-

 

 

 

88.00

 

 

 

3.18 %
Cartwright, Gene (11)

 

 

-

 

 

 

-

 

 

 

110.00

 

 

 

3.97 %
Case, Flynn (12)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Faupel, Mark (13)

 

 

-

 

 

 

-

 

 

 

97.00

 

 

 

3.50 %
Fieldhouse Pro Funds (14)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Imhoff, John E. (15)

 

 

10.00

 

 

 

0.93 %

 

 

-

 

 

 

-

 

James, Michael C. (16)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

K2 Medical (17)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Maloof, Dolores (18)

 

 

25.00

 

 

 

2.33 %

 

 

-

 

 

 

-

 

Narbut, Laurence (19)

 

 

200.00

 

 

 

18.67 %

 

 

-

 

 

 

-

 

Rosalind Master Fund (20)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Wells Plus 6ix Multi Strategy (21)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

All directors and executive officers as a group (5 persons) (22)

 

 

10.00

 

 

 

0.93 %

 

 

295.00

 

 

 

10.65 %

 

 
64

Table of Contents

 

(1)

Except as otherwise indicated in the footnotes to this table and pursuant to applicable community property laws, the persons named in the table have sole voting and investment power with respect to all shares of common stock.

(2)

Percentage ownership is based on 1,379,174 shares of common stock outstanding as of June 17, 2022. Beneficial ownership is determined in accordance with the rules of the SEC, based on factors that include voting and investment power with respect to shares. Shares of common stock subject to convertible securities convertible or exercisable within 60 days after the record date, are deemed outstanding for purposes of computing the percentage ownership of the person holding those securities but are not deemed outstanding for purposes of computing the percentage ownership of any other person. Note that certain of our outstanding securities, including certain warrants and the shares of Series C1 preferred stock held by the persons listed in this table, have anti-dilution ratchet or price-protection provisions that, when triggered, will increase the number of shares of common stock underlying such securities. Subject to customary exceptions, these provisions are triggered anytime we issue shares of common stock to third parties at a price lower than the then-current conversion price or exercise price of the subject securities. As a result, the beneficial ownership reported in this table is only as of the date presented, and the beneficial ownership amounts of the persons in this table may increase on a future date, even though such persons have not actually acquired any additional shares of common stock.

(3)

As of June 17, 2022, there were 286 shares of Series C preferred stock outstanding, and each such share was convertible into approximately 100 shares of common stock.

(4)

As of June 17, 2022, there were 1,049.25 shares of Series C1 preferred stock outstanding, and each such share was convertible into approximately 100 shares of common stock.

(5)

As of June 17, 2022, there were 3,262.25 shares of Series C2 preferred stock outstanding, and each such share was convertible into approximately 100 shares of common stock.

(6)

As of June 17, 2022, there were 438 shares of Series D preferred stock outstanding, and each such share was convertible into approximately 150 shares of common stock.

(7)

As of June 17, 2022, there were 888 shares of Series E preferred stock outstanding, and each such share was convertible into approximately 100 shares of common stock.

(8)

As of June 17, 2022, there were 1,071 shares of Series F preferred stock outstanding, and each such share was convertible into approximately 200 shares of common stock.

(9)

As of June 17, 2022, there were 2,771 shares of Series F-2 preferred stock outstanding, and each such share was convertible into approximately 200 shares of common stock.

(10)

Shares of common stock consists of 51,754 shares of common stock directly held, 11,966 shares issuable upon exercise of warrants, and 17,600 shares issuable upon conversion of 88 shares of Series F-2 preferred stock.

(11)

Shares of common stock consist of 7,601 shares of common stock directly held, 10,000 shares issuable upon exercise of warrants, 22,000 shares issuable upon conversion of 110 shares of Series F-2 preferred stock, 7,500 shares issuable upon conversion of 50 shares of Series D preferred stock and 20,000 shares issuable upon exercise of stock options. Dr. Cartwright is the CEO and is on the Board of Directors.

(12)

Shares of common stock consists of 87,404 shares of common stock directly held.

(13)

Shares of common stock consist of 5,971 shares of common stock directly held, 7,600 shares issuable upon exercise of warrants, 20,000 shares issuable upon exercise of stock options, 19,400 shares issuable upon conversion of 97 shares of Series F-2 preferred stock, 5,700 shares issuable upon conversion of 38 shares of Series D preferred stock and 29,925 shares issuable upon conversion of 299.25 shares of Series C2 preferred stock. Dr. Faupel is the COO and is on the Board of Directors.

(14)

Shares of common stock consist of 105,971 shares of common stock directly held, 5,000 shares issuable upon exercise of warrants and 10,441 shares issuable upon conversion of the 10% debenture.

(15)

Shares of common stock consist of 192,259 shares of common stock directly held, 70,094 shares issuable upon exercise of warrants, 2,500 shares issuable upon exercise of stock options, 2,000 shares issuable upon conversion of 10 shares of Series F preferred stock, 45,000 shares issuable upon conversion of 300 shares of Series D preferred stock and 240,075 shares issuable upon conversion of 2,400.75 shares of Series C2 preferred stock. Dr. Imhoff is on the Board of Directors.

(16)

Shares of common stock consist of 639 shares of common stock directly held, 123 shares issuable upon exercise of warrants and 2,500 shares issuable upon exercise of stock options. Mr. James is on the Board of Directors.

(17)

Shares of common stock consists of 25,852 shares of common stock directly held and 70,433 shares issuable upon exercise of warrants.

(18)

Shares of common stock consists of 6,367 shares of common stock directly held, 10,000 shares issuable upon exercise of warrants, 56,225 shares issuable upon conversion of 562.25 shares of Series C2 preferred stock, and 7,500 shares issuable upon conversion of 50 shares of Series D preferred stock and 5,000 shares issuable upon conversion of 25 shares of Series F preferred stock.

(19)

Shares of common stock consists of 42,903 shares of common stock directly held and 40,000 shares issuable upon conversion of 200 shares of Series F preferred stock.

(20)

Shares of common stock consists of 67,975 shares of common stock directly held, 25,000 shares issuable upon exercise of warrants and 50,000 shares issuable upon conversion of 250 shares of Series F-2 preferred stock.

(21)

Shares of common stock consists of 59,830 shares of common stock directly held, 15,000 shares issuable upon exercise of warrants and 31,032 shares issuable upon conversion of the 10% debenture.

(22)

Shares of common stock consists of 258,224 shares of common stock directly held, 99,783 shares issuable upon exercise of warrants, 45,001 shares issuable upon exercise of stock options, 2,000 shares issuable upon conversion of 10 shares of Series F preferred stock, 59,000 shares issuable upon conversion of 295 shares of Series F-2 preferred stock, 58,200 shares issuable upon conversion of 388 shares of Series D preferred stock and 270,000 shares issuable upon conversion of 2,700 shares of Series C2 preferred stock.

 

 
65

Table of Contents

 

DESCRIPTION OF SECURITIES

 

General

 

Our Certificate of Incorporation authorizes the issuance of up to 500,000,000 shares of common stock, par value $0.001 per share, and 5,000,000 shares of preferred stock, par value $0.001 per share. As of the date of this prospectus, we had 1,379,174 shares of common stock issued and outstanding, 286 shares of Series C preferred stock issued and outstanding, 1,049.25 shares of Series C1 preferred stock issued and outstanding, 3,262.25 shares of Series C2 preferred stock issued and outstanding, 438 shares of Series D preferred stock issued and outstanding, 888 shares of Series E preferred stock issued and outstanding, 1,071 shares of Series F preferred stock issued and outstanding, and 2,771 shares of Series F-2 preferred stock issued and outstanding.

 

On December 30, 2021, the Board approved a 1-for-20 reverse stock split (the “Reverse Stock Split”), and we filed a Certificate of Amendment to the Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect the Reverse Stock Split. As a result, the total number of shares of common stock held by each stockholder was automatically changed and reclassified into a smaller number of shares such that each 20 shares of common stock were reclassified into one share of common stock. No fractional shares were issued in connection with the Reverse Stock Split. In lieu of any fractional shares, we issued one whole share of the post-Reverse Stock Split common stock to stockholders who otherwise would have received a fractional share as a result of the Reverse Stock Split. On November 18, 2021, we submitted an Issuer Company Related Action Notification regarding the Reverse Stock Split to FINRA. FINRA approved it on May 9, 2022 and the Reverse Stock Split will be effective on the approximate date of the Nasdaq uplisting and financing, expected to be on or near June 30, 2022.

 

Common Stock

 

Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. An election of directors by our stockholders is determined by a plurality of the votes cast by the stockholders entitled to vote on the election. Other matters are decided by the affirmative vote of our stockholders having a majority in voting power of the votes cast by the stockholders present or represented and voting on such matter. Holders of common stock are entitled to receive proportionately any dividends as may be declared by our board of directors, subject to any preferential dividend rights of outstanding preferred stock.

 

In the event of our liquidation or dissolution, the holders of common stock are entitled to receive proportionately all assets available for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock. Holders of common stock have no preemptive, subscription, redemption or conversion rights. The rights, preferences and privileges of holders of common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future.

 

Preferred Stock

 

Our Certificate of Incorporation authorizes the issuance of 5,000,000 shares of blank check preferred stock with such designations, rights and preferences as may be determined from time to time by our board of directors. As of the date of this prospectus, there are 2,771 shares of Series F-2, 1,071 shares of Series F, 888 shares of Series E, 438 shares of Series D, 286 shares of Series C, 1,049.25 shares of Series C1 and 3,262.25 shares of Series C2 preferred stock issued and outstanding. Accordingly, our board of directors is empowered, without stockholder approval, to issue preferred stock with dividend, liquidation, redemption, voting or other rights which could adversely affect the voting power or other rights of the holders of common stock. We may issue some or all of the preferred stock to effect a business transaction. In addition, the preferred stock could be utilized as a method of discouraging, delaying or preventing a change in control of us.

 

Series C Convertible Preferred Stock

 

Pursuant to the Series C certificate of designations, shares of Series C preferred stock are convertible into common stock by their holder at any time and may be mandatorily convertible upon the achievement of specified average trading prices for our common stock, subject to customary adjustments, including for any accrued but unpaid dividends and pursuant to certain anti-dilution provisions, as set forth in the Series C certificate of designations. The conversion price will automatically adjust downward to 80% of the then-current market price of our common stock 15 trading days after any reverse stock split of our common stock, and 5 trading days after any conversions of our outstanding convertible debt.

 

Holders of the Series C preferred stock are entitled to quarterly cumulative dividends at an annual rate of 12.0% until 42 months after the original issuance date (the “Dividend End Date”), payable in cash or, subject to certain conditions, our common stock. In addition, upon conversion of the Series C preferred stock prior to the Dividend End Date, we will also pay to the converting holder a “make-whole payment” equal to the number of unpaid dividends through the Dividend End Date on the converted shares. The Series C preferred stock generally has no voting rights except as required by Delaware law. Upon our liquidation or sale to or merger with another corporation, each share will be entitled to a liquidation preference of $1,000, plus any accrued but unpaid dividends. In addition, the purchasers of the Series C preferred stock received, on a pro rata basis, warrants exercisable to purchase an aggregate of approximately 1 share of our common stock.

 

 
66

Table of Contents

  

Series C1 Convertible Preferred Stock

 

The Series C1 preferred stock has terms that are substantially the same as the Series C preferred stock, except that the Series C1 preferred stock does not pay dividends (unless and to the extent declared on the common stock) or at-the-market “make-whole payments” and, while it has the same anti-dilution protections afforded the Series C preferred stock, it does not automatically reset in connection with a reverse stock split or conversion of our outstanding convertible debt.

 

Series C2 Convertible Preferred Stock

 

The terms of the Series C2 Preferred Stock are substantially the same as the Series C1 Preferred Stock, except that (i) shares of Series C1 preferred stock may not be convertible into the Company’s common stock by their holder for a period of 180 days following the date of the filing of the Certificate of Designation (the “Lock-Up Period”); (ii) the Series C2 preferred stock has the right to vote as a single class with the Company’s common stock on an as-converted basis, notwithstanding the Lock-Up Period; and (iii) the Series C2 preferred stock will automatically convert into that number of securities sold in the next Qualified Financing (as defined in the Exchange Agreement) determined by dividing the stated value ($1,000 per share) of such share of Series C2 preferred stock by the purchase price of the securities sold in the Qualified Financing.

 

Series D Convertible Preferred Stock

 

As of the date of this prospectus, 6,000 shares have been designated as Series D Convertible Preferred Stock (“Series D Preferred Stock”), of which 438 shares are issued and outstanding. The following is a summary of the rights, privileges and preferences of the Series D Preferred Stock, which such summary is qualified in its entirety by the Series D Certificate of Designation.

 

Each share of Series D Preferred Stock has a par value of $0.001 per share and a stated value equal to $763, subject to increase set forth in its Certificate of Designation (the "Stated Value").

 

Each holder of Series D Preferred Stock is entitled to receive cumulative dividends of 10% per annum, payable quarterly in cash or, following the listing of the Company’s common stock on certain Canadian trading markets and at the option of the Company, shares of common stock.

 

Upon any liquidation, dissolution or winding-up of the Company, the holders shall be entitled to receive an amount equal to the Stated Value, plus any accrued and unpaid dividends thereon and any other fees or liquidated damages then due and owing before any distribution or payment shall be made to the holders of common stock and any other securities junior to Series D Preferred Stock.

 

Each share of Series D Preferred Stock is convertible, at any time for a period of 5 years after issuance, into shares of common stock. The conversion price for the Series D Preferred Stock is $5.00, subject to adjustment set forth in the Series D Certificate of Designation (the “Series D Conversion Price”). The conversion of Series D Preferred Stock is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder of the Series D Preferred Stock. If the average of the VWAPs (as defined under the Series D Certificate of Designation) for any consecutive 5 trading day period (“Series D Measurement Period”) exceeds 200% of the then Series D Conversion Price and the average daily trading volume of the common stock on the primary trading market exceeds a number of shares per trading day during the Series D Measurement Period (subject to adjustments), the Company may redeem the then outstanding Series D Preferred Stock, for cash in an amount equal to aggregate Stated Value then outstanding plus accrued but unpaid dividends.

 

Except for certain matters affecting the rights of Series D Preferred Stock or as otherwise required by law, the holders of Series D Preferred Stock do not have voting rights.

 

 
67

Table of Contents

  

Series E Convertible Preferred Stock

 

As of the date of this prospectus, 6,000 shares have been designated as Series E Convertible Preferred Stock (“Series E Preferred Stock”), of which 888 shares are issued and outstanding. The following is a summary of the rights, privileges and preferences of the Series E Preferred Stock, which such summary is qualified in its entirety by the Series E Certificate of Designation.

 

Each share of Series E Preferred Stock has a par value of $0.001 per share and a Stated Value equal to $1,000, subject to increase set forth in its Certificate of Designation.

 

Each holder of Series E Preferred Stock is entitled to receive cumulative dividends of 8% per annum, payable annually in cash or, following the listing of the Company’s common stock on certain Canadian trading markets and at the option of the Company, shares of common stock.

 

Upon any liquidation, dissolution or winding-up of the Company, the holders shall be entitled to receive an amount equal to the Stated Value, plus any accrued and unpaid dividends thereon and any other fees or liquidated damages then due and owing before any distribution or payment shall be made to the holders of common stock and any other securities junior to Series D Preferred Stock.

 

Each share of Series E Preferred Stock is convertible, at any time for a period of 5 years after issuance, into that number of shares of common stock. The conversion price for the Series E Preferred Stock is $5.00, subject to adjustment set forth in the Series E Certificate of Designation (the “Series E Conversion Price”). The conversion of Series E Preferred Stock is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder of the Series E Preferred Stock. If the average of the VWAPs (as defined under the Series E Certificate of Designation) for any consecutive 5 trading day period (“Series E Measurement Period”) exceeds 200% of the then Series E Conversion Price and the average daily trading volume of the common stock on the primary trading market exceeds a number of shares per trading day during the Series E Measurement Period (subject to adjustments), the Company may redeem the then outstanding Series E Preferred Stock, for cash in an amount equal to aggregate Stated Value then outstanding plus accrued but unpaid dividends.

 

Except for certain matters affecting the rights of Series E Preferred Stock or as otherwise required by law, the holders of Series E Preferred Stock do not have voting rights.

 

Series F Convertible Preferred Stock

 

As of the date of this prospectus, 1,500 shares have been designated as Series F Convertible Preferred Stock (“Series F Preferred Stock”), of which 1,071 shares are issued and outstanding. The following is a summary of the rights, privileges and preferences of the Series F Preferred Stock, which such summary is qualified in its entirety by the Series F Certificate of Designation.

 

Each share of Series F Preferred Stock has a par value of $0.001 per share and a Stated Value equal to $1,000, subject to increase set forth in its Certificate of Designation.

 

Each holder of Series F Preferred Stock is entitled to receive cumulative dividends of 6% per annum, payable annually in cash or, following the listing of the Company’s common stock on certain Canadian trading markets and at the option of the Company, shares of common stock.

 

Upon any liquidation, dissolution or winding-up of the Company, the holders shall be entitled to receive an amount equal to the Stated Value, plus any accrued and unpaid dividends thereon and any other fees or liquidated damages then due and owing before any distribution or payment shall be made to the holders of common stock and any other securities junior to Series F Preferred Stock.

 

 
68

Table of Contents

  

Each share of Series F Preferred is convertible, at any time for a period of 5 years after issuance, into that number of shares of Common Stock, determined by dividing the Stated Value by $5.00, subject to certain adjustments set forth in the Series F Certificate of Designation (the “Series F-2 Conversion Price”). The conversion of Series F-2 Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder of the Series F Preferred. If the average of the VWAPs (as defined in the Series F-2 Certificate of Designation) for any consecutive 5 trading day period (“Measurement Period”) exceeds 200% of the then Series F-2 Conversion Price and the average daily trading volume of the Common Stock on the primary trading market exceeds 50 shares per trading day during the Measurement Period (subject to adjustments), the Company may redeem the then outstanding Series F Preferred, for cash in an amount equal to aggregate Stated Value then outstanding plus accrued but unpaid dividends.

 

Except for certain matters affecting the rights of Series F Preferred Stock or as otherwise required by law, the holders of Series F Preferred Stock do not have voting rights.

 

Series F-2 Convertible Preferred Stock

 

As of the date of this prospectus, 3,500 shares have been designated as Series F-2 Convertible Preferred Stock (“Series F-2 Preferred Stock”), of which 2,771 shares are issued and outstanding. The following is a summary of the rights, privileges and preferences of the Series F-2 Preferred Stock, which such summary is qualified in its entirety by the Series F-2 Certificate of Designation.

 

Each share of Series F-2 Preferred Stock has a par value of $0.001 per share and a Stated Value equal to $1,000, subject to increase set forth in its Certificate of Designation.

 

Each holder of Series F-2 Preferred Stock is entitled to receive cumulative dividends of 6% per annum, payable annually in cash or, following the listing of the Company’s common stock on certain Canadian trading markets and at the option of the Company, shares of common stock.

 

Upon any liquidation, dissolution or winding-up of the Company, the holders shall be entitled to receive an amount equal to the Stated Value, plus any accrued and unpaid dividends thereon and any other fees or liquidated damages then due and owing before any distribution or payment shall be made to the holders of common stock and any other securities junior to Series F-2 Preferred Stock.

 

Each share of Series F-2 Preferred is convertible, at any time for a period of 5 years after issuance, into that number of shares of Common Stock, determined by dividing the Stated Value by $5.00, subject to certain adjustments set forth in the Series F-2 Certificate of Designation (the “Series F-2 Conversion Price”). The conversion of Series F-2 Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder of the Series F-2 Preferred. If the average of the VWAPs (as defined in the Series F-2 Certificate of Designation) for any consecutive 5 trading day period (“Measurement Period”) exceeds 200% of the then Series F-2 Conversion Price and the average daily trading volume of the Common Stock on the primary trading market exceeds 50 shares per trading day during the Measurement Period (subject to adjustments), the Company may redeem the then outstanding Series F-2 Preferred, for cash in an amount equal to aggregate Stated Value then outstanding plus accrued but unpaid dividends.

 

Except for certain matters affecting the rights of Series F-2 Preferred Stock or as otherwise required by law, the holders of Series F-2 Preferred Stock do not have voting rights.

 

Series G Callable Preferred Stock

 

The Series G Callable Preferred Stock (“Series G Preferred Stock”) consists of 1,000,000 shares. As of the date of this prospectus both $78,500 and $53,500, tranches of Series G Preferred Stock have been redeemed.

 

Each share of Series G Preferred Stock had a par value of $0.001 per share and a Stated Value equal to $1.00, as set forth in the Certificate of Designation.

 

Series G Preferred Stock had no right to vote on any matters requiring shareholder approval or any matters on which shareholders were permitted to vote. With respect to any voting rights of the Series G Preferred Stock set forth, the Series G Preferred Stock voted as a class, each share of Series G Preferred Stock had one vote on any such matter, and any such approval was given via a written consent in lieu of a meeting of the Series G Preferred stockholders.

 

 
69

Table of Contents

  

Each share of Series G Preferred Stock carried an annual dividend in the amount of eight percent (8%) of the Stated Value (the "Dividend Rate"), which was cumulative, payable solely upon redemption, liquidation or conversion. Upon the occurrence of an Event of Default (as defined herein), the Dividend Rate automatically increased to twenty two percent (22%).

 

At any time after the date of the issuance of shares of Series G Preferred Stock, the Company had the right, at the Company’s option, to redeem all of the shares of Series G Preferred Stock by paying an amount equal to: (i) the number of shares of Series G Preferred Stock multiplied by the Stated Value (including accrued dividends) (ii) multiplied by the corresponding percentage as follows: Day 1-60, 105%; Day 61-90, 110%; Day 91-120, 115%; and Day 121-180, 122%. After the expiration of the 180 days following the issuance date, except for mandatory redemption, the Company had no right to redeem the Series G Preferred Stock. Mandatory redemption occurred within 24 months. In addition, if the Company did not redeem the Series G Preferred Stock then the holder would have the option to convert into shares of common stock. The variable conversion price was the value equal to a discount of 19% of the trading price, which is calculated as the average of the three lowest closing bid prices over the previous fifteen trading days. The conversion of Series G Preferred Stock was subject to a 4.99% beneficial ownership limitation, which was able to be increased to 9.99% at the election of the holder of the Series G Preferred Stock. As of the date of this prospectus, the Series G Preferred Stock is fully redeemed.

  

Warrants

 

Pre-Funded Warrants

 

The following summary of certain terms and provisions of the pre-funded warrants that are being offered hereby is not complete and is subject to, and qualified in its entirety by, the provisions of the pre-funded warrant, the form of which is filed as an exhibit to the registration statement of which this prospectus forms a part. Prospective investors should carefully review the terms and provisions of the form of pre-funded warrant for a complete description of the terms and conditions of the pre-funded warrants.

 

Duration and Exercise Price

 

Each pre-funded warrant offered hereby will have an initial exercise price per share equal to $0.01. The pre-funded warrants will be immediately exercisable and will not expire prior to exercise. The exercise price and number of shares of common stock issuable upon exercise is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock.

 

Exercisability

 

The pre-funded warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full for the number of shares of our common stock purchased upon such exercise (except in the case of a cashless exercise as discussed below). A holder (together with its affiliates) may not exercise any portion of the pre-funded warrant to the extent that the holder would own more than 4.99% of the outstanding common stock immediately after exercise, except that upon at least 61 days’ prior notice from the holder to us, the holder may increase the amount of beneficial ownership of outstanding stock after exercising the holder’s pre-funded warrants up to 9.99% of the number of shares of our common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the pre-funded warrants and Delaware law. Purchasers of pre-funded warrants in this offering may also elect prior to the issuance of the pre-funded warrants to have the initial exercise limitation set at 9.99% of our outstanding common stock.

 

Cashless Exercise

 

If, at the time a holder exercises its pre-funded warrants, a registration statement registering the issuance of the shares of common stock underlying the pre-funded warrants under the Securities Act is not then effective or available for the issuance of such shares, then in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price,